[{"id_": "doc_af45085b0761601c47279596f8c901ccad8138a518fe38e57fb86fbb6db97389", "url": "https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-emergency-use-novavax-covid-19-vaccine-adjuvanted", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_5fd74c4e3d1b3922669eb3f3a1180550a12044f3cee647dd3a45b5da042962e6", "text": "[\u2026]Authorizing an additional COVID-19 vaccine expands the available vaccine options for the prevention of COVID-19, including the most severe outcomes that can occur such as hospitalization and death[\u2026]", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_aa01359cf7d47e5c3440c18c5140b73d6a3f02110ac56f495cb6a27c3c66025d", "text": "COVID-19 vaccine", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_85e7cf54cbb04af12bb2f0611ac8e4e91ef7f3edc15a73d429a9298e7f8ed681", "text": "hospitalization", "location": null, "probability": null}, {"id_": "ent_sig_52c8e02987ccb1b0eef9c7c966aebf03c92a159aafda37fbcf03f4838dbcd48d", "text": "death", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_901f177478a858f6d8e9b198d11cc748dadbbc9aacc407aa8f396c4ab37e8d11", "medProdID": "ent_mep_aa01359cf7d47e5c3440c18c5140b73d6a3f02110ac56f495cb6a27c3c66025d", "sigID": "ent_sig_85e7cf54cbb04af12bb2f0611ac8e4e91ef7f3edc15a73d429a9298e7f8ed681", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_735c9b026254536f9964602119c442bcdb75526784865bc4d4d747bcaf4debaf", "medProdID": "ent_mep_aa01359cf7d47e5c3440c18c5140b73d6a3f02110ac56f495cb6a27c3c66025d", "sigID": "ent_sig_52c8e02987ccb1b0eef9c7c966aebf03c92a159aafda37fbcf03f4838dbcd48d", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_5fd74c4e3d1b3922669eb3f3a1180550a12044f3cee647dd3a45b5da042962e6": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_f5e91bf416a6c9c0d028d3754d60cbdc66755e148ec164563d206a9e0ead855b", "url": "https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_3793d47ae8e1c80708d2f316fce8ce89a410f3a8784e9769e328873d5bf7b167", "text": "The prescribing information for Leqembi includes a warning for amyloid-related imaging abnormalities (ARIA), which are known to occur with antibodies of this class. ARIA usually does not have symptoms, although serious and life-threatening events rarely may occur. ARIA most commonly presents as temporary swelling in areas of the brain that usually resolves over time and may be accompanied by small spots of bleeding in or on the surface of the brain, though some people may have symptoms such as headache, confusion, dizziness, vision changes, nausea and seizure. Another warning for Leqembi is for a risk of infusion-related reactions, with symptoms such as flu-like symptoms, nausea, vomiting and changes in blood pressure. The most common side effects of Leqembi were infusion-related reactions, headache and ARIA.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_508502e47f4076ed3a502bf5af222a998605923ed4079fb4233b274fa4e8ef66", "text": "Leqembi", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_cf5d4174a5abd242b567d475fb47794fdd01ed0a56f54aa9f9746b58b8739b49", "text": "amyloid-related imaging abnormalities (ARIA)", "location": null, "probability": null}, {"id_": "ent_sig_af01552701dc72586c8081e180a63cc0a27a9d1153fcf8da7b0ff2aa1cbd196e", "text": "temporary swelling in areas of the brain", "location": null, "probability": null}, {"id_": "ent_sig_221c5f71dbef02330605327524c017e1015bd57a392b3c40dcccd782bfdcee0b", "text": "small spots of bleeding in or on the surface of the brain", "location": null, "probability": null}, {"id_": "ent_sig_cfa9ac1e084975b5d6463e32652c85bad6355a5ab32399618f89f222e68dc335", "text": "headache", "location": null, "probability": null}, {"id_": "ent_sig_32c870923fced53850ca46019948ffac0a578ddd8696ad2c112cdd4ed37a5aa9", "text": "confusion", "location": null, "probability": null}, {"id_": "ent_sig_35be0fa611e43c36a6a8450b630e7c4704242638f4bc01682b51b05127962c47", "text": "dizziness", "location": null, "probability": null}, {"id_": "ent_sig_72ecaded5eff3ce296ae32fd0fc4e3fc3edcfe397be3cc5b1384a818aa9b5695", "text": "vision changes", "location": null, "probability": null}, {"id_": "ent_sig_e31040de4051bb5c21170eea8d3690ac4706d9fd6d119771e743936fae3f878b", "text": "nausea", "location": null, "probability": null}, {"id_": "ent_sig_4b879e9f69bb529b01a404642c9f11fbbb4a28c844bff8759ebe522baf65ff34", "text": "seizure", "location": null, "probability": null}, {"id_": "ent_sig_05d9dc83d7bf06ea922be1d752ae6a595c60cd5aca480da4e0fc2c899517e377", "text": "infusion-related reactions", "location": null, "probability": null}, {"id_": "ent_sig_23f8168c265d8eab1323165ba964569281a6b7f46196c5330a1cc20d3c9fa7db", "text": " flu-like symptoms", "location": null, "probability": null}, {"id_": "ent_sig_e31040de4051bb5c21170eea8d3690ac4706d9fd6d119771e743936fae3f878b", "text": "nausea", "location": null, "probability": null}, {"id_": "ent_sig_c629da3c8da3dc80e2e1b7dda8e852a32abce5544acd905d8fcf010780d93528", "text": "vomiting", "location": null, "probability": null}, {"id_": "ent_sig_e23f0f8a45458f91d8de5416a6016909f6eac0bcebd507d130968a055fd766d7", "text": "changes in blood pressure", "location": null, "probability": null}, {"id_": "ent_sig_05d9dc83d7bf06ea922be1d752ae6a595c60cd5aca480da4e0fc2c899517e377", "text": "infusion-related reactions", "location": null, "probability": null}, {"id_": "ent_sig_cfa9ac1e084975b5d6463e32652c85bad6355a5ab32399618f89f222e68dc335", "text": "headache", "location": null, "probability": null}, {"id_": "ent_sig_5ba1ee4df514a72f825471c6d777585b7ef743b32b757eae0729a4d379b2d179", "text": "ARIA", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_ccdcdb477433d2b348d17d6e1e648fbc4f174805a05c555f8c86b04438bbf719", "medProdID": "ent_mep_508502e47f4076ed3a502bf5af222a998605923ed4079fb4233b274fa4e8ef66", "sigID": "ent_sig_cf5d4174a5abd242b567d475fb47794fdd01ed0a56f54aa9f9746b58b8739b49", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_a028782524461bb79a7c8b30c75cc386346931c13853cc2bd7f3248e3bc4ecda", "medProdID": "ent_mep_508502e47f4076ed3a502bf5af222a998605923ed4079fb4233b274fa4e8ef66", "sigID": "ent_sig_af01552701dc72586c8081e180a63cc0a27a9d1153fcf8da7b0ff2aa1cbd196e", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_d2858795b0d74c15a619f06e40c5fd9c3b59247f5b40f608697ee52946c10a60", "medProdID": "ent_mep_508502e47f4076ed3a502bf5af222a998605923ed4079fb4233b274fa4e8ef66", "sigID": "ent_sig_221c5f71dbef02330605327524c017e1015bd57a392b3c40dcccd782bfdcee0b", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_c4137a25f38921e30a646609394362303c4f492f3b765b2d28a17e0c4dc8ab7e", "medProdID": "ent_mep_508502e47f4076ed3a502bf5af222a998605923ed4079fb4233b274fa4e8ef66", "sigID": "ent_sig_cfa9ac1e084975b5d6463e32652c85bad6355a5ab32399618f89f222e68dc335", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_811707cbb1549ba9d05c4f37d43458792ec037e859c0051499de85fc0d3070a1", "medProdID": "ent_mep_508502e47f4076ed3a502bf5af222a998605923ed4079fb4233b274fa4e8ef66", "sigID": "ent_sig_32c870923fced53850ca46019948ffac0a578ddd8696ad2c112cdd4ed37a5aa9", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_aa53f86e06e8f30ae81dbedb381052a95a040ee41faabf01a507351fbe388027", "medProdID": "ent_mep_508502e47f4076ed3a502bf5af222a998605923ed4079fb4233b274fa4e8ef66", "sigID": "ent_sig_35be0fa611e43c36a6a8450b630e7c4704242638f4bc01682b51b05127962c47", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_b967ef1ae06778a865aeeac42af7fbe7bfe7572341502d60e7453d20687fe012", "medProdID": "ent_mep_508502e47f4076ed3a502bf5af222a998605923ed4079fb4233b274fa4e8ef66", "sigID": "ent_sig_72ecaded5eff3ce296ae32fd0fc4e3fc3edcfe397be3cc5b1384a818aa9b5695", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_e8deca493e2b1a58f93b907964e286fce33d7ea2c8d1e1ba00bf9d9b2022a90b", "medProdID": "ent_mep_508502e47f4076ed3a502bf5af222a998605923ed4079fb4233b274fa4e8ef66", "sigID": "ent_sig_e31040de4051bb5c21170eea8d3690ac4706d9fd6d119771e743936fae3f878b", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_7e909008e61b2e8eca30816dd2a3a3b83f6d450142fb9bd813bb680aa93090a7", "medProdID": "ent_mep_508502e47f4076ed3a502bf5af222a998605923ed4079fb4233b274fa4e8ef66", "sigID": "ent_sig_4b879e9f69bb529b01a404642c9f11fbbb4a28c844bff8759ebe522baf65ff34", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_27a71cd6577490b738d1e69a71e2ff3bbcdc2171ddf97a7aa15182aa555f5f5d", "medProdID": "ent_mep_508502e47f4076ed3a502bf5af222a998605923ed4079fb4233b274fa4e8ef66", "sigID": "ent_sig_05d9dc83d7bf06ea922be1d752ae6a595c60cd5aca480da4e0fc2c899517e377", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_ddd750c0fa4757262a0f47e88fd6f6a4c0947404530090d212811413851fbff8", "medProdID": "ent_mep_508502e47f4076ed3a502bf5af222a998605923ed4079fb4233b274fa4e8ef66", "sigID": "ent_sig_23f8168c265d8eab1323165ba964569281a6b7f46196c5330a1cc20d3c9fa7db", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_e8deca493e2b1a58f93b907964e286fce33d7ea2c8d1e1ba00bf9d9b2022a90b", "medProdID": "ent_mep_508502e47f4076ed3a502bf5af222a998605923ed4079fb4233b274fa4e8ef66", "sigID": "ent_sig_e31040de4051bb5c21170eea8d3690ac4706d9fd6d119771e743936fae3f878b", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_808de435363ed818ada75270cd2a5df7aa5651c4dd64b1dee50cad3dfa009dbb", "medProdID": "ent_mep_508502e47f4076ed3a502bf5af222a998605923ed4079fb4233b274fa4e8ef66", "sigID": "ent_sig_c629da3c8da3dc80e2e1b7dda8e852a32abce5544acd905d8fcf010780d93528", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_b25bd4936f76cf8bb1b6d0d3334f0fd61f04f1454d9ea60e81be6217f9d372b0", "medProdID": "ent_mep_508502e47f4076ed3a502bf5af222a998605923ed4079fb4233b274fa4e8ef66", "sigID": "ent_sig_e23f0f8a45458f91d8de5416a6016909f6eac0bcebd507d130968a055fd766d7", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_27a71cd6577490b738d1e69a71e2ff3bbcdc2171ddf97a7aa15182aa555f5f5d", "medProdID": "ent_mep_508502e47f4076ed3a502bf5af222a998605923ed4079fb4233b274fa4e8ef66", "sigID": "ent_sig_05d9dc83d7bf06ea922be1d752ae6a595c60cd5aca480da4e0fc2c899517e377", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_c4137a25f38921e30a646609394362303c4f492f3b765b2d28a17e0c4dc8ab7e", "medProdID": "ent_mep_508502e47f4076ed3a502bf5af222a998605923ed4079fb4233b274fa4e8ef66", "sigID": "ent_sig_cfa9ac1e084975b5d6463e32652c85bad6355a5ab32399618f89f222e68dc335", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_68a7924fdf81c47945ca07bead8855d31313b0353e8e88d7ee172ff7b2596eca", "medProdID": "ent_mep_508502e47f4076ed3a502bf5af222a998605923ed4079fb4233b274fa4e8ef66", "sigID": "ent_sig_5ba1ee4df514a72f825471c6d777585b7ef743b32b757eae0729a4d379b2d179", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_3793d47ae8e1c80708d2f316fce8ce89a410f3a8784e9769e328873d5bf7b167": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_e414995f4aa57c993181c937c5bf240760c7afdd14a4aac6d69e95a4e707fe38", "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-new-hiv-drug-adults-limited-treatment-options", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_4d89aa19b55b83bb3662ddb00b770b9a2b0e596d36e48f3096479d0450172bd3", "text": "The most common adverse reactions with Sunlenca were injection site reactions and nausea. Most injection site reactions were described as swelling, pain or redness. Sunlenca comes with certain warnings and precautions. Injection site reactions described as nodules or indurations may be persistent in some patients. Additional warnings and precautions include the risk of developing immune reconstitution syndrome, which is when the immune system overreacts after starting HIV treatment. Also, small (residual) amounts of Sunlenca can remain in the body for up to a year or longer; low levels of drug caused by missing doses of Sunlenca or failing to maintain a fully suppressive HIV treatment regimen after stopping Sunlenca could lead to an increased risk of developing viral resistance. Residual amounts of Sunlenca could also lead to potential drug interactions.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_a3a409dcab4b0b3c3f35cc34404c0c3e011e4db8ebe05e740f1dddc179015bc9", "text": "Sunlenca", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_68263f9495f8504e564ce0d85851950d938135fd1754bbce4b0c2a64f9665b81", "text": "injection site reactions", "location": null, "probability": null}, {"id_": "ent_sig_e31040de4051bb5c21170eea8d3690ac4706d9fd6d119771e743936fae3f878b", "text": "nausea", "location": null, "probability": null}, {"id_": "ent_sig_a40c2e8d54e6e05624a813d774b6f59766c187bf6cd673ea6a142faf70938d88", "text": "swelling", "location": null, "probability": null}, {"id_": "ent_sig_5c78c8e7160e76ba9b6c41f74247bb7ba4887f5c06faecd6b9a009785b248c72", "text": "pain", "location": null, "probability": null}, {"id_": "ent_sig_662e921fe0db4a3305eb6b635661d5552fe7ecb2e2c52dbeda7545a6ccdee0f7", "text": "redness", "location": null, "probability": null}, {"id_": "ent_sig_b0b6e79953b010d789e2a75aba610d02ac67a8fd1af53c663047d6a4136c99fb", "text": "nodules", "location": null, "probability": null}, {"id_": "ent_sig_05e230b0964307e086fc55cf61317f0b014ba03a1f7ff688b82d76478f492a7a", "text": "indurations", "location": null, "probability": null}, {"id_": "ent_sig_a739aa8bec7db752aad897369b2b53727780d26f085401f2fe470982eda28d60", "text": "immune reconstitution syndrome", "location": null, "probability": null}, {"id_": "ent_sig_49a15484d18ff5e2f3085484575d7a9e2aad83db4ea154800ab86ce475123d00", "text": "viral resistance", "location": null, "probability": null}, {"id_": "ent_sig_77737625c60a3f2b921eede46296d118d8baae652041e94a4dbcf7bbed4426c4", "text": "potential drug interactions", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_d6be83db99303ae6e49d1bc2ff83d67c9fe95d95677f00ebc85d70886530c72e", "medProdID": "ent_mep_a3a409dcab4b0b3c3f35cc34404c0c3e011e4db8ebe05e740f1dddc179015bc9", "sigID": "ent_sig_68263f9495f8504e564ce0d85851950d938135fd1754bbce4b0c2a64f9665b81", "causality": null, "seriousness": null, "severity": 0.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_d5905c068f6eacbd2e0ecdb343d9b983c04245a2207aaa276612454128901764", "medProdID": "ent_mep_a3a409dcab4b0b3c3f35cc34404c0c3e011e4db8ebe05e740f1dddc179015bc9", "sigID": "ent_sig_e31040de4051bb5c21170eea8d3690ac4706d9fd6d119771e743936fae3f878b", "causality": null, "seriousness": null, "severity": 0.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_1d862ad134f11eb0f97c5b788ad3cdcf643b1a83cb70f8d7e780f1152e6c5c05", "medProdID": "ent_mep_a3a409dcab4b0b3c3f35cc34404c0c3e011e4db8ebe05e740f1dddc179015bc9", "sigID": "ent_sig_a40c2e8d54e6e05624a813d774b6f59766c187bf6cd673ea6a142faf70938d88", "causality": null, "seriousness": null, "severity": 0.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_887a72edbb7f1dadc9f2b84ee3cf092f43d087e93d44e87fc375374b3ed74b33", "medProdID": "ent_mep_a3a409dcab4b0b3c3f35cc34404c0c3e011e4db8ebe05e740f1dddc179015bc9", "sigID": "ent_sig_5c78c8e7160e76ba9b6c41f74247bb7ba4887f5c06faecd6b9a009785b248c72", "causality": null, "seriousness": null, "severity": 0.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_34d55ec3bc552a6815f21980ea2b16d6300181861a7c6e3870bf5d8b7afa1c96", "medProdID": "ent_mep_a3a409dcab4b0b3c3f35cc34404c0c3e011e4db8ebe05e740f1dddc179015bc9", "sigID": "ent_sig_662e921fe0db4a3305eb6b635661d5552fe7ecb2e2c52dbeda7545a6ccdee0f7", "causality": null, "seriousness": null, "severity": 0.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_9006391c3751b1b3dc2e471e69d194c3c0258e3702d98250f00cfefd2bf263ff", "medProdID": "ent_mep_a3a409dcab4b0b3c3f35cc34404c0c3e011e4db8ebe05e740f1dddc179015bc9", "sigID": "ent_sig_b0b6e79953b010d789e2a75aba610d02ac67a8fd1af53c663047d6a4136c99fb", "causality": null, "seriousness": null, "severity": 0.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_ac757bbdb0891bfb05c74d581ff275e17ca2f3fc1e0da4cf117f8112213acb5e", "medProdID": "ent_mep_a3a409dcab4b0b3c3f35cc34404c0c3e011e4db8ebe05e740f1dddc179015bc9", "sigID": "ent_sig_05e230b0964307e086fc55cf61317f0b014ba03a1f7ff688b82d76478f492a7a", "causality": null, "seriousness": null, "severity": 0.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_046aec730c74ea6160acfe290fa4a888ef9035fe2e89f07fb61902424b157916", "medProdID": "ent_mep_a3a409dcab4b0b3c3f35cc34404c0c3e011e4db8ebe05e740f1dddc179015bc9", "sigID": "ent_sig_a739aa8bec7db752aad897369b2b53727780d26f085401f2fe470982eda28d60", "causality": null, "seriousness": null, "severity": 0.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_20f69773a36f24dd0a4cbf9cb22de81d2adbddaa6e65704e0216e066504cfbbb", "medProdID": "ent_mep_a3a409dcab4b0b3c3f35cc34404c0c3e011e4db8ebe05e740f1dddc179015bc9", "sigID": "ent_sig_49a15484d18ff5e2f3085484575d7a9e2aad83db4ea154800ab86ce475123d00", "causality": null, "seriousness": null, "severity": 0.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_1cdbee56767ebf20a2caeed76d7c9987d6033b7c30284be7fbddd5aac1fad3f9", "medProdID": "ent_mep_a3a409dcab4b0b3c3f35cc34404c0c3e011e4db8ebe05e740f1dddc179015bc9", "sigID": "ent_sig_77737625c60a3f2b921eede46296d118d8baae652041e94a4dbcf7bbed4426c4", "causality": null, "seriousness": null, "severity": 0.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_4d89aa19b55b83bb3662ddb00b770b9a2b0e596d36e48f3096479d0450172bd3": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_669a03537742857731cad9cfc2cb2193fede5fecfe486aaee543299900f8718d", "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-high-risk-non-muscle-invasive-bladder-cancer", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_cd2ad79d7b5dad31e63c2759fb6e0b3db39ce6096040a703a79e3bf9a34a4ca8", "text": "The most common adverse reactions associated with Adstiladrin included bladder discharge, fatigue, bladder spasm, urinary urgency, hematuria (presence of blood in urine), chills, fever, and painful urination. Individuals who are immunosuppressed, or immune-deficient should not come into contact with Adstiladrin.\u00a0", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_abff474784627ec70af7402d0a231a31d74bfff3e1b736d94fb2ba6037ee4229", "text": "Adstiladrin", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_fe5d3a418c71f45ecb6da88ee1dc311575d31254ddd9a6f875e2ae63195133a7", "text": "bladder discharge", "location": null, "probability": null}, {"id_": "ent_sig_4064e6a9a434b058fcae69eb01a5374e91705380e2f4b9fd940120c6696fc050", "text": "fatigue", "location": null, "probability": null}, {"id_": "ent_sig_74b079fad9840156acf6f6991752febb02e03d6b65668ccefd4e8a6595543d77", "text": "bladder spasm", "location": null, "probability": null}, {"id_": "ent_sig_ef0956c0a2d79f8fb73c681090969a7d2a2bc227d2bb8d6c13eade2549c1a4b1", "text": "urinary urgency", "location": null, "probability": null}, {"id_": "ent_sig_acfe4a2fcbb5f49f23fc6d68d4cfa8e4699a6c116164240c86da04ac5a0b08d8", "text": "hematuria (presence of blood in urine)", "location": null, "probability": null}, {"id_": "ent_sig_472ecbc56f4626868e34c9511ad741569207544c59f27caa589e28d9b9f0427f", "text": "chills", "location": null, "probability": null}, {"id_": "ent_sig_1e44a1c45388c81c1a4bba7c14aa8d54cf11d442c99efc62a68d103cfdd308b8", "text": "fever", "location": null, "probability": null}, {"id_": "ent_sig_413eb938817434889c7a741c77be8675e0cc321ad9318acde00a716bb1b19737", "text": "painful urination", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_b8ecd47db0436e36095b742598b12a62cd5a5d164c27047dc8dd2ca806823d94", "medProdID": "ent_mep_abff474784627ec70af7402d0a231a31d74bfff3e1b736d94fb2ba6037ee4229", "sigID": "ent_sig_fe5d3a418c71f45ecb6da88ee1dc311575d31254ddd9a6f875e2ae63195133a7", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_1b9897462eef5b5853d63647556301076fad1afdb0d0f052ceb460753e2f66fe", "medProdID": "ent_mep_abff474784627ec70af7402d0a231a31d74bfff3e1b736d94fb2ba6037ee4229", "sigID": "ent_sig_4064e6a9a434b058fcae69eb01a5374e91705380e2f4b9fd940120c6696fc050", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_4dd0359df3df5fdcdfc24c6931d355ce6957a1e11b8d612254d60d8d0c48ddee", "medProdID": "ent_mep_abff474784627ec70af7402d0a231a31d74bfff3e1b736d94fb2ba6037ee4229", "sigID": "ent_sig_74b079fad9840156acf6f6991752febb02e03d6b65668ccefd4e8a6595543d77", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_4fa5d38efaa3c639afe381e994e6e48f8083e8caa6c81ca16a4e818f32ba0532", "medProdID": "ent_mep_abff474784627ec70af7402d0a231a31d74bfff3e1b736d94fb2ba6037ee4229", "sigID": "ent_sig_ef0956c0a2d79f8fb73c681090969a7d2a2bc227d2bb8d6c13eade2549c1a4b1", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_5884629d84c00c66590fbf3110783f5e32ee9cec75a11e32cfb635de9812af5d", "medProdID": "ent_mep_abff474784627ec70af7402d0a231a31d74bfff3e1b736d94fb2ba6037ee4229", "sigID": "ent_sig_acfe4a2fcbb5f49f23fc6d68d4cfa8e4699a6c116164240c86da04ac5a0b08d8", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_a24fc64d974fbd26da4f6488782f70ad388d3dfc6b976e4d0cd21bea2752aa08", "medProdID": "ent_mep_abff474784627ec70af7402d0a231a31d74bfff3e1b736d94fb2ba6037ee4229", "sigID": "ent_sig_472ecbc56f4626868e34c9511ad741569207544c59f27caa589e28d9b9f0427f", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_7189ec3ef3ea21fc3e5582f5243f62f8e31ff5851a233bff489712e330bfe860", "medProdID": "ent_mep_abff474784627ec70af7402d0a231a31d74bfff3e1b736d94fb2ba6037ee4229", "sigID": "ent_sig_1e44a1c45388c81c1a4bba7c14aa8d54cf11d442c99efc62a68d103cfdd308b8", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_437bc8594b191b5f46893b57adda16ef49f927f7675650d4631d5ff1e5caec6f", "medProdID": "ent_mep_abff474784627ec70af7402d0a231a31d74bfff3e1b736d94fb2ba6037ee4229", "sigID": "ent_sig_413eb938817434889c7a741c77be8675e0cc321ad9318acde00a716bb1b19737", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_cd2ad79d7b5dad31e63c2759fb6e0b3db39ce6096040a703a79e3bf9a34a4ca8": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_65355ad91c50a4680c8278f4f3b78f43fac0fa524d2308f5ba7916453c9ce763", "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-option-patients-als", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_541d720f418c2b9e6fef175e83c83e42c00459ca48604aa132285228e12cd31d", "text": "The most common adverse reactions experienced with Relyvrio were diarrhea, abdominal pain, nausea and upper respiratory tract infection. Relyvrio contains taurursodiol, a bile acid, which may cause worsening diarrhea in patients with disorders that interfere with bile acid circulation. ", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_24661649eacb9d5f58c4e590519633f80f782bbf2d63e919a4d88decbe4e85c8", "text": "Relyvrio", "location": null, "probability": null}, {"id_": "ent_mep_2164a3a8f2b10809bd3682fd3e3c22b7cd2fb5d059ad4e69683503e597872274", "text": "taurursodiol", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_e854059ec21a3914d72d07747429273646a97d1a70cbfdce2ac3b57106ca5ac5", "text": "diarrhea", "location": null, "probability": null}, {"id_": "ent_sig_47df24df96cfdb191c74cbba045e8bf8641f121cd59e03a7653cec397430d7d2", "text": "abdominal pain", "location": null, "probability": null}, {"id_": "ent_sig_e31040de4051bb5c21170eea8d3690ac4706d9fd6d119771e743936fae3f878b", "text": "nausea", "location": null, "probability": null}, {"id_": "ent_sig_dc1a9aa35f55c8fa5469d118e2bb2474c45dada7f507ff29f5ff35fc0f117b0f", "text": "upper respiratory tract infection", "location": null, "probability": null}, {"id_": "ent_sig_e854059ec21a3914d72d07747429273646a97d1a70cbfdce2ac3b57106ca5ac5", "text": "diarrhea", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_fe63df3f1e78c7fce7046442ff37bfd9573bff0c131af2d9481f3219620bac8e", "medProdID": "ent_mep_24661649eacb9d5f58c4e590519633f80f782bbf2d63e919a4d88decbe4e85c8", "sigID": "ent_sig_e854059ec21a3914d72d07747429273646a97d1a70cbfdce2ac3b57106ca5ac5", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_71f51ac711e6333e14e5d139ce7317e189b9fe3729d64f1580d18d0d06aaac3e", "medProdID": "ent_mep_24661649eacb9d5f58c4e590519633f80f782bbf2d63e919a4d88decbe4e85c8", "sigID": "ent_sig_47df24df96cfdb191c74cbba045e8bf8641f121cd59e03a7653cec397430d7d2", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_e73f21221432b273c8a1c2ac089e0c200a60cc19101b610e70bdac3e0d5f262f", "medProdID": "ent_mep_24661649eacb9d5f58c4e590519633f80f782bbf2d63e919a4d88decbe4e85c8", "sigID": "ent_sig_e31040de4051bb5c21170eea8d3690ac4706d9fd6d119771e743936fae3f878b", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_ef3d2dfdffa0edebb1411f63fee59ec081538fb12242d9ed94f4b5bd23cced70", "medProdID": "ent_mep_24661649eacb9d5f58c4e590519633f80f782bbf2d63e919a4d88decbe4e85c8", "sigID": "ent_sig_dc1a9aa35f55c8fa5469d118e2bb2474c45dada7f507ff29f5ff35fc0f117b0f", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_fe63df3f1e78c7fce7046442ff37bfd9573bff0c131af2d9481f3219620bac8e", "medProdID": "ent_mep_24661649eacb9d5f58c4e590519633f80f782bbf2d63e919a4d88decbe4e85c8", "sigID": "ent_sig_e854059ec21a3914d72d07747429273646a97d1a70cbfdce2ac3b57106ca5ac5", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_a680f03fe14ae7600017b51dae6b9ed299a7aad67b88e87c416a3e4e5e3f431a", "medProdID": "ent_mep_2164a3a8f2b10809bd3682fd3e3c22b7cd2fb5d059ad4e69683503e597872274", "sigID": "ent_sig_e854059ec21a3914d72d07747429273646a97d1a70cbfdce2ac3b57106ca5ac5", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_fa77cef7115fca204165f16f7ef717c0350a023b3e974fbc8b6a81b5d183c8a7", "medProdID": "ent_mep_2164a3a8f2b10809bd3682fd3e3c22b7cd2fb5d059ad4e69683503e597872274", "sigID": "ent_sig_47df24df96cfdb191c74cbba045e8bf8641f121cd59e03a7653cec397430d7d2", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_6dd413542af41330c05ee1e5b9fffec99ba51b7467e018d0eba042b40650ff62", "medProdID": "ent_mep_2164a3a8f2b10809bd3682fd3e3c22b7cd2fb5d059ad4e69683503e597872274", "sigID": "ent_sig_e31040de4051bb5c21170eea8d3690ac4706d9fd6d119771e743936fae3f878b", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_6c9d912ae8b8313c1fc1e33a43cb9110cac7a21079040b5cb5089d07f5b59421", "medProdID": "ent_mep_2164a3a8f2b10809bd3682fd3e3c22b7cd2fb5d059ad4e69683503e597872274", "sigID": "ent_sig_dc1a9aa35f55c8fa5469d118e2bb2474c45dada7f507ff29f5ff35fc0f117b0f", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_a680f03fe14ae7600017b51dae6b9ed299a7aad67b88e87c416a3e4e5e3f431a", "medProdID": "ent_mep_2164a3a8f2b10809bd3682fd3e3c22b7cd2fb5d059ad4e69683503e597872274", "sigID": "ent_sig_e854059ec21a3914d72d07747429273646a97d1a70cbfdce2ac3b57106ca5ac5", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_541d720f418c2b9e6fef175e83c83e42c00459ca48604aa132285228e12cd31d": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_dc8f6a6e2c75f9edde041c48dcd6d9c2858bb5939446782a7a1b66fa6017e1ae", "url": "https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/january-march-2022-potential-signals-serious-risksnew-safety-information-identified-fda-adverse", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_e1b1ec9bdf0dde8c010332f86cd0e917273f2e3ac725be6a4f1049fa77257dec", "text": "On Website: Betadine (povidone-iodine) // intentional product misuse\nIn report: PRODUCT may lead to SIGNAL..", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_7a6b70b1d24504a21a25fa981eb0a8867e6765640fd58a94bd37b8d24f60d7c8", "text": "Betadine (povidone-iodine)", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_1a72dd4283169712179b1888e72293dd680ff2b2dac6208c25fb9ac96e7ced52", "text": "intentional product misuse", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_316809f565ed85312da18ccff60192142e4be0fc2bf0a87901567e51df466841", "medProdID": "ent_mep_7a6b70b1d24504a21a25fa981eb0a8867e6765640fd58a94bd37b8d24f60d7c8", "sigID": "ent_sig_1a72dd4283169712179b1888e72293dd680ff2b2dac6208c25fb9ac96e7ced52", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_e1b1ec9bdf0dde8c010332f86cd0e917273f2e3ac725be6a4f1049fa77257dec": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_2f1860f2e8c40d27d474b4303bac65f667396ca26730021e7f42fc000f6bc781", "url": "https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-possible-increased-risk-death-and-serious-side-effects-cancer-drug-copiktra", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_d0fcebf5bcaabc1f5bd6f7c1c6991bd1070636f5a60b802096ab84897aceef20", "text": "FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib)", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_79f900ec300a8bd4ed2e50dcced53efc6810478a3bbe1a16acc13ff525f0432f", "text": "Copiktra (duvelisib)", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_52c8e02987ccb1b0eef9c7c966aebf03c92a159aafda37fbcf03f4838dbcd48d", "text": "death", "location": null, "probability": null}, {"id_": "ent_sig_7115ccd5f60d6ad2179ecc839367ee479d0aa3f0bb83ba7188f2dabc71895254", "text": "serious side effects", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_c1122064cb01f02c563eb326733711fe20c4e63347169ff799c19572c08856fc", "medProdID": "ent_mep_79f900ec300a8bd4ed2e50dcced53efc6810478a3bbe1a16acc13ff525f0432f", "sigID": "ent_sig_52c8e02987ccb1b0eef9c7c966aebf03c92a159aafda37fbcf03f4838dbcd48d", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_6674cfbe9d2a0e6b9a60cd1a298955648ff28c1b12ce91a7f7398511f020b2b2", "medProdID": "ent_mep_79f900ec300a8bd4ed2e50dcced53efc6810478a3bbe1a16acc13ff525f0432f", "sigID": "ent_sig_7115ccd5f60d6ad2179ecc839367ee479d0aa3f0bb83ba7188f2dabc71895254", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_d0fcebf5bcaabc1f5bd6f7c1c6991bd1070636f5a60b802096ab84897aceef20": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_0506eee43bff2049a3ba33124bb81fe65c459160d73a849a93bddf58eadfbfe2", "url": "https://www.fda.gov/news-events/press-announcements/fda-warns-manufacturer-marketing-illegal-flavored-nicotine-gummies", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_13b35a38552a92a6f5c94ddb051a26e718978adc55c1ead49b3d749fc6ad5830", "text": "Today, the U.S. Food and Drug Administration issued a warning letter for marketing illegal flavored nicotine gummies \u2013 the first warning letter for this type of product. These types of gummies are of particular public concern because of their resemblance to kid-friendly food or candy products and the potential to cause severe nicotine toxicity or even death among young children.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_ff52ea63f739980cc61e634e4872e55cdbf68b8ca8367c1c220a382aadff63d7", "text": "flavored nicotine gummies", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_0a2be4b5947fd8fea51de301b08ddce8a31f5dad6d17b91db626597db89c8c3c", "text": "nicotine toxicity", "location": null, "probability": null}, {"id_": "ent_sig_52c8e02987ccb1b0eef9c7c966aebf03c92a159aafda37fbcf03f4838dbcd48d", "text": "death", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_3d6bfed882c016b996aaa2773476e4f33f0b94a10be89e9508007f1a58b47c05", "medProdID": "ent_mep_ff52ea63f739980cc61e634e4872e55cdbf68b8ca8367c1c220a382aadff63d7", "sigID": "ent_sig_0a2be4b5947fd8fea51de301b08ddce8a31f5dad6d17b91db626597db89c8c3c", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_6a7d84d54470592509a50e91faee364b39dba8d11ed10914ea454d886cf27602", "medProdID": "ent_mep_ff52ea63f739980cc61e634e4872e55cdbf68b8ca8367c1c220a382aadff63d7", "sigID": "ent_sig_52c8e02987ccb1b0eef9c7c966aebf03c92a159aafda37fbcf03f4838dbcd48d", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}, {"id_": "ent_d7c476c6d76122abcef002a6ddf4268b08b15ef4cccebc726884fb70bdb602d1", "text": "The manufacturer states that each gummy contains 1 milligram of nicotine with 12 gummies (12 mg) per tin. Research indicates that ingesting 1 to 4 milligrams of nicotine could be severely toxic to a child under 6 years of age depending on the child\u2019s body weight. However, nicotine toxicity among youth of any age may lead to nausea, vomiting, abdominal pain, increased blood pressure and heart rate, seizures, respiratory failure, coma and even death. Nicotine is also highly addictive and exposure during adolescence can harm the developing brain.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_9cf3886f2bbc9660b15a9b7a9e49ef53eafba433827265ce1c63b2b8199c78f2", "text": "gummy", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_04651cd5fa4e877d46f1ee74a89bc548b37471afde7b7881b150fb6b08f7e1ca", "text": "toxic", "location": null, "probability": null}, {"id_": "ent_sig_e31040de4051bb5c21170eea8d3690ac4706d9fd6d119771e743936fae3f878b", "text": "nausea", "location": null, "probability": null}, {"id_": "ent_sig_c629da3c8da3dc80e2e1b7dda8e852a32abce5544acd905d8fcf010780d93528", "text": "vomiting", "location": null, "probability": null}, {"id_": "ent_sig_47df24df96cfdb191c74cbba045e8bf8641f121cd59e03a7653cec397430d7d2", "text": "abdominal pain", "location": null, "probability": null}, {"id_": "ent_sig_07e846a2abc387022e5e17752c0ede6c2b8581bb6601d277369bc7cc76b4e66c", "text": "increased blood pressure and heart rate", "location": null, "probability": null}, {"id_": "ent_sig_14a329d678cf228ac0ee9ce8574a163255a6e3959f9c48dbde81ee4a0e83e090", "text": "seizures", "location": null, "probability": null}, {"id_": "ent_sig_0f60b78bec3ef9d8748736e7053cfb8acd6bf0f04042108f0ecce6ca2acdef19", "text": "respiratory failure", "location": null, "probability": null}, {"id_": "ent_sig_b477cc5dc15d0c0f00422fd41c1f886b9fb059fc6bf692eceed35c5bf5084fb4", "text": "coma", "location": null, "probability": null}, {"id_": "ent_sig_52c8e02987ccb1b0eef9c7c966aebf03c92a159aafda37fbcf03f4838dbcd48d", "text": "death", "location": null, "probability": null}, {"id_": "ent_sig_e20b0478aad09320df380fdebe1420d5f9abde9e1e256365f132926c323b8101", "text": "addictive", "location": null, "probability": null}, {"id_": "ent_sig_2b045c93c7ef2dd4ac14b3bc3603800ccda638adfd288f17f1049525738712e3", "text": "harm the developing brain", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_d4a37926b0074a50683ce4b96bfc18e2cc69f59f8d1e4a6506c59eb5b8d4b6de", "medProdID": "ent_mep_9cf3886f2bbc9660b15a9b7a9e49ef53eafba433827265ce1c63b2b8199c78f2", "sigID": "ent_sig_04651cd5fa4e877d46f1ee74a89bc548b37471afde7b7881b150fb6b08f7e1ca", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_528b5f12db2c5ec125937ae6125bb67079b91822184a262bd7eb222dcd87abda", "medProdID": "ent_mep_9cf3886f2bbc9660b15a9b7a9e49ef53eafba433827265ce1c63b2b8199c78f2", "sigID": "ent_sig_e31040de4051bb5c21170eea8d3690ac4706d9fd6d119771e743936fae3f878b", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_fb59070a3ef8dd9b022194d7811db7fdad4cfe03c9fc2c2f5e43bf10af6579c6", "medProdID": "ent_mep_9cf3886f2bbc9660b15a9b7a9e49ef53eafba433827265ce1c63b2b8199c78f2", "sigID": "ent_sig_c629da3c8da3dc80e2e1b7dda8e852a32abce5544acd905d8fcf010780d93528", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_c19598f293248eab6b3c1aecf40b2f85c78206207060124fd8b0e24ab7e59a22", "medProdID": "ent_mep_9cf3886f2bbc9660b15a9b7a9e49ef53eafba433827265ce1c63b2b8199c78f2", "sigID": "ent_sig_47df24df96cfdb191c74cbba045e8bf8641f121cd59e03a7653cec397430d7d2", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_cd60c3c43d42b0ad7203844018e135e948b1d0c9f5b48d709b67e3bc66441e44", "medProdID": "ent_mep_9cf3886f2bbc9660b15a9b7a9e49ef53eafba433827265ce1c63b2b8199c78f2", "sigID": "ent_sig_07e846a2abc387022e5e17752c0ede6c2b8581bb6601d277369bc7cc76b4e66c", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_f6a5c764992b4df9e97d51d5ea0091c19b96b79cc356ab2cb357313dd079ff0f", "medProdID": "ent_mep_9cf3886f2bbc9660b15a9b7a9e49ef53eafba433827265ce1c63b2b8199c78f2", "sigID": "ent_sig_14a329d678cf228ac0ee9ce8574a163255a6e3959f9c48dbde81ee4a0e83e090", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_7897753c33d4f29ed3d05bacc565f3720fdee2fc38e9d984cf980fcb4547f704", "medProdID": "ent_mep_9cf3886f2bbc9660b15a9b7a9e49ef53eafba433827265ce1c63b2b8199c78f2", "sigID": "ent_sig_0f60b78bec3ef9d8748736e7053cfb8acd6bf0f04042108f0ecce6ca2acdef19", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_af63992eb4e0676d8385ecde4051c832fd6f486375c67b2b4b9f6176bf87e4d0", "medProdID": "ent_mep_9cf3886f2bbc9660b15a9b7a9e49ef53eafba433827265ce1c63b2b8199c78f2", "sigID": "ent_sig_b477cc5dc15d0c0f00422fd41c1f886b9fb059fc6bf692eceed35c5bf5084fb4", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_acaf4bd98117aee69efa88012908c325a52977d93e1423f32f2e705bd124604a", "medProdID": "ent_mep_9cf3886f2bbc9660b15a9b7a9e49ef53eafba433827265ce1c63b2b8199c78f2", "sigID": "ent_sig_52c8e02987ccb1b0eef9c7c966aebf03c92a159aafda37fbcf03f4838dbcd48d", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_7c90cef152432b43ecfd813da4414ac6f185684af410094d6f0cce165bb707c3", "medProdID": "ent_mep_9cf3886f2bbc9660b15a9b7a9e49ef53eafba433827265ce1c63b2b8199c78f2", "sigID": "ent_sig_e20b0478aad09320df380fdebe1420d5f9abde9e1e256365f132926c323b8101", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_3b3c9b6a39fedc462f9167b93a6a44b3170f4a0ed1efcf575b9b7d0f38235248", "medProdID": "ent_mep_9cf3886f2bbc9660b15a9b7a9e49ef53eafba433827265ce1c63b2b8199c78f2", "sigID": "ent_sig_2b045c93c7ef2dd4ac14b3bc3603800ccda638adfd288f17f1049525738712e3", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_13b35a38552a92a6f5c94ddb051a26e718978adc55c1ead49b3d749fc6ad5830": 0, "ent_d7c476c6d76122abcef002a6ddf4268b08b15ef4cccebc726884fb70bdb602d1": 1}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_3c5e475b3b56ec4b4601a3aec664ccb88a2366ce801f454c8fd65ea02dd57a88", "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/bemfola", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_4ce5679ab3a8f856fb921c35f642c7d41c53919ebf7c6af4a9dcdc677c61663b", "text": "The most common side effects with Bemfola (which may affect more than 1 in 10 people) are reactions at the injection site (pain, redness, bruising, swelling or irritation). ", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_f90439bc4c035792c62c4966fb53c8cad271e5f74b936903d495afa0295dacef", "text": "Bemfola", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_1bcf04fe26a15db950b0e04dae79a6081c6ff09cf0aa043a14d764306815680e", "text": "reactions at the injection site (pain, redness, bruising, swelling or irritation)", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_7dd1c41b85c5a0912b2414b271f3e1a6c7c0f23ba94302c86b11e53884fa0569", "medProdID": "ent_mep_f90439bc4c035792c62c4966fb53c8cad271e5f74b936903d495afa0295dacef", "sigID": "ent_sig_1bcf04fe26a15db950b0e04dae79a6081c6ff09cf0aa043a14d764306815680e", "causality": null, "seriousness": null, "severity": 0.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_4ce5679ab3a8f856fb921c35f642c7d41c53919ebf7c6af4a9dcdc677c61663b": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_4350b0c101a6ab346a3ebfb1d64de856ab81cbdfe6a19842fd3a9063cc83dd9d", "url": "https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-benefits-risks-context", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_6e629be384daa772e6bc9fa95f0172d028c06cc4104ed1a9d90633c6be257182", "text": "The benefits of Vaxzevria outweigh its risks in adults of all age groups; however, very rare cases of blood clots with low blood platelets1\u00a0have occurred following vaccination.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_5392c36a70b7c656a64c4c16d8971d1883c750543edb25258b12007a73e0ecb9", "text": "Vaxzevria", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_e2c06aa336daefc434f914bdb6580c56b2e921e6701c2dcbf8046bd004707725", "text": "blood clots with low blood platelets", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_4db8299baf287bbf5f5c731ffd4a454fd832513129e1dd6fcac48e9f1a3be1e0", "medProdID": "ent_mep_5392c36a70b7c656a64c4c16d8971d1883c750543edb25258b12007a73e0ecb9", "sigID": "ent_sig_e2c06aa336daefc434f914bdb6580c56b2e921e6701c2dcbf8046bd004707725", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_6e629be384daa772e6bc9fa95f0172d028c06cc4104ed1a9d90633c6be257182": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_b9468a6dbd3a8b9a6185e4356de3eb9aaf711359043049b43bd069428a082abe", "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/rybrevant", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_d6e9dd7ce63677ff84e056d0e2ae58735a0555f96d762bb332521895a770e821", "text": "The most common side effects with Rybrevant (which may affect more than 1 in 5 people) are rash, infusion-related reactions, nail toxicity (nail abnormalities with pain or discomfort), hypoalbuminaemia (low blood levels of the protein albumin), oedema (fluid retention), tiredness, stomatitis (inflammation of the lining of the mouth), nausea (feeling sick), and constipation. The most common serious side effects (which may affect more than 1 in 100 people) are interstitial lung disease (disorders causing scarring in the lungs), infusion-related reactions and rash.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_33f0500374325f915a9966ee898c8fca427379c1ca95582727b55dcd66def78f", "text": "Rybrevant", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_4f6f064362e732b6e4c261ee5d62cede08eeb4437a5b54b19023324091224d26", "text": "rash", "location": null, "probability": null}, {"id_": "ent_sig_05d9dc83d7bf06ea922be1d752ae6a595c60cd5aca480da4e0fc2c899517e377", "text": "infusion-related reactions", "location": null, "probability": null}, {"id_": "ent_sig_218d6d42724d4cb4681547cac6a48c3cfbd8d357aef6207f853363f9984a8ae2", "text": "nail toxicity", "location": null, "probability": null}, {"id_": "ent_sig_b08159c3dfbe34986f7205b54b554c75a92721ff7a6538f48d6b5bcfffd5c6d9", "text": "hypoalbuminaemia", "location": null, "probability": null}, {"id_": "ent_sig_298331bb1ffef6f39e2f9ecf46e3a403ba4613d7bb218f0d8953d2dc87a8e1da", "text": "oedema", "location": null, "probability": null}, {"id_": "ent_sig_8b2bdeeb3bcc92fa0371527c959edff75be89ecfc1201cce378b72b43f1e0ddc", "text": "tiredness", "location": null, "probability": null}, {"id_": "ent_sig_155fc2b062ef1e69719818a1b4a10e007c872f4236ffa7290b73e238c3c6ac24", "text": "stomatitis", "location": null, "probability": null}, {"id_": "ent_sig_e31040de4051bb5c21170eea8d3690ac4706d9fd6d119771e743936fae3f878b", "text": "nausea", "location": null, "probability": null}, {"id_": "ent_sig_f79c7ed641f29accf092913c66710a0997459a12412e1dfcce93f73476cf84ea", "text": "constipation", "location": null, "probability": null}, {"id_": "ent_sig_53bbf2305552f5c3461b80c08f150f9aba9f83f0f48a986efc3a2a5ca4df2a67", "text": "interstitial lung disease", "location": null, "probability": null}, {"id_": "ent_sig_05d9dc83d7bf06ea922be1d752ae6a595c60cd5aca480da4e0fc2c899517e377", "text": "infusion-related reactions", "location": null, "probability": null}, {"id_": "ent_sig_4f6f064362e732b6e4c261ee5d62cede08eeb4437a5b54b19023324091224d26", "text": "rash", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_786e30c800b1317e97cb5aaf1dd8d1bb49973e042765dbe715a37c244cdc808d", "medProdID": "ent_mep_33f0500374325f915a9966ee898c8fca427379c1ca95582727b55dcd66def78f", "sigID": "ent_sig_4f6f064362e732b6e4c261ee5d62cede08eeb4437a5b54b19023324091224d26", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_cb2be468142c7e90bc51e553a3b8ac95b9de80d10514459430ec8017b540e3c0", "medProdID": "ent_mep_33f0500374325f915a9966ee898c8fca427379c1ca95582727b55dcd66def78f", "sigID": "ent_sig_05d9dc83d7bf06ea922be1d752ae6a595c60cd5aca480da4e0fc2c899517e377", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_d88f2a2cadd395ea986ae73f7a2466fdda094a85d26e611380bd40b398247eb9", "medProdID": "ent_mep_33f0500374325f915a9966ee898c8fca427379c1ca95582727b55dcd66def78f", "sigID": "ent_sig_218d6d42724d4cb4681547cac6a48c3cfbd8d357aef6207f853363f9984a8ae2", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_de6a4dfd0173b160c8661799cbc0a76c6df86c8500a12a05b6579b71ccbaa37e", "medProdID": "ent_mep_33f0500374325f915a9966ee898c8fca427379c1ca95582727b55dcd66def78f", "sigID": "ent_sig_b08159c3dfbe34986f7205b54b554c75a92721ff7a6538f48d6b5bcfffd5c6d9", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_4c4e5bebccdf051dfacf4bc14c540df362e4482c44834f425ef02e73ff0b13f1", "medProdID": "ent_mep_33f0500374325f915a9966ee898c8fca427379c1ca95582727b55dcd66def78f", "sigID": "ent_sig_298331bb1ffef6f39e2f9ecf46e3a403ba4613d7bb218f0d8953d2dc87a8e1da", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_5096e6b57c563d0c4e4e3c2b39d517978d277c04bfcbaf414285d725d5229f28", "medProdID": "ent_mep_33f0500374325f915a9966ee898c8fca427379c1ca95582727b55dcd66def78f", "sigID": "ent_sig_8b2bdeeb3bcc92fa0371527c959edff75be89ecfc1201cce378b72b43f1e0ddc", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_6e0d3542b12f33481614d5dd4b10fd361f04da09fa24f5940a86f8f74a4413bd", "medProdID": "ent_mep_33f0500374325f915a9966ee898c8fca427379c1ca95582727b55dcd66def78f", "sigID": "ent_sig_155fc2b062ef1e69719818a1b4a10e007c872f4236ffa7290b73e238c3c6ac24", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_43919ace30d8a14e2cd38865b7ffa057f97430aa74fc4cf6d07cffdeb2051954", "medProdID": "ent_mep_33f0500374325f915a9966ee898c8fca427379c1ca95582727b55dcd66def78f", "sigID": "ent_sig_e31040de4051bb5c21170eea8d3690ac4706d9fd6d119771e743936fae3f878b", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_954517f66c8644b24c0dee52bd00ef056b3e19579d31a511e9dce465dcfbf0e9", "medProdID": "ent_mep_33f0500374325f915a9966ee898c8fca427379c1ca95582727b55dcd66def78f", "sigID": "ent_sig_f79c7ed641f29accf092913c66710a0997459a12412e1dfcce93f73476cf84ea", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_0d5f8a773c7ad66d4d14a7223b2f42bdca38ee27ba6383ce2817bfa400b0dd33", "medProdID": "ent_mep_33f0500374325f915a9966ee898c8fca427379c1ca95582727b55dcd66def78f", "sigID": "ent_sig_53bbf2305552f5c3461b80c08f150f9aba9f83f0f48a986efc3a2a5ca4df2a67", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_cb2be468142c7e90bc51e553a3b8ac95b9de80d10514459430ec8017b540e3c0", "medProdID": "ent_mep_33f0500374325f915a9966ee898c8fca427379c1ca95582727b55dcd66def78f", "sigID": "ent_sig_05d9dc83d7bf06ea922be1d752ae6a595c60cd5aca480da4e0fc2c899517e377", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_786e30c800b1317e97cb5aaf1dd8d1bb49973e042765dbe715a37c244cdc808d", "medProdID": "ent_mep_33f0500374325f915a9966ee898c8fca427379c1ca95582727b55dcd66def78f", "sigID": "ent_sig_4f6f064362e732b6e4c261ee5d62cede08eeb4437a5b54b19023324091224d26", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_d6e9dd7ce63677ff84e056d0e2ae58735a0555f96d762bb332521895a770e821": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_1de52a8d5feb31082d25e1e9805d27dc58e86475dc0647b92b477cd17e6480ab", "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/siklos", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_64ec2c0ea8afc09559a01c038b82ecc8db08ec0c7665177fdb70b254b48e6b74", "text": "The most common side effect with Siklos (seen in more than one patient in 10) is bone marrow suppression, causing neutropenia (low levels of neutrophils, a type of white blood cell), reticulocytopenia (low levels of reticulocytes, a type of immature red blood cell) and macrocytosis (enlargement of red blood cells). ", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_a9d69ad7c918937eaa705fb89e86804abf5fdaae43881ee21f114e88476b88ec", "text": "Siklos", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_55421993789198d0cb6f7cea3bd53d683b72451021dbbb7cac59257c833bb4db", "text": "bone marrow suppression", "location": null, "probability": null}, {"id_": "ent_sig_398925f4d9618ac4e59db61b92420b9395a0ffa76a72247d163a715ba76416ca", "text": "causing neutropenia", "location": null, "probability": null}, {"id_": "ent_sig_6d565ac83996c9dce50717d5c0c22673806cab1b251c1901240fb69b436636d7", "text": "reticulocytopenia", "location": null, "probability": null}, {"id_": "ent_sig_9c1078d21e80d5ef9817e6233ac617ef9ad5bc2066d35ead654ee9ffe7a95cb7", "text": "macrocytosis", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_d039bd4718999ffad47425ab7aa360ee174b5a2509a749b8c50a04a772ad05b9", "medProdID": "ent_mep_a9d69ad7c918937eaa705fb89e86804abf5fdaae43881ee21f114e88476b88ec", "sigID": "ent_sig_55421993789198d0cb6f7cea3bd53d683b72451021dbbb7cac59257c833bb4db", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_988a3f06bf6a29414d717d73f0ec0b338ede770f02cda68ec17b5a2ae8a21d4c", "medProdID": "ent_mep_a9d69ad7c918937eaa705fb89e86804abf5fdaae43881ee21f114e88476b88ec", "sigID": "ent_sig_398925f4d9618ac4e59db61b92420b9395a0ffa76a72247d163a715ba76416ca", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_692930f64f21b78471133a5cbcfbe230df9db1a01c58fd57445d3f3acfd343e0", "medProdID": "ent_mep_a9d69ad7c918937eaa705fb89e86804abf5fdaae43881ee21f114e88476b88ec", "sigID": "ent_sig_6d565ac83996c9dce50717d5c0c22673806cab1b251c1901240fb69b436636d7", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_414175962bd891bf08f947c219bc4895e192ef2f48b61e36d89d5e8dff35720c", "medProdID": "ent_mep_a9d69ad7c918937eaa705fb89e86804abf5fdaae43881ee21f114e88476b88ec", "sigID": "ent_sig_9c1078d21e80d5ef9817e6233ac617ef9ad5bc2066d35ead654ee9ffe7a95cb7", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}, {"id_": "ent_97e9aaad8adbfb503448ad6af10281c7bb43561ef057c6c3347f6ae8b567b70f", "text": "In men treated with Siklos, reversible oligospermia or azoospermia (reduced or absent production of healthy sperm) is also very commonly seen.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_a9d69ad7c918937eaa705fb89e86804abf5fdaae43881ee21f114e88476b88ec", "text": "Siklos", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_46697a99da658520cea29ee1390a3858c65fcd44de7e61713d1a9a64558ee6a1", "text": "oligospermia", "location": null, "probability": null}, {"id_": "ent_sig_a831ca2260948f2f9aa04541cbcc6dab7a867ba56ed3c2839c9cb622f345f395", "text": "azoospermia", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_eb37a4f74618ca0844d983cd2323d93458f6e83f974c4927152b6a70a3f14907", "medProdID": "ent_mep_a9d69ad7c918937eaa705fb89e86804abf5fdaae43881ee21f114e88476b88ec", "sigID": "ent_sig_46697a99da658520cea29ee1390a3858c65fcd44de7e61713d1a9a64558ee6a1", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_5fee439a7485258777f1130e3b44ad24c724e88c291ff45e89d8bf1554a25433", "medProdID": "ent_mep_a9d69ad7c918937eaa705fb89e86804abf5fdaae43881ee21f114e88476b88ec", "sigID": "ent_sig_a831ca2260948f2f9aa04541cbcc6dab7a867ba56ed3c2839c9cb622f345f395", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_64ec2c0ea8afc09559a01c038b82ecc8db08ec0c7665177fdb70b254b48e6b74": 0, "ent_97e9aaad8adbfb503448ad6af10281c7bb43561ef057c6c3347f6ae8b567b70f": 1}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_17dd30a65393eb04d1631a7fcd187b35c7008a59bd0dcfa251d5ef496ed020c7", "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/pluvicto", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_e1530e107bbff427d583f8cf2d87b8df6cd6c42a97ba86b42ed582df712e7c44", "text": "The most common side effects with Pluvicto (which may affect more than 1 in 10 people) are tiredness, dry mouth, nausea (feeling sick), anaemia (low levels of red blood cells), decreased appetite and constipation.\nThe most common serious side effects (which may affect up to 1 in 20 people) are anaemia, thrombocytopenia (low levels of blood platelets), lymphopenia (low levels of lymphocytes, a type of white blood cell) and tiredness.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_78222ed696d63bbcf4d66410d4442992a42f09a122385ac66f6bc43342e2c103", "text": "Pluvicto", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_8b2bdeeb3bcc92fa0371527c959edff75be89ecfc1201cce378b72b43f1e0ddc", "text": "tiredness", "location": null, "probability": null}, {"id_": "ent_sig_5dcd828a4604d3fe4e9535b9628cc4df80bff3607de72e7a9ee8b6eec35ae4bf", "text": "dry mouth", "location": null, "probability": null}, {"id_": "ent_sig_a19fb2d7fadf4391f474f6e5770507ab0e4d83c2d3638aa8fa4393a66725caec", "text": " nausea", "location": null, "probability": null}, {"id_": "ent_sig_51c04d2319180c79f7ec888ad338b59e1daac4b0cd435bf781f285c33157b069", "text": "anaemia", "location": null, "probability": null}, {"id_": "ent_sig_d04cb5ad2dd1cfe8f95bd85febdef0e35fa82f340cc47c67b30bc5a3d1f89650", "text": "decreased appetite", "location": null, "probability": null}, {"id_": "ent_sig_f79c7ed641f29accf092913c66710a0997459a12412e1dfcce93f73476cf84ea", "text": "constipation", "location": null, "probability": null}, {"id_": "ent_sig_51c04d2319180c79f7ec888ad338b59e1daac4b0cd435bf781f285c33157b069", "text": "anaemia", "location": null, "probability": null}, {"id_": "ent_sig_06ea0cc5c018c11de3f1fb612ce19be6f9760ce3fce07afed1308daedf378360", "text": "thrombocytopenia", "location": null, "probability": null}, {"id_": "ent_sig_54d474312f22619ac53d8bf7a47e384de4f5d82a704896bf012671d11a3dc14f", "text": "lymphopenia", "location": null, "probability": null}, {"id_": "ent_sig_8b2bdeeb3bcc92fa0371527c959edff75be89ecfc1201cce378b72b43f1e0ddc", "text": "tiredness", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_61fe793a8b1eaf5b22e4c99ea22f14e24d58ecd5ad559a3b8a09dbee7a6ef137", "medProdID": "ent_mep_78222ed696d63bbcf4d66410d4442992a42f09a122385ac66f6bc43342e2c103", "sigID": "ent_sig_8b2bdeeb3bcc92fa0371527c959edff75be89ecfc1201cce378b72b43f1e0ddc", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_e3cc475a7e07e19906ff06daa7390e9082e8e0a95824cea0e2aef5840a3cebb1", "medProdID": "ent_mep_78222ed696d63bbcf4d66410d4442992a42f09a122385ac66f6bc43342e2c103", "sigID": "ent_sig_5dcd828a4604d3fe4e9535b9628cc4df80bff3607de72e7a9ee8b6eec35ae4bf", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_b5d5950556034fba65157a0318f080c291f8c1f5d977ea456e199d2699439c88", "medProdID": "ent_mep_78222ed696d63bbcf4d66410d4442992a42f09a122385ac66f6bc43342e2c103", "sigID": "ent_sig_a19fb2d7fadf4391f474f6e5770507ab0e4d83c2d3638aa8fa4393a66725caec", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_26626510884d3c549bf5592c85bf3fab2db91ae2cfcc0a33828afa3e739d3e8b", "medProdID": "ent_mep_78222ed696d63bbcf4d66410d4442992a42f09a122385ac66f6bc43342e2c103", "sigID": "ent_sig_51c04d2319180c79f7ec888ad338b59e1daac4b0cd435bf781f285c33157b069", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_31d3085d0badbaf7065a6dc41e4135aedda819f5ba1c5731b21329f2015a3477", "medProdID": "ent_mep_78222ed696d63bbcf4d66410d4442992a42f09a122385ac66f6bc43342e2c103", "sigID": "ent_sig_d04cb5ad2dd1cfe8f95bd85febdef0e35fa82f340cc47c67b30bc5a3d1f89650", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_d77ad2d231cefedcb308b8a8a3ba5efba4741e0401a31a67c661ba453ffebeb2", "medProdID": "ent_mep_78222ed696d63bbcf4d66410d4442992a42f09a122385ac66f6bc43342e2c103", "sigID": "ent_sig_f79c7ed641f29accf092913c66710a0997459a12412e1dfcce93f73476cf84ea", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_26626510884d3c549bf5592c85bf3fab2db91ae2cfcc0a33828afa3e739d3e8b", "medProdID": "ent_mep_78222ed696d63bbcf4d66410d4442992a42f09a122385ac66f6bc43342e2c103", "sigID": "ent_sig_51c04d2319180c79f7ec888ad338b59e1daac4b0cd435bf781f285c33157b069", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_dd47636d990891efc489e33b4f297b819cd3aa885e4fb275905ac234e8cab206", "medProdID": "ent_mep_78222ed696d63bbcf4d66410d4442992a42f09a122385ac66f6bc43342e2c103", "sigID": "ent_sig_06ea0cc5c018c11de3f1fb612ce19be6f9760ce3fce07afed1308daedf378360", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_50e47aa3c6b6e10dc6a31e078e3471c99b4b957123ae51f4ab74d83e420a00cc", "medProdID": "ent_mep_78222ed696d63bbcf4d66410d4442992a42f09a122385ac66f6bc43342e2c103", "sigID": "ent_sig_54d474312f22619ac53d8bf7a47e384de4f5d82a704896bf012671d11a3dc14f", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_61fe793a8b1eaf5b22e4c99ea22f14e24d58ecd5ad559a3b8a09dbee7a6ef137", "medProdID": "ent_mep_78222ed696d63bbcf4d66410d4442992a42f09a122385ac66f6bc43342e2c103", "sigID": "ent_sig_8b2bdeeb3bcc92fa0371527c959edff75be89ecfc1201cce378b72b43f1e0ddc", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_e1530e107bbff427d583f8cf2d87b8df6cd6c42a97ba86b42ed582df712e7c44": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_c21280009b21cf6ac1eb023b4a839828f8f7d35b9ff37b26b2fe6ef7c61573c3", "url": "https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-28-november-1-december-2022", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_c697b55c0a10736de0fa9bb4e55e428cf49696a8a5577fc1175cc4ca184386f1", "text": "The available data showed that use of pholcodine in the 12 months before general anaesthesia with neuromuscular blocking agents (NMBA) is a risk factor for developing an anaphylactic reaction (a sudden, severe and life-threatening allergic reaction) to NMBAs.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_3d0f0483d4ef84e9a3d313e6015695065959ab8a31f5ff569fe860d1895acb80", "text": "pholcodine", "location": null, "probability": null}, {"id_": "ent_mep_93a5493661314598fa25d5cc8725348e474702d66cb05d34c804774a5ef02c6e", "text": "neuromuscular blocking agents (NMBA)", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_68c91cc87da00affe1d14b7e3eeaf76ac6d85a9fff9ad2bc8bf040f7d3b68440", "text": "anaphylactic reaction (a sudden, severe and life-threatening allergic reaction)", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_4c09dcc5dda4457c8afcde30b44cfb9335a5c732541848f54c752beb694161ab", "medProdID": "ent_mep_3d0f0483d4ef84e9a3d313e6015695065959ab8a31f5ff569fe860d1895acb80", "sigID": "ent_sig_68c91cc87da00affe1d14b7e3eeaf76ac6d85a9fff9ad2bc8bf040f7d3b68440", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_5aef8439afdb380b5a024f8325040ed4f0160de9d0858742e4bcd6bb8eaa0661", "medProdID": "ent_mep_93a5493661314598fa25d5cc8725348e474702d66cb05d34c804774a5ef02c6e", "sigID": "ent_sig_68c91cc87da00affe1d14b7e3eeaf76ac6d85a9fff9ad2bc8bf040f7d3b68440", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_c697b55c0a10736de0fa9bb4e55e428cf49696a8a5577fc1175cc4ca184386f1": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_fa18f6fbf4db01618e419e858098ab58dbaadd66f78198bc19d70bb8b478f3b4", "url": "https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-9-12-january-2023", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_3c9659ade6b967a228ad10a4e2fae485c4000c7134ffc62f3e17681887b436eb", "text": "Fatal cases of acute liver failure were recently reported in patients treated with Zolgensma (onasemnogene abeparvovec), a gene therapy medicine for the treatment of spinal muscular atrophy (SMA), a serious rare condition of the nerves that causes muscle wasting and weakness.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_3b13a4b75109bbf3e2d900892a7df9c45bf9e90079d609d5daaafe4e9c837deb", "text": "Zolgensma", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_1abc7866da13be83000fab4c44c0d70ae645d25e45e3f4d7e9e12b949d9a61de", "text": "acute liver failure", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_5b77afff27798cba4197327d2086b78f0973126591c8d47f8485c123bc3421c6", "medProdID": "ent_mep_3b13a4b75109bbf3e2d900892a7df9c45bf9e90079d609d5daaafe4e9c837deb", "sigID": "ent_sig_1abc7866da13be83000fab4c44c0d70ae645d25e45e3f4d7e9e12b949d9a61de", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_3c9659ade6b967a228ad10a4e2fae485c4000c7134ffc62f3e17681887b436eb": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_d6f9be8cb06eae4d0a250f51b4f9ab384bb054cf5bb3192fc0539fcaeec85430", "url": "https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-24-27-october-2022", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_9c999d810ca59246b6363218a2663be67d3665f6b960fe450446f4f63e980c05", "text": "The PRAC has confirmed its recommendation to withdraw the marketing authorisations for amfepramone obesity medicines. It found that the medicines were being used for longer than the recommended maximum period of 3 months, thereby potentially increasing the risk of serious side effects, such as pulmonary arterial hypertension (high blood pressure in the lungs) and dependency. The medicines were also being used in patients with a history of heart disease or psychiatric disorders, increasing their risk of heart and psychiatric problems. In addition, there was evidence of use during pregnancy, which could pose risks to the unborn baby.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_c4d84f732a823cc84c799ccb768a4ea09e05a61ef28542565b4a7dde82aac117", "text": "amfepramone obesity medicines", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_3c4360b587d12f9286b49418785d3831e9f8368d1f8c77fd85c0f5711cf116df", "text": "pulmonary arterial hypertension", "location": null, "probability": null}, {"id_": "ent_sig_f26350dafe3f19aabfd69ac463fb5daf76015c9a2763e76e2ad32fc0fcfedf31", "text": "dependency", "location": null, "probability": null}, {"id_": "ent_sig_addbd9af436dfd3aee1083a3d126ee867fdb1640c0b78747a5c97d0079022a4a", "text": "heart and psychiatric problems", "location": null, "probability": null}, {"id_": "ent_sig_58421e5bdffab103a932d0361ec1bbb87590301db800ee454d6bdbbfc038fb78", "text": "risks to the unborn baby", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_8df908811e9367d2f12bcf0afe83d56cd63aae9f9a21a98614a3557d8b47faac", "medProdID": "ent_mep_c4d84f732a823cc84c799ccb768a4ea09e05a61ef28542565b4a7dde82aac117", "sigID": "ent_sig_3c4360b587d12f9286b49418785d3831e9f8368d1f8c77fd85c0f5711cf116df", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_510c3c0a362ead0351be9f7fddb4b4c762bfdfe3e2be8fb3b734624107de50ce", "medProdID": "ent_mep_c4d84f732a823cc84c799ccb768a4ea09e05a61ef28542565b4a7dde82aac117", "sigID": "ent_sig_f26350dafe3f19aabfd69ac463fb5daf76015c9a2763e76e2ad32fc0fcfedf31", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_ec1ad96fcb652ce034036615796dd4c670d4c88b0ef328bcc1b46da38b457e56", "medProdID": "ent_mep_c4d84f732a823cc84c799ccb768a4ea09e05a61ef28542565b4a7dde82aac117", "sigID": "ent_sig_addbd9af436dfd3aee1083a3d126ee867fdb1640c0b78747a5c97d0079022a4a", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_77cb1e196209e8830df07c799bb994140a8837eb3c70c33294feeb3049658e91", "medProdID": "ent_mep_c4d84f732a823cc84c799ccb768a4ea09e05a61ef28542565b4a7dde82aac117", "sigID": "ent_sig_58421e5bdffab103a932d0361ec1bbb87590301db800ee454d6bdbbfc038fb78", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_9c999d810ca59246b6363218a2663be67d3665f6b960fe450446f4f63e980c05": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_82372ceb5f21c4be6ac64b5cb50c5a522c6d153d0cfbdaafb46cf9cfc6ceb9f3", "url": "https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-29-august-1-september-2022", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_6be974a434a196a76645852dae5547718aa80dc8094d66dd2795f39575d1154c", "text": "Use of topiramate in pregnant women is known to increase the risk of birth defects.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_99b797b65414a228aa430fe91cd6560e1c6bd38452848f3c12ec859035c41dcd", "text": "topiramate", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_c0bfc0722374a313be1a7a14d3b59ee88be3fb97eedcd7ea6f3e3c04d0532324", "text": "birth defects", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_e549b1add8aff4c147fa11fe1da8431a0e16c6bfe5599660350fa6903a0d46d1", "medProdID": "ent_mep_99b797b65414a228aa430fe91cd6560e1c6bd38452848f3c12ec859035c41dcd", "sigID": "ent_sig_c0bfc0722374a313be1a7a14d3b59ee88be3fb97eedcd7ea6f3e3c04d0532324", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}, {"id_": "ent_8b08bb75a9b9a4db547d636002d3f6980bc66eacd2d55eff6d68785843b71656", "text": "The review was triggered by a recent study1 which suggested a possible increase in the risk of neurodevelopmental disorders, in particular autism spectrum disorders and intellectual disability, in children whose mothers were taking topiramate during pregnancy.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_99b797b65414a228aa430fe91cd6560e1c6bd38452848f3c12ec859035c41dcd", "text": "topiramate", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_ac6d0296791056b1a58fd6e768e630de99515afb883b2fc078fba3adc1dd451c", "text": "neurodevelopmental disorders", "location": null, "probability": null}, {"id_": "ent_sig_3eabc5497c4c0d55db1d7c3b572335b0aec0604342598651d307fe0c9cab7882", "text": "autism spectrum disorders", "location": null, "probability": null}, {"id_": "ent_sig_5e4b1da51206488d42f920b3d8514b7d5ec44bd9d54e64d73e3db93e842a5478", "text": "intellectual disability", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_d17e6b57e72c719f71a6db7d2f188eae9d5bbf95635b90549f9cbba91bd55172", "medProdID": "ent_mep_99b797b65414a228aa430fe91cd6560e1c6bd38452848f3c12ec859035c41dcd", "sigID": "ent_sig_ac6d0296791056b1a58fd6e768e630de99515afb883b2fc078fba3adc1dd451c", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_6e2f192cab2aa3d7029a4b5cf01f9c16a67eb0bd6cb891147f91faf881d6822a", "medProdID": "ent_mep_99b797b65414a228aa430fe91cd6560e1c6bd38452848f3c12ec859035c41dcd", "sigID": "ent_sig_3eabc5497c4c0d55db1d7c3b572335b0aec0604342598651d307fe0c9cab7882", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_b435367965cf30b856b4e7e45b4dcb0a1b5327f1c6c902c788219784cd0ce256", "medProdID": "ent_mep_99b797b65414a228aa430fe91cd6560e1c6bd38452848f3c12ec859035c41dcd", "sigID": "ent_sig_5e4b1da51206488d42f920b3d8514b7d5ec44bd9d54e64d73e3db93e842a5478", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_6be974a434a196a76645852dae5547718aa80dc8094d66dd2795f39575d1154c": 0, "ent_8b08bb75a9b9a4db547d636002d3f6980bc66eacd2d55eff6d68785843b71656": 1}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_25d98561b6ad09fa92d112374bd4cf10a8befc0a718178ecd366a09555e76b38", "url": "https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-26-29-september-2022", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_84aa163c3c45882404ecd521709ece33b84443c7fb4f89d66d39fdc0c49c3570", "text": "The PRAC found that, when taken at higher than recommended doses or for a prolonged period of time, codeine with ibuprofen can cause damage to the kidneys, preventing them from removing acids properly from the blood into the urine (renal tubular acidosis). Kidney malfunction can also cause very low levels of potassium in the blood (hypokalaemia), which in turn may cause symptoms such as muscle weakness and light-headedness.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_2799aaf63fda7b827cf4876c6821a6a5cd259e4fadc66ecc784054668dca6db1", "text": "codeine with ibuprofen", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_89308dc461eb0da20db842e3787a889b78c7ef70872c90ac8ce6d002b269f194", "text": "damage to the kidneys", "location": null, "probability": null}, {"id_": "ent_sig_4ac8d64478455f2ddd40e4157966ba6331fd366755ed09a0d7be80448a5843dd", "text": "muscle weakness", "location": null, "probability": null}, {"id_": "ent_sig_5ffedabd3420ec1a1da31fbff3c6cbfdf1dda289a107a3ba09efd455db2ce238", "text": "light-headedness", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_18a7d8ead6500a54709dce7afbf4de12a0cb1c320fae2eb4aeaa80da40b88741", "medProdID": "ent_mep_2799aaf63fda7b827cf4876c6821a6a5cd259e4fadc66ecc784054668dca6db1", "sigID": "ent_sig_89308dc461eb0da20db842e3787a889b78c7ef70872c90ac8ce6d002b269f194", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_eb86bc6681a7876fa6a68ed3b058a3a0166060d1d733fa5184a11647694f2b97", "medProdID": "ent_mep_2799aaf63fda7b827cf4876c6821a6a5cd259e4fadc66ecc784054668dca6db1", "sigID": "ent_sig_4ac8d64478455f2ddd40e4157966ba6331fd366755ed09a0d7be80448a5843dd", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_b74a72ee1c22d1933b3f7a445d71dedc2ddea5c9a7add2abce28a68d342bc63b", "medProdID": "ent_mep_2799aaf63fda7b827cf4876c6821a6a5cd259e4fadc66ecc784054668dca6db1", "sigID": "ent_sig_5ffedabd3420ec1a1da31fbff3c6cbfdf1dda289a107a3ba09efd455db2ce238", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}, {"id_": "ent_c2d13126cb6962a2272daf796b4dfa756600a80e1677a91659a1cfd6cbf42c42", "text": "The PRAC has recommended a change to the product information for codeine with ibuprofen combination medicines to include a warning of serious harms, including death, particularly when taken for prolonged periods at higher than recommended doses.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_2799aaf63fda7b827cf4876c6821a6a5cd259e4fadc66ecc784054668dca6db1", "text": "codeine with ibuprofen", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_52c8e02987ccb1b0eef9c7c966aebf03c92a159aafda37fbcf03f4838dbcd48d", "text": "death", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_bb3ae9cc189b57b1197f0caa9b3a84d2a0e5dff9a7a7a49022abb2b0b73fee75", "medProdID": "ent_mep_2799aaf63fda7b827cf4876c6821a6a5cd259e4fadc66ecc784054668dca6db1", "sigID": "ent_sig_52c8e02987ccb1b0eef9c7c966aebf03c92a159aafda37fbcf03f4838dbcd48d", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_84aa163c3c45882404ecd521709ece33b84443c7fb4f89d66d39fdc0c49c3570": 0, "ent_c2d13126cb6962a2272daf796b4dfa756600a80e1677a91659a1cfd6cbf42c42": 1}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_f88d7398c09fd289d70109305def8f998539dcd2bfc886fe1b1aa2e44db36ab8", "url": "https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-24-27-october-2022-prac_en.pdf", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_e69f2bbcdcadd2f6d8070eed15173d1ebbaae38776f6c1444e13b5e1221de5fa", "text": "Based on the available evidence it is considered that a causal relationship between myelitis transverse and durvalumab is at least a reasonable possibility [\u2026].\nAttention: there are also relavant information in tables, currently out of scope?", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_a8c0108ba96a95a52c2cd16e5df0b274a4b4de00318cbac969a39ade37687de7", "text": "durvalumab", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_19b23c7848de18b9d50ac27eba21f81f3beae92fbf2541aa080bab17d86cabdd", "text": "myelitis transverse", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_b58387e3bee64f1edaf85238a752b94c54850e4fa44b5b9b2a3cc9ba8bc2373b", "medProdID": "ent_mep_a8c0108ba96a95a52c2cd16e5df0b274a4b4de00318cbac969a39ade37687de7", "sigID": "ent_sig_19b23c7848de18b9d50ac27eba21f81f3beae92fbf2541aa080bab17d86cabdd", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_e69f2bbcdcadd2f6d8070eed15173d1ebbaae38776f6c1444e13b5e1221de5fa": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_5f04eda98b0675358383d1bc2f19568c9c3e3609e8c9e5c3630bb5a5db8c32fa", "url": "https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022_en.pdf", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_60c9096ce3ab70119572b780a4b4f326fc917d0f3bf306700c201846b7257912", "text": "Given the mechanism of action of IMFINZI, other potential immune-mediated adverse reactions may occur. The following immune-related adverse reactions have been observed in patients treated with IMFINZI monotherapy: myasthenia gravis, myelitis transverse, myositis, polymyositis, meningitis, encephalitis, Guillain-Barr\u00e9 syndrome, immune thrombocytopenia, cystitis noninfective and pancreatitis (see section 4.8). [\u2026]", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_058654150662543ed40526da7faf6bbf8460c74f683c3d169d7a585279f24f3b", "text": "IMFINZI", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_8d0b2626049fe76369cae8ebb69e6d80339a0a26547ffc905a84f68212843f9f", "text": "immune-mediated adverse reactions", "location": null, "probability": null}, {"id_": "ent_sig_76df5f197fc8800a316e04722d00b1444001ea8ead304684b7645ca3ac298e64", "text": "myasthenia gravis", "location": null, "probability": null}, {"id_": "ent_sig_19b23c7848de18b9d50ac27eba21f81f3beae92fbf2541aa080bab17d86cabdd", "text": "myelitis transverse", "location": null, "probability": null}, {"id_": "ent_sig_17fde6016837073efa954cdf43cfa182f6849448f94d7ca29db4f03fbf27e095", "text": "myositis", "location": null, "probability": null}, {"id_": "ent_sig_90cf16d0ff3bdc4f924c3d8755d8b3871ec15f97fc5b18dd381af14119cf6151", "text": "polymyositis", "location": null, "probability": null}, {"id_": "ent_sig_d17319f88b572f2313342402d4fc5039f44993aaa5e5e47f97f54a4f721403f1", "text": "meningitis", "location": null, "probability": null}, {"id_": "ent_sig_b321a717098c13654047fbfbd7ade04b484238d08972c8d320d4d5e792680ab2", "text": "encephalitis", "location": null, "probability": null}, {"id_": "ent_sig_c69437e951bb4dbccddf835e20eb7299168df941697310d91905c807a853674d", "text": "Guillain-Barr\u00e9 syndrome", "location": null, "probability": null}, {"id_": "ent_sig_b9e10d1c71424f6662a36c3ce3fecccff8fa5d885b8cba8237277e640adf295d", "text": "immune thrombocytopenia", "location": null, "probability": null}, {"id_": "ent_sig_4f42b17c793dbf1fdcee0cab2f7f37fe2ffe6ac5406a37cd023fd8cf9b50957a", "text": "cystitis noninfective", "location": null, "probability": null}, {"id_": "ent_sig_7b1ac0d911c7d3a7c6f5591a148dc33f38c25c71a1fadb68b1c1923a4d4d2c8a", "text": "pancreatitis", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_10b409ed3e83012f968e88cf1f5ab017a9fefc45801e4cc91acc032e269a3c13", "medProdID": "ent_mep_058654150662543ed40526da7faf6bbf8460c74f683c3d169d7a585279f24f3b", "sigID": "ent_sig_8d0b2626049fe76369cae8ebb69e6d80339a0a26547ffc905a84f68212843f9f", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_b1db69973f8fd1e9503f973692b43b9eb12f2d3f5b677b2ec11027a41ff934c2", "medProdID": "ent_mep_058654150662543ed40526da7faf6bbf8460c74f683c3d169d7a585279f24f3b", "sigID": "ent_sig_76df5f197fc8800a316e04722d00b1444001ea8ead304684b7645ca3ac298e64", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_6090a32b514aa1fb72201310a2aa1b3ae0abe56b5179e71a0a8e3a27344903ca", "medProdID": "ent_mep_058654150662543ed40526da7faf6bbf8460c74f683c3d169d7a585279f24f3b", "sigID": "ent_sig_19b23c7848de18b9d50ac27eba21f81f3beae92fbf2541aa080bab17d86cabdd", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_e4c99af73c28465b5b9da8272443d57b601bf681c72cfabc01f59359084af3a2", "medProdID": "ent_mep_058654150662543ed40526da7faf6bbf8460c74f683c3d169d7a585279f24f3b", "sigID": "ent_sig_17fde6016837073efa954cdf43cfa182f6849448f94d7ca29db4f03fbf27e095", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_de76c1ea79650a6b3c9f339207d58923aa684c4b3d63b296205b123237c51040", "medProdID": "ent_mep_058654150662543ed40526da7faf6bbf8460c74f683c3d169d7a585279f24f3b", "sigID": "ent_sig_90cf16d0ff3bdc4f924c3d8755d8b3871ec15f97fc5b18dd381af14119cf6151", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_6fcc1992eeb2c14f7f2218ac6591d7014aa12b282252bd6ae6cb664dd55205b3", "medProdID": "ent_mep_058654150662543ed40526da7faf6bbf8460c74f683c3d169d7a585279f24f3b", "sigID": "ent_sig_d17319f88b572f2313342402d4fc5039f44993aaa5e5e47f97f54a4f721403f1", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_e3371af53dc15b53904bd7d6e14be910705b55b02fb1b7c8c0a9beac7e59e4d2", "medProdID": "ent_mep_058654150662543ed40526da7faf6bbf8460c74f683c3d169d7a585279f24f3b", "sigID": "ent_sig_b321a717098c13654047fbfbd7ade04b484238d08972c8d320d4d5e792680ab2", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_9f2d943705aa6febd811f4f8214af378a084a0fa5d622b2d5ab97a3c3f82a7bf", "medProdID": "ent_mep_058654150662543ed40526da7faf6bbf8460c74f683c3d169d7a585279f24f3b", "sigID": "ent_sig_c69437e951bb4dbccddf835e20eb7299168df941697310d91905c807a853674d", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_80f16c568cd2096033c7a428d166b60fd64372596cee99304302eb18ac5bce14", "medProdID": "ent_mep_058654150662543ed40526da7faf6bbf8460c74f683c3d169d7a585279f24f3b", "sigID": "ent_sig_b9e10d1c71424f6662a36c3ce3fecccff8fa5d885b8cba8237277e640adf295d", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_be9405591202d8ff1a5a97d98881483dc01e80ab710a3ad711512115c00b7da5", "medProdID": "ent_mep_058654150662543ed40526da7faf6bbf8460c74f683c3d169d7a585279f24f3b", "sigID": "ent_sig_4f42b17c793dbf1fdcee0cab2f7f37fe2ffe6ac5406a37cd023fd8cf9b50957a", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_ce27f02417c5c21119ae7aa288ffab2ff6346acf7b7813169904720b2089f45a", "medProdID": "ent_mep_058654150662543ed40526da7faf6bbf8460c74f683c3d169d7a585279f24f3b", "sigID": "ent_sig_7b1ac0d911c7d3a7c6f5591a148dc33f38c25c71a1fadb68b1c1923a4d4d2c8a", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_60c9096ce3ab70119572b780a4b4f326fc917d0f3bf306700c201846b7257912": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_3ce00465d55adea44eedebd45c254064b6643217dcbf50e6f197cb06c360d234", "url": "https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_en.pdf", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_e2d22ae43f5733e7215e39b006c49e64e2e908c2c42aceefdca5f1e01e7f1394", "text": "Severe hypokalaemia and renal tubular acidosis have been reported due to prolonged use of ibuprofen at higher than recommended doses. This risk is increased with the use of codeine/ibuprofen as patients may become dependent on the codeine component (see warning on Opioid use disorder, section 4.8 and section 4.9). Presenting signs and symptoms included reduced level of consciousness and generalised weakness. ", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_a7f187a6f4f060d524a66aec16bf9a61c37ad5628df0f7b1ee3aa91b34f6da52", "text": "ibuprofen", "location": null, "probability": null}, {"id_": "ent_mep_917bc6e70a3eb757646836529bbbf88f9fd9654a0960e8f08264fce23976ed0e", "text": "codeine", "location": null, "probability": null}, {"id_": "ent_mep_a7f187a6f4f060d524a66aec16bf9a61c37ad5628df0f7b1ee3aa91b34f6da52", "text": "ibuprofen", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_1524432f43ee53c104c4d565c53b7ef695b87af3f7c1793eac068e0454f2f7f9", "text": "hypokalaemia", "location": null, "probability": null}, {"id_": "ent_sig_00de11f3bdc5e27e6fb92fddcd232707cd589c543cfecc5868c8995ca774711e", "text": "renal tubular acidosis", "location": null, "probability": null}, {"id_": "ent_sig_75846e529667722d646a18ae052b393391cfe1ffe98c45f2952a63723938c003", "text": "dependent", "location": null, "probability": null}, {"id_": "ent_sig_7a7b18e5203d087b42956943a329a497df057a16ca958642616afcc9b3dd349b", "text": "reduced level of consciousness", "location": null, "probability": null}, {"id_": "ent_sig_5a3d2495495859fd2ed5d66ee4189a87705f0c49e67bebc56b83096af18bf612", "text": "generalised weakness", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_bc964c055471c81abb0a95bd44f10c174c471e7b0d54b96b51449c0e8a80822c", "medProdID": "ent_mep_a7f187a6f4f060d524a66aec16bf9a61c37ad5628df0f7b1ee3aa91b34f6da52", "sigID": "ent_sig_1524432f43ee53c104c4d565c53b7ef695b87af3f7c1793eac068e0454f2f7f9", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_113bd68bbe630448138cf256cb2e1e64a85cf2cb4501f9560bb299f6b67f1522", "medProdID": "ent_mep_a7f187a6f4f060d524a66aec16bf9a61c37ad5628df0f7b1ee3aa91b34f6da52", "sigID": "ent_sig_00de11f3bdc5e27e6fb92fddcd232707cd589c543cfecc5868c8995ca774711e", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_4e7651fea5478d89425d3abd64305ba0ba45a6b48f3a2c6683a3d6ea7dfed16c", "medProdID": "ent_mep_a7f187a6f4f060d524a66aec16bf9a61c37ad5628df0f7b1ee3aa91b34f6da52", "sigID": "ent_sig_75846e529667722d646a18ae052b393391cfe1ffe98c45f2952a63723938c003", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_99328612e70d5da6096d0169a508d3cbddeaac250de51bc986273f5be89b1a03", "medProdID": "ent_mep_a7f187a6f4f060d524a66aec16bf9a61c37ad5628df0f7b1ee3aa91b34f6da52", "sigID": "ent_sig_7a7b18e5203d087b42956943a329a497df057a16ca958642616afcc9b3dd349b", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_384615697381a6e3b1f2409dd7a55e7ccbcf5c8156597516995c5007cc092eb0", "medProdID": "ent_mep_a7f187a6f4f060d524a66aec16bf9a61c37ad5628df0f7b1ee3aa91b34f6da52", "sigID": "ent_sig_5a3d2495495859fd2ed5d66ee4189a87705f0c49e67bebc56b83096af18bf612", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_860f3fea81893e6c52dd538a9e18c9fcf119a29d8f7e407dd5d41be7a2438196", "medProdID": "ent_mep_917bc6e70a3eb757646836529bbbf88f9fd9654a0960e8f08264fce23976ed0e", "sigID": "ent_sig_1524432f43ee53c104c4d565c53b7ef695b87af3f7c1793eac068e0454f2f7f9", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_8332372dffe494c3582b02d28911b3147e7716fd9b5e35ffce9ee25189c687c0", "medProdID": "ent_mep_917bc6e70a3eb757646836529bbbf88f9fd9654a0960e8f08264fce23976ed0e", "sigID": "ent_sig_00de11f3bdc5e27e6fb92fddcd232707cd589c543cfecc5868c8995ca774711e", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_6655f919077df87c6f60963c357e886cf31d94f179479b241eb8b8ecdcb7714f", "medProdID": "ent_mep_917bc6e70a3eb757646836529bbbf88f9fd9654a0960e8f08264fce23976ed0e", "sigID": "ent_sig_75846e529667722d646a18ae052b393391cfe1ffe98c45f2952a63723938c003", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_53bfd55854fcb82d475578f9a71adbde7e9fa30c003000b0ebb57335f532d18a", "medProdID": "ent_mep_917bc6e70a3eb757646836529bbbf88f9fd9654a0960e8f08264fce23976ed0e", "sigID": "ent_sig_7a7b18e5203d087b42956943a329a497df057a16ca958642616afcc9b3dd349b", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_3b8dab981b21fdf158ce02df55e0b43f74e8c48eb392f1a7af02426900e50e30", "medProdID": "ent_mep_917bc6e70a3eb757646836529bbbf88f9fd9654a0960e8f08264fce23976ed0e", "sigID": "ent_sig_5a3d2495495859fd2ed5d66ee4189a87705f0c49e67bebc56b83096af18bf612", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_bc964c055471c81abb0a95bd44f10c174c471e7b0d54b96b51449c0e8a80822c", "medProdID": "ent_mep_a7f187a6f4f060d524a66aec16bf9a61c37ad5628df0f7b1ee3aa91b34f6da52", "sigID": "ent_sig_1524432f43ee53c104c4d565c53b7ef695b87af3f7c1793eac068e0454f2f7f9", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_113bd68bbe630448138cf256cb2e1e64a85cf2cb4501f9560bb299f6b67f1522", "medProdID": "ent_mep_a7f187a6f4f060d524a66aec16bf9a61c37ad5628df0f7b1ee3aa91b34f6da52", "sigID": "ent_sig_00de11f3bdc5e27e6fb92fddcd232707cd589c543cfecc5868c8995ca774711e", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_4e7651fea5478d89425d3abd64305ba0ba45a6b48f3a2c6683a3d6ea7dfed16c", "medProdID": "ent_mep_a7f187a6f4f060d524a66aec16bf9a61c37ad5628df0f7b1ee3aa91b34f6da52", "sigID": "ent_sig_75846e529667722d646a18ae052b393391cfe1ffe98c45f2952a63723938c003", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_99328612e70d5da6096d0169a508d3cbddeaac250de51bc986273f5be89b1a03", "medProdID": "ent_mep_a7f187a6f4f060d524a66aec16bf9a61c37ad5628df0f7b1ee3aa91b34f6da52", "sigID": "ent_sig_7a7b18e5203d087b42956943a329a497df057a16ca958642616afcc9b3dd349b", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_384615697381a6e3b1f2409dd7a55e7ccbcf5c8156597516995c5007cc092eb0", "medProdID": "ent_mep_a7f187a6f4f060d524a66aec16bf9a61c37ad5628df0f7b1ee3aa91b34f6da52", "sigID": "ent_sig_5a3d2495495859fd2ed5d66ee4189a87705f0c49e67bebc56b83096af18bf612", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}, {"id_": "ent_959d538c6952fe34674a75c6c607ff93762892b260c518c37197202b4f2dce54", "text": "Ibuprofen induced renal tubular acidosis should be considered in patients with unexplained hypokalaemia and metabolic acidosis.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_385b3a48652b5a4cf223c574aa9a0faedeb18ba276ef05008b9e9e4b59ca20b6", "text": "Ibuprofen", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_494abcf7821617b9cddb8347ffdd5ba271c2d1a966863bf8409462ea5012922c", "text": "renal tubular", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_9253ba6c071ea4949bd65fc69208d9507010bad784415f41dbcdc3eb2a7ee266", "medProdID": "ent_mep_385b3a48652b5a4cf223c574aa9a0faedeb18ba276ef05008b9e9e4b59ca20b6", "sigID": "ent_sig_494abcf7821617b9cddb8347ffdd5ba271c2d1a966863bf8409462ea5012922c", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_e2d22ae43f5733e7215e39b006c49e64e2e908c2c42aceefdca5f1e01e7f1394": 0, "ent_959d538c6952fe34674a75c6c607ff93762892b260c518c37197202b4f2dce54": 1}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_b27601e6d1e7a2646f9ead6a2e5b832edfcb0f1b6e3fb14ddf1312c0b4883586", "url": "https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-4-7-july-2022-prac-meeting_en.pdf", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_e723be8473f2840be8f2cb1d71a51bda1eb2c3c2f8c3623c55ea26064c2e40e3", "text": "table: Cetuximab\nNephrotic syndrome", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_905db75ddbd6a6a0260dcb052ccc61ec4418869df1ef1286b86ac3637d11508c", "text": "Cetuximab", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_4f1d119ebcd6fb2896ef4df0aa87229bed290501d38b769ae0455c374503c3f6", "text": "Nephrotic syndrome", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_abd0c7cf0e0f0455c73ef9de3e3be2d8312ecf098545080ce5eb383ded58e1df", "medProdID": "ent_mep_905db75ddbd6a6a0260dcb052ccc61ec4418869df1ef1286b86ac3637d11508c", "sigID": "ent_sig_4f1d119ebcd6fb2896ef4df0aa87229bed290501d38b769ae0455c374503c3f6", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_e723be8473f2840be8f2cb1d71a51bda1eb2c3c2f8c3623c55ea26064c2e40e3": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_c83ba0a60160c7763527fed18f0840f48a87a3348ca2fcf524fa1814e7ed7a72", "url": "https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-7-10-march-2022-prac-meeting_en.pdf", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_89231a5d4aced3847c2f1395c4db8c3de359b85d48dbc0bb16a94e41ff4af885", "text": "There have been reports of increased blood levels of another calcineurin inhibitor during concomitant use with cannabidiol.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_763c6035768bc0aa490cd95e93c5ac7584626e02207504e8928d533622cb3370", "text": "cannabidiol", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_9da3c898827ae43716653809ccd43b328df45f08e8e977812687a4e1563516d8", "text": "increased blood levels of another calcineurin inhibitor", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_e963dcf0091e49a0f9a4f0181ec7cd77e1fb96923259bc17c5383c56226b6c71", "medProdID": "ent_mep_763c6035768bc0aa490cd95e93c5ac7584626e02207504e8928d533622cb3370", "sigID": "ent_sig_9da3c898827ae43716653809ccd43b328df45f08e8e977812687a4e1563516d8", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_89231a5d4aced3847c2f1395c4db8c3de359b85d48dbc0bb16a94e41ff4af885": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_10af0b3f20f3911ef236e6ffc0b4ac7f476d08cf501631dacbd6c83b8d72aef3", "url": "https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-terlipressin-serious-fatal-respiratory-failure/septic-shock-patients-type-1-hepatorenal-syndrome-type-1-hrs_en.pdf", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_f8c4bec2c4218ed65d8830ac361f9b1264c5f082cc1b6a6b976a9265ed09a39d", "text": "Terlipressin: Serious or fatal respiratory failure and sepsis/septic shock in patients with type 1 hepatorenal syndrome (type 1 HRS)", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_0de7f9832bf4f08086dea4f49f3e68214757e432f049820585419c207231615e", "text": "Terlipressin", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_eef05b885ea552f7457d4a2c910e9c8fc6edc5812aafacbb91fa564195080e1f", "text": "Serious or fatal respiratory failure", "location": null, "probability": null}, {"id_": "ent_sig_ea5a5217ed4195f6eaff51399042f5b5cc7ed0f6ea21466f9d36630f49e2ff95", "text": "sepsis/septic shock", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_751d1675154ec6f0bdd5bc0ab255bd40760b0002dbfec19098c963ff1c75da7b", "medProdID": "ent_mep_0de7f9832bf4f08086dea4f49f3e68214757e432f049820585419c207231615e", "sigID": "ent_sig_eef05b885ea552f7457d4a2c910e9c8fc6edc5812aafacbb91fa564195080e1f", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_429a85c87fe2a8ff02a96d2ea13ec21a014e3215354cb26760586b2c68e03621", "medProdID": "ent_mep_0de7f9832bf4f08086dea4f49f3e68214757e432f049820585419c207231615e", "sigID": "ent_sig_ea5a5217ed4195f6eaff51399042f5b5cc7ed0f6ea21466f9d36630f49e2ff95", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_f8c4bec2c4218ed65d8830ac361f9b1264c5f082cc1b6a6b976a9265ed09a39d": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_04a87096203cbc1febc8b79554234d667af0af41238da4c4505defda0be7043b", "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/karvezide", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_d0b3b56ae2beba7fff924a01bef826147be9f764af93ad642fdf2d03d14479e0", "text": "The most common side effects with Karvezide (seen in between 1 and 10 patients in 100) are dizziness, nausea (feeling sick) or vomiting, abnormal urination, fatigue (tiredness), and increases in blood urea nitrogen (BUN, a breakdown product of protein), creatinine (a breakdown product of muscle) and creatine kinase (an enzyme found in muscles).", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_b4bde29c8235a5f1dea4518e4c471d6e8e1e339ba003d159f7da87057f9d2195", "text": "Karvezide", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_35be0fa611e43c36a6a8450b630e7c4704242638f4bc01682b51b05127962c47", "text": "dizziness", "location": null, "probability": null}, {"id_": "ent_sig_e31040de4051bb5c21170eea8d3690ac4706d9fd6d119771e743936fae3f878b", "text": "nausea", "location": null, "probability": null}, {"id_": "ent_sig_c629da3c8da3dc80e2e1b7dda8e852a32abce5544acd905d8fcf010780d93528", "text": "vomiting", "location": null, "probability": null}, {"id_": "ent_sig_c651fd89bd76856d2c7e0d053d13779d4d82b0ad03d920f8267f3be86db3e28f", "text": "abnormal urination", "location": null, "probability": null}, {"id_": "ent_sig_4064e6a9a434b058fcae69eb01a5374e91705380e2f4b9fd940120c6696fc050", "text": "fatigue", "location": null, "probability": null}, {"id_": "ent_sig_78d37b8d3afcc61eabeea4df5f7ef5f923cab0f4fb1a55561f787ad9bf5056a9", "text": "increases in blood urea nitrogen (BUN, a breakdown product of protein), creatinine (a breakdown product of muscle) and creatine kinase (an enzyme found in muscles)", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_3a383d4653cd49e1cd081009f43e882bf36a0a701d772d3b6ecba2bcda05674e", "medProdID": "ent_mep_b4bde29c8235a5f1dea4518e4c471d6e8e1e339ba003d159f7da87057f9d2195", "sigID": "ent_sig_35be0fa611e43c36a6a8450b630e7c4704242638f4bc01682b51b05127962c47", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_389deb1043bcd78836a30cfba9d8e54f5d9e3f10b1098d4358b23ee82b4ebcbd", "medProdID": "ent_mep_b4bde29c8235a5f1dea4518e4c471d6e8e1e339ba003d159f7da87057f9d2195", "sigID": "ent_sig_e31040de4051bb5c21170eea8d3690ac4706d9fd6d119771e743936fae3f878b", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_1e7f0fadd4bac14081b7e599228f5d9a84d7295a9b9f2facdb020dcb8921b8b3", "medProdID": "ent_mep_b4bde29c8235a5f1dea4518e4c471d6e8e1e339ba003d159f7da87057f9d2195", "sigID": "ent_sig_c629da3c8da3dc80e2e1b7dda8e852a32abce5544acd905d8fcf010780d93528", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_ad9f113a807adadfcdcba635f6ebe772843d1994bff16a0cd0ac170db2ad50b3", "medProdID": "ent_mep_b4bde29c8235a5f1dea4518e4c471d6e8e1e339ba003d159f7da87057f9d2195", "sigID": "ent_sig_c651fd89bd76856d2c7e0d053d13779d4d82b0ad03d920f8267f3be86db3e28f", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_c330b1de4d0f4a46ebbeaa480b31f26698c597b87b196ccfacc012e677bbc444", "medProdID": "ent_mep_b4bde29c8235a5f1dea4518e4c471d6e8e1e339ba003d159f7da87057f9d2195", "sigID": "ent_sig_4064e6a9a434b058fcae69eb01a5374e91705380e2f4b9fd940120c6696fc050", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_ad0413acf216342e4b836321332eb69c3fe7315fa327c8c2456097ab1513e46b", "medProdID": "ent_mep_b4bde29c8235a5f1dea4518e4c471d6e8e1e339ba003d159f7da87057f9d2195", "sigID": "ent_sig_78d37b8d3afcc61eabeea4df5f7ef5f923cab0f4fb1a55561f787ad9bf5056a9", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_d0b3b56ae2beba7fff924a01bef826147be9f764af93ad642fdf2d03d14479e0": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_f090969c00b8ab411c6868515085c8d19c288447d72bb23044d1ef8a60ef5542", "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/veklury", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_138aedee6619e8c3a4df4bc9770846ebf7030149214d8c5ecd6fbd2901b3cdd6", "text": "The most common side effect with Veklury (which may affect more than 1 in 10 people) in healthy volunteers is raised blood levels of liver enzymes (a sign of liver problems). The most common side effects in patients with COVID-19 is nausea (feeling sick), which may affect up to 1 in 10 people.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_cf1837147a2e64e9f42be93eed5a49c0fe28636d2b8ffc850913c61a0fba33c6", "text": "Veklury", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_48d474adc5aaa625cea7464b48b3b52286f88efef471e2323ed09f18706222bc", "text": "raised blood levels of liver enzymes", "location": null, "probability": null}, {"id_": "ent_sig_e31040de4051bb5c21170eea8d3690ac4706d9fd6d119771e743936fae3f878b", "text": "nausea", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_6824360f8e247491cf0e7762d345553ce2858815e88f1b16b33cea0779158aa0", "medProdID": "ent_mep_cf1837147a2e64e9f42be93eed5a49c0fe28636d2b8ffc850913c61a0fba33c6", "sigID": "ent_sig_48d474adc5aaa625cea7464b48b3b52286f88efef471e2323ed09f18706222bc", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_bc1dbba0d4fb525adc2299877873768539d29cfa8f5e633255097ad27ab8c78c", "medProdID": "ent_mep_cf1837147a2e64e9f42be93eed5a49c0fe28636d2b8ffc850913c61a0fba33c6", "sigID": "ent_sig_e31040de4051bb5c21170eea8d3690ac4706d9fd6d119771e743936fae3f878b", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_138aedee6619e8c3a4df4bc9770846ebf7030149214d8c5ecd6fbd2901b3cdd6": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_8434e66ce087ea53e64cc85df193ffb62966a74ebe52a95cb61063f6145978e2", "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/duoplavin-0", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_80f148662dfef8f2d45a46edae8f0fefbdd884d5b52a7a42f37a594e9a115ee1", "text": "The most common side effects with DuoPlavin (seen in between 1 and 10 patients in 100) are haematoma (a collection of blood under the skin), epistaxis (nosebleeds), gastrointestinal haemorrhage (bleeding in the stomach or gut), diarrhoea, abdominal pain (stomach ache), dyspepsia (heartburn), bruising, and bleeding where the skin is punctured.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_2e885e120c104cd3f49acd5e16c7192c153c18ad4e3acd50eb97e73985ea7546", "text": "DuoPlavin", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_b5d8f7c8c5a087f45e1cc739fee91cbcad08c93e1a1ea7d604306150c419c416", "text": "haematoma", "location": null, "probability": null}, {"id_": "ent_sig_a98699db0e2124e9a4504bbf61c5ffb10d4e43f4bc3a25b9f35090b07a03db01", "text": "epistaxis", "location": null, "probability": null}, {"id_": "ent_sig_8fc496bc0fd59ab6691bb0e44135bf17e530f30d1cf8f2f325a9f91394de1fa3", "text": "gastrointestinal haemorrhage", "location": null, "probability": null}, {"id_": "ent_sig_036a81a775bd01c6ab064ffcc1fd4727d2cc58aed06d942679a9b5fc864d78ee", "text": "diarrhoea", "location": null, "probability": null}, {"id_": "ent_sig_47df24df96cfdb191c74cbba045e8bf8641f121cd59e03a7653cec397430d7d2", "text": "abdominal pain", "location": null, "probability": null}, {"id_": "ent_sig_90657a90a4466455d9ba78138d68f1d471ace2f1d068c469bbce67f65c38ae08", "text": "bruising", "location": null, "probability": null}, {"id_": "ent_sig_44660f869e4e519d4b0bcb0697d9075568886a501ddc0f3c608b83b4f39e364b", "text": "bleeding", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_ec4b948595f7fcca2f35ba454360c29f9568fd1416320a2529264dc02929b262", "medProdID": "ent_mep_2e885e120c104cd3f49acd5e16c7192c153c18ad4e3acd50eb97e73985ea7546", "sigID": "ent_sig_b5d8f7c8c5a087f45e1cc739fee91cbcad08c93e1a1ea7d604306150c419c416", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_9159ad1bbc424e17f21bcb968ee31d620b13fbf1a9e9e30d22dffffc4bb56270", "medProdID": "ent_mep_2e885e120c104cd3f49acd5e16c7192c153c18ad4e3acd50eb97e73985ea7546", "sigID": "ent_sig_a98699db0e2124e9a4504bbf61c5ffb10d4e43f4bc3a25b9f35090b07a03db01", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_71cfe23e0f3388816f2c1c0b8fe384052883d01e328feee9686b6a50bcae8153", "medProdID": "ent_mep_2e885e120c104cd3f49acd5e16c7192c153c18ad4e3acd50eb97e73985ea7546", "sigID": "ent_sig_8fc496bc0fd59ab6691bb0e44135bf17e530f30d1cf8f2f325a9f91394de1fa3", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_f2dc1d4b7f063d2d67e8f37c79192b0adb306f3648f7fce8e01b562c2ef5dd5e", "medProdID": "ent_mep_2e885e120c104cd3f49acd5e16c7192c153c18ad4e3acd50eb97e73985ea7546", "sigID": "ent_sig_036a81a775bd01c6ab064ffcc1fd4727d2cc58aed06d942679a9b5fc864d78ee", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_2e769fb6d94578860e1b398f1c2e42028c1070b865944a4c2c3931df79610a19", "medProdID": "ent_mep_2e885e120c104cd3f49acd5e16c7192c153c18ad4e3acd50eb97e73985ea7546", "sigID": "ent_sig_47df24df96cfdb191c74cbba045e8bf8641f121cd59e03a7653cec397430d7d2", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_fab2ed9c888014f30e30e817897dcccd2f91b79bdb49c106b1803edf43277f00", "medProdID": "ent_mep_2e885e120c104cd3f49acd5e16c7192c153c18ad4e3acd50eb97e73985ea7546", "sigID": "ent_sig_90657a90a4466455d9ba78138d68f1d471ace2f1d068c469bbce67f65c38ae08", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_e5b7ad426e12ab9edf73366da563bd046ac5baf42da1f67810ce87617fb76759", "medProdID": "ent_mep_2e885e120c104cd3f49acd5e16c7192c153c18ad4e3acd50eb97e73985ea7546", "sigID": "ent_sig_44660f869e4e519d4b0bcb0697d9075568886a501ddc0f3c608b83b4f39e364b", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_80f148662dfef8f2d45a46edae8f0fefbdd884d5b52a7a42f37a594e9a115ee1": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_19d0a449420c7f58bdb7bd44b1a4c27137a2823f60a1141ba6253b8c418353df", "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/revinty-ellipta", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_12ae193b40146e87d92e966243563ff7cba3cc33a969df0045713a8454999ba9", "text": "The most common side effects with Revinty Ellipta (which may affect more than 1 in 10 people) are headache and nasopharyngitis (inflammation of the nose and throat). More serious side effects include pneumonia and fractures (seen in up to 1 in 10 people), which were reported more often in patients with COPD than those with asthma.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_b75b67fb70e1dad01048d77df8f1967e0b1e0ed26a739c2f1ac74963ec2e3900", "text": "Revinty Ellipta", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_cfa9ac1e084975b5d6463e32652c85bad6355a5ab32399618f89f222e68dc335", "text": "headache", "location": null, "probability": null}, {"id_": "ent_sig_09e9f6643be13ab5654a0987e6345dc7a7fd7d99b1fa8f365a3dfd86cecff458", "text": "nasopharyngitis", "location": null, "probability": null}, {"id_": "ent_sig_72a8df6694d5ca048ceff27150a6513bf8b9077c214662b1736a2a6e92efcbd4", "text": "pneumonia", "location": null, "probability": null}, {"id_": "ent_sig_61a17b7a6e35523001b0ece79e531df9f33cae591b76bb880d72e780dc9d5b8a", "text": "fractures", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_b98f4717e68bfec6c233e487fc9011040617e7b511ca0c78a7c429360e61060a", "medProdID": "ent_mep_b75b67fb70e1dad01048d77df8f1967e0b1e0ed26a739c2f1ac74963ec2e3900", "sigID": "ent_sig_cfa9ac1e084975b5d6463e32652c85bad6355a5ab32399618f89f222e68dc335", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_510959ab6f130d62bdda692a423e5fb039bbca1fdadc2ea43b0c84de396cf5da", "medProdID": "ent_mep_b75b67fb70e1dad01048d77df8f1967e0b1e0ed26a739c2f1ac74963ec2e3900", "sigID": "ent_sig_09e9f6643be13ab5654a0987e6345dc7a7fd7d99b1fa8f365a3dfd86cecff458", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_d6c92245f41fe17894ecfe4ec9a984ead5f9247cbc0e566628322c436b66ccd2", "medProdID": "ent_mep_b75b67fb70e1dad01048d77df8f1967e0b1e0ed26a739c2f1ac74963ec2e3900", "sigID": "ent_sig_72a8df6694d5ca048ceff27150a6513bf8b9077c214662b1736a2a6e92efcbd4", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_b02909ccf0b68ad69616bb2bd4d17bc2366788c190441a5f187b89ff2ad52f2e", "medProdID": "ent_mep_b75b67fb70e1dad01048d77df8f1967e0b1e0ed26a739c2f1ac74963ec2e3900", "sigID": "ent_sig_61a17b7a6e35523001b0ece79e531df9f33cae591b76bb880d72e780dc9d5b8a", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_12ae193b40146e87d92e966243563ff7cba3cc33a969df0045713a8454999ba9": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_b27a013cb28cf6d610b8212cf8aa34c8f14f073b6af2f03b4d62d4d5eb69c5a3", "url": "https://pubmed.ncbi.nlm.nih.gov/33985964/", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_b5b83b1b51d4cc013c755fbfa815f9d8e7d734cc3051fc49fec70bd9316fe01d", "text": "Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_21f7d552080a7aebb40d71c7794181bd86dd979acc3c75d962f0ab2fa054d5d0", "text": "Pfizer-BioNTech and Oxford-AstraZeneca vaccines", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_4f8413e951f36c2874ed0fc163e683822f5619ca459b56f87a1f79ef80113606", "text": "symptoms", "location": null, "probability": null}, {"id_": "ent_sig_a978c64bab56acd75c4af83b10d6617502acf58042fcd9335b0f6cac5be3ab77", "text": "hospital admissions", "location": null, "probability": null}, {"id_": "ent_sig_2b18339675891662b2900b52b4b00c95943a316eb48b626dce57e2a4af7d3523", "text": "mortality", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_02ea9f4f37c8715f103e48a862cf3b424a51f449fae9ceddc17f9fa8026002cc", "medProdID": "ent_mep_21f7d552080a7aebb40d71c7794181bd86dd979acc3c75d962f0ab2fa054d5d0", "sigID": "ent_sig_4f8413e951f36c2874ed0fc163e683822f5619ca459b56f87a1f79ef80113606", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_50aa0a5ed5a3a99e5fd20ad100cc56dbfaabf1471a7c1f7228c7589b150425af", "medProdID": "ent_mep_21f7d552080a7aebb40d71c7794181bd86dd979acc3c75d962f0ab2fa054d5d0", "sigID": "ent_sig_a978c64bab56acd75c4af83b10d6617502acf58042fcd9335b0f6cac5be3ab77", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_3c1e5c9ccd7dbb385c8fb22ef465163e7f1bc5b7062c5c755980b9aebae754dc", "medProdID": "ent_mep_21f7d552080a7aebb40d71c7794181bd86dd979acc3c75d962f0ab2fa054d5d0", "sigID": "ent_sig_2b18339675891662b2900b52b4b00c95943a316eb48b626dce57e2a4af7d3523", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_b5b83b1b51d4cc013c755fbfa815f9d8e7d734cc3051fc49fec70bd9316fe01d": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_42e7bb40def6bb43eb894b961fd85b082bc7e8920ba744f0ff29908282e7c553", "url": "https://pubmed.ncbi.nlm.nih.gov/34755408/", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_6d1e26a0d21773f985f7e2d9b50b3d7d15a6b38c3814e93513c97e27efc7ad30", "text": "Rare adverse events have also been reported soon after administration of viral vector and mRNA vaccines.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_a4de3c72892a49ef4c3c7a584dde21c9e9b5207e84f522f1c079413ca800a940", "text": "viral vector and mRNA vaccines", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_2ec0df12b367befed81263b064c563f5e585e95f42758adab3eb495c90578273", "text": "adverse events", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_9962808f625038d96e41b9a81530b6196ba379807c7a94fe3af0205a012988c7", "medProdID": "ent_mep_a4de3c72892a49ef4c3c7a584dde21c9e9b5207e84f522f1c079413ca800a940", "sigID": "ent_sig_2ec0df12b367befed81263b064c563f5e585e95f42758adab3eb495c90578273", "causality": null, "seriousness": null, "severity": 0.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_6d1e26a0d21773f985f7e2d9b50b3d7d15a6b38c3814e93513c97e27efc7ad30": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_a53990e1129d244501bb6e9aea58502e02a2a5139f5d4881325ae55e9196cc1f", "url": "https://pubmed.ncbi.nlm.nih.gov/34707048/", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_8f8195d6d57767f804f32afc348be2978042d65cda250202afc45c009fe8bda6", "text": "A 65-year-old man experienced cough and shortness of breath 3 days after receiving the first dose of the Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine. Chest X-ray revealed bilateral infiltrates, and the desaturation deteriorated rapidly. ", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_d8bc5f4dcc92a829ef9d0ded114bdc6955df1e0edf80b4778d826c4c92520989", "text": "Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_866ab33b8463db1b3906ff42fe1112bb52aaca7c4ae0d82275413ba672a40ee7", "text": "cough", "location": null, "probability": null}, {"id_": "ent_sig_8e11ac43dbca88a20e8231de90e7dc9d25da776b849d5694afecfabd6adcc564", "text": "shortness of breath", "location": null, "probability": null}, {"id_": "ent_sig_9588b2be6bd120c2bb31bcbfc36ea9f0bdcc64c422a74bbbd705230906fdee0e", "text": "bilateral infiltrates", "location": null, "probability": null}, {"id_": "ent_sig_9499678aeb59f10dd8ff93f8142c9915471b93babd9db76f6e94f3dd578f602b", "text": "desaturation deteriorated", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_9ec143acdd5567e758c02de60faa20b06ea66280cfda1c2f00cdd59a9aa557c4", "medProdID": "ent_mep_d8bc5f4dcc92a829ef9d0ded114bdc6955df1e0edf80b4778d826c4c92520989", "sigID": "ent_sig_866ab33b8463db1b3906ff42fe1112bb52aaca7c4ae0d82275413ba672a40ee7", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_41a35050f6ab82ed3bafa4e42277ed93cbe9a98e6ca889889e28e1baf9aa202c", "medProdID": "ent_mep_d8bc5f4dcc92a829ef9d0ded114bdc6955df1e0edf80b4778d826c4c92520989", "sigID": "ent_sig_8e11ac43dbca88a20e8231de90e7dc9d25da776b849d5694afecfabd6adcc564", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_6ec44c252a702715f5388a2a368778821c1d9684edd1229166aa2929587ea58c", "medProdID": "ent_mep_d8bc5f4dcc92a829ef9d0ded114bdc6955df1e0edf80b4778d826c4c92520989", "sigID": "ent_sig_9588b2be6bd120c2bb31bcbfc36ea9f0bdcc64c422a74bbbd705230906fdee0e", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_2a5eceb4c3f4ed6a9067cc6f376ac8c906eab77a6b4c54728b89536b611c1501", "medProdID": "ent_mep_d8bc5f4dcc92a829ef9d0ded114bdc6955df1e0edf80b4778d826c4c92520989", "sigID": "ent_sig_9499678aeb59f10dd8ff93f8142c9915471b93babd9db76f6e94f3dd578f602b", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}, {"id_": "ent_7f2980635e90a1939f48ec9340c4ad7870e8386eadff9d8588c4f305c13415a4", "text": "Based on these findings, the patient was diagnosed with COVID-19 vaccine-induced pneumonitis. The timing of the onset of pneumonitis after vaccination and the results of intradermal testing suggest that Type IV hypersensitivity against COVID-19 vaccine may have been responsible for this clinical condition.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_aa01359cf7d47e5c3440c18c5140b73d6a3f02110ac56f495cb6a27c3c66025d", "text": "COVID-19 vaccine", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_083e60d7936a6ff74bfb481c5e19b27fe633d74bcced768f523aa3471d0f8e88", "text": "pneumonitis", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_136cb9d33df2d7a935b7fa07f0495c676d1003a583c5fe1e6842763ee798c742", "medProdID": "ent_mep_aa01359cf7d47e5c3440c18c5140b73d6a3f02110ac56f495cb6a27c3c66025d", "sigID": "ent_sig_083e60d7936a6ff74bfb481c5e19b27fe633d74bcced768f523aa3471d0f8e88", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_8f8195d6d57767f804f32afc348be2978042d65cda250202afc45c009fe8bda6": 0, "ent_7f2980635e90a1939f48ec9340c4ad7870e8386eadff9d8588c4f305c13415a4": 1}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_d6d67f2554d7d259fc22905c1a2200ca165ecd4f8e929aa6c55af78684a8315d", "url": "https://pubmed.ncbi.nlm.nih.gov/34420869/", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_1fb94dd862d7fece9c6967874432d6a13af903d406de30cad434511edd10bd8a", "text": "In spite of their undisputed role in reducing the severity of the disease and reduction of the disease burden in the community, there have been case reports of serious side effects with these vaccines. We aim to describe a case report of myocarditis following administration of the Janssen vaccine in a healthy, young male and review the available literature on COVID-19 vaccine related myocarditis and its possible pathogenesis. This case and literature review notes a temporal association between COVID-19 vaccination and myocarditis. ", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_8f3e03b254a6d891195a63a07328ca5b3542144eb7489cc830b34607be25b17f", "text": "Janssen vaccine", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_6685efec0b76fcdda55d032fde1ccdd5c59b1c5254c5ffe36bc66387169e6242", "text": "myocarditis", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_c209c8ee85318137480eb7d80a96c630947d57b1df44c308b2e468d16462d2f8", "medProdID": "ent_mep_8f3e03b254a6d891195a63a07328ca5b3542144eb7489cc830b34607be25b17f", "sigID": "ent_sig_6685efec0b76fcdda55d032fde1ccdd5c59b1c5254c5ffe36bc66387169e6242", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_1fb94dd862d7fece9c6967874432d6a13af903d406de30cad434511edd10bd8a": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_ceb62bcc6a01f9f8f9a7f31d0806717a484c0333de95d30b9ab7f2a2040b892e", "url": "https://pubmed.ncbi.nlm.nih.gov/32744074/", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_72be278626e0baa7c576c93ae22fcefa3818401c03c9a551ca59d1734b0d8601", "text": "We synthetized data about acne pathogenesis and mechanism of action, efficacy, and safety of isotretinoin.\nExpert opinion: This drug is effective, despite common, controllable, and reversible mucocutaneous side effects. Serious adverse events are rare and represent individual reactions. Teratogenicity is the most severe, requiring rigorous control.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_e67829c3acde78ae94309c15fd4e5e560aa9490a1373ba86d33bc009f2a2a98c", "text": "isotretinoin", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_af0ed5e39fad98205de274bf5d0fa4d3c0625dea435ccacdf69fccc972654257", "text": "Teratogenicity", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_1848b6f4003b564ca6220f7158c7c792c914cce45c2595bc347476d74ce37fc2", "medProdID": "ent_mep_e67829c3acde78ae94309c15fd4e5e560aa9490a1373ba86d33bc009f2a2a98c", "sigID": "ent_sig_af0ed5e39fad98205de274bf5d0fa4d3c0625dea435ccacdf69fccc972654257", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_72be278626e0baa7c576c93ae22fcefa3818401c03c9a551ca59d1734b0d8601": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_44f7b8d714b2b27be5f669f22f5f65df5c964d1c6903f63989dee8a59e9871ee", "url": "https://pubmed.ncbi.nlm.nih.gov/27671426/", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_21e7e748bd9998d9f705223c46df2fc48241848216a2883dbbee6d387ca33da8", "text": "Furthermore, apoptosis may be the underlying and unifying mechanism of the adverse effects of isotretinoin on neural crest cells (teratogenicity), hippocampal neurones (depression), epidermal keratinocytes and mucosa cells (mucocutaneous side-effects), hair follicle cells (telogen effluvium), intestinal epithelial cells (inflammatory bowel disease), skeletal muscle cells (myalgia and release of creatine kinase), and hepatocytes (release of transaminases and very low-density lipoproteins)", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_e67829c3acde78ae94309c15fd4e5e560aa9490a1373ba86d33bc009f2a2a98c", "text": "isotretinoin", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_74fd2e753c4e2cd9afcadf0a6667fc47ef068c8a782d50e2f3c3907fc666d4c8", "text": "depression", "location": null, "probability": null}, {"id_": "ent_sig_4e63c3e1b8d2b1defcbe33bfeb8b15a0e74f989a9377f4056527192d9ec1aee9", "text": "inflammatory bowel disease", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_6a611bb0b0b8d76eb630e5e4a464f5e4e8743a0dea12b74454b63a858258f3eb", "medProdID": "ent_mep_e67829c3acde78ae94309c15fd4e5e560aa9490a1373ba86d33bc009f2a2a98c", "sigID": "ent_sig_74fd2e753c4e2cd9afcadf0a6667fc47ef068c8a782d50e2f3c3907fc666d4c8", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_c4fd422f83bb2adcc7427d0adf0726254a7efef2e1e07327773649826c3cb09c", "medProdID": "ent_mep_e67829c3acde78ae94309c15fd4e5e560aa9490a1373ba86d33bc009f2a2a98c", "sigID": "ent_sig_4e63c3e1b8d2b1defcbe33bfeb8b15a0e74f989a9377f4056527192d9ec1aee9", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_21e7e748bd9998d9f705223c46df2fc48241848216a2883dbbee6d387ca33da8": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_86a2a157d03d27d8951b7e31ee17a8e676118c8d2f94ea32c62fb2b323b74bfc", "url": "https://pubmed.ncbi.nlm.nih.gov/28705050/", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_19c2986da191f0fef023fc20d4e7967bbfbcb91e4cd65259e100e9dfd07cf69c", "text": "Isotretinoin (ITT) is the most effective treatment available, but serious adverse effects, including a possible association with depression and suicide, limit its use. We review the current literature regarding the association of ITT with depression and suicide. Case reports and database studies show a clear association, and this association is biologically plausible.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_4880e5568cec9020c45d587ef15d439bd88b603d3167718f93ff219cd5737a3c", "text": "Isotretinoin", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_74fd2e753c4e2cd9afcadf0a6667fc47ef068c8a782d50e2f3c3907fc666d4c8", "text": "depression", "location": null, "probability": null}, {"id_": "ent_sig_5304378d007825ccb10495d27c4dbddbcc77040639b83e69bda4ebea0703cfbd", "text": "suicide", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_ed5be79b588e95ca3110a848e5cc6042248036ca9fdb2ab76b03dab3df8aa376", "medProdID": "ent_mep_4880e5568cec9020c45d587ef15d439bd88b603d3167718f93ff219cd5737a3c", "sigID": "ent_sig_74fd2e753c4e2cd9afcadf0a6667fc47ef068c8a782d50e2f3c3907fc666d4c8", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_b73c501a1705eb74992e9b695c5cbf26bc477fd2ee3e777d261a9873d6c0db33", "medProdID": "ent_mep_4880e5568cec9020c45d587ef15d439bd88b603d3167718f93ff219cd5737a3c", "sigID": "ent_sig_5304378d007825ccb10495d27c4dbddbcc77040639b83e69bda4ebea0703cfbd", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_19c2986da191f0fef023fc20d4e7967bbfbcb91e4cd65259e100e9dfd07cf69c": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_ee7a8a28101d62462db63f05d4ce68cfeed573a222605c54ce0401b88fb2614c", "url": "https://pubmed.ncbi.nlm.nih.gov/31765029/", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_b7b0b7d54792ce21dba3b4904f2a86669e64f23ec405e917293958f9ba82975c", "text": "Isotretinoin is the mainstay treatment in severe acne; however, its musculoskeletal adverse effects such as lower-back pain can be disabling. Herein, we present four cases of isotretinoin-induced sacroiliitis with variable severity. We also present a review of the literature of isotretinoin-induced sacroiliitis. ", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_4880e5568cec9020c45d587ef15d439bd88b603d3167718f93ff219cd5737a3c", "text": "Isotretinoin", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_4910cfc970e244d671db1a3c7dd1c32f8221b357a9b23b426e30a59e8b10d4e9", "text": "musculoskeletal adverse effects", "location": null, "probability": null}, {"id_": "ent_sig_82225b8a74d43cf6a74dba386bac6dd22cbba8b8bdd38e14f762633f49ed9c0c", "text": "lower-back pain", "location": null, "probability": null}, {"id_": "ent_sig_558c267ab4ab2300dd00cdbfb718dd32d54f0a3715f20c4e7af9c2566f1a93e3", "text": "sacroiliitis", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_8b1a1b552f7d22d6e844b10c06554f80f2a421d062df198715160caaf5b860e3", "medProdID": "ent_mep_4880e5568cec9020c45d587ef15d439bd88b603d3167718f93ff219cd5737a3c", "sigID": "ent_sig_4910cfc970e244d671db1a3c7dd1c32f8221b357a9b23b426e30a59e8b10d4e9", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_a14470af10d0842d2ac676638b0fa3ef023237db8e50ea80129796b0b30b8381", "medProdID": "ent_mep_4880e5568cec9020c45d587ef15d439bd88b603d3167718f93ff219cd5737a3c", "sigID": "ent_sig_82225b8a74d43cf6a74dba386bac6dd22cbba8b8bdd38e14f762633f49ed9c0c", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_d33d416629351c4ed387414f70e1caf1bcce901ccdb8c98d726f7308270f7343", "medProdID": "ent_mep_4880e5568cec9020c45d587ef15d439bd88b603d3167718f93ff219cd5737a3c", "sigID": "ent_sig_558c267ab4ab2300dd00cdbfb718dd32d54f0a3715f20c4e7af9c2566f1a93e3", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_b7b0b7d54792ce21dba3b4904f2a86669e64f23ec405e917293958f9ba82975c": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_13e0e74b45413478a045dbdeacd5c92e397e508ea491d1ffb5908217f20a895b", "url": "https://www.swissmedic.ch/swissmedic/en/home/news/mitteilungen/uaw-affenpocken.html", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_e6b1c08431e84afc0daaee2c7ae740ad4c1a24057ed83a272e6b7037d95bcc84", "text": "Reporting suspected adverse reactions following vaccination against mpox (monkeypox)", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_fb17be17a50fcd307d58b570cfdab98325a1ca80aed6089d4a85b6fd54621bb8", "text": "vaccination against mpox", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_065edd5335053d59afb970a80ce0f127b1cdc1f67aa0c4680a3c04805f40a9d2", "text": "adverse reactions", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_0d787aac8eee0dfaa8a2e4599c7105c2e8dfd845460d482c8aeb34662c3b436d", "medProdID": "ent_mep_fb17be17a50fcd307d58b570cfdab98325a1ca80aed6089d4a85b6fd54621bb8", "sigID": "ent_sig_065edd5335053d59afb970a80ce0f127b1cdc1f67aa0c4680a3c04805f40a9d2", "causality": null, "seriousness": null, "severity": 0.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_e6b1c08431e84afc0daaee2c7ae740ad4c1a24057ed83a272e6b7037d95bcc84": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_7e23514c1c6c4d185acf61fea29274553392d5eb1ded7bb8a431b529c0a16216", "url": "https://www.swissmedic.ch/swissmedic/de/home/news/coronavirus-covid-19/covid-19-vaccines-safety-update-17.html", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_686c192b0d19dce65e72d4a363d18cfe734a6915372432ab46c95df3cdf499de", "text": "10'866 (69\u00a0%) der Meldungen beziehen sich auf den Covid-19 Impfstoff Spikevax\u00ae von Moderna (mit rund 62\u00a0% der verabreichten Impfdosen der in der Schweiz am h\u00e4ufigsten angewandte Impfstoff) und 4'434 (28\u00a0%) auf den Impfstoff Comirnaty\u00ae von Pfizer/BioNTech (rund 37 % der verabreichten Impfdosen). In einigen F\u00e4llen wurde der Impfstoff nicht spezifiziert. Rund 38 % der F\u00e4lle wurden von den Meldenden als schwerwiegend eingestuft. In diesen Meldungen liegt das mittlere Alter der Betroffenen bei 52,7 Jahren. Am h\u00e4ufigsten wurde \u00fcber Fieber, Kopfschmerzen, M\u00fcdigkeit, Sch\u00fcttelfrost, \u00dcbelkeit und Schwindelgef\u00fchl berichtet. Diese bekannten Reaktionen \u00fcberwiegen auch bei den nicht-schwerwiegenden F\u00e4llen.\nIn 224 der schwerwiegenden F\u00e4lle wurde \u00fcber einen Todesfall in unterschiedlichem zeitlichen Abstand zur Impfung berichtet. Die Verstorbenen waren im Durchschnitt 78,9 Jahre alt. Bei der vertieften Analyse dieser F\u00e4lle gab es auf Basis der jeweils vorliegenden Daten trotz einer zeitlichen Assoziation andere wahrscheinlichere Ursachen, die das Ereignis erkl\u00e4ren k\u00f6nnen.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_f21b1ef1db04e703bbc49865840a745c75fd7deed564ec14b3918269d4887d81", "text": "Spikevax", "location": null, "probability": null}, {"id_": "ent_mep_3bd97142f3a6c8cf037d60851acc7e95dee9704527ecacf9153e3e975a4ba5b1", "text": "Comirnaty", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_269570e632703ee1fd124a11245409695a50d0d3e2f50248dc4b54b21e9bccbd", "text": "Fieber", "location": null, "probability": null}, {"id_": "ent_sig_fb6f480580063cbe47ba6e6d00b6dbda3e5179466abad256a62b1720cabdfc77", "text": "Kopfschmerzen", "location": null, "probability": null}, {"id_": "ent_sig_35c4e3487d8aef823aca763e5e44189b2876941b8fba604123680fcac6d08781", "text": "M\u00fcdigkeit", "location": null, "probability": null}, {"id_": "ent_sig_43d5560c9e39d6c41783e770c29c4a8f2dc214665d6ecae6fb0ca7f304e55203", "text": "Sch\u00fcttelfrost", "location": null, "probability": null}, {"id_": "ent_sig_4feb594d371aa3e6ef36b3954d218ec217af5cd472f46cb290abf7bbc8a13348", "text": "\u00dcbelkeit", "location": null, "probability": null}, {"id_": "ent_sig_70675324eef0949e005e97d1676f07e1114d2c1a1ba250c940ecf268553e68ad", "text": "Schwindelgef\u00fchl", "location": null, "probability": null}, {"id_": "ent_sig_8b6a0a5f44f9325ec7b7eeb3dff1a4deb7834f00d534af1e71e3fe7d6970ede1", "text": "Todesfall", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_712c9e88d2d896d718f8d2afe2741b37cb3d4e1fb76477ed356a63905f54a95a", "medProdID": "ent_mep_f21b1ef1db04e703bbc49865840a745c75fd7deed564ec14b3918269d4887d81", "sigID": "ent_sig_269570e632703ee1fd124a11245409695a50d0d3e2f50248dc4b54b21e9bccbd", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_e966d21d6d5fd6a290f9e7dc54688eb23d9ae40e1abf1d20ff2a8a9929ccbbd4", "medProdID": "ent_mep_f21b1ef1db04e703bbc49865840a745c75fd7deed564ec14b3918269d4887d81", "sigID": "ent_sig_fb6f480580063cbe47ba6e6d00b6dbda3e5179466abad256a62b1720cabdfc77", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_eb4d0bb3adcf119c5db08c8dfbeb2dc0d7289639a0ab9ecea387a0c4dbbc7dda", "medProdID": "ent_mep_f21b1ef1db04e703bbc49865840a745c75fd7deed564ec14b3918269d4887d81", "sigID": "ent_sig_35c4e3487d8aef823aca763e5e44189b2876941b8fba604123680fcac6d08781", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_a3868f632062651c20a79e487ded1023ed862fa0a7cf3fdeeb2235723116df7d", "medProdID": "ent_mep_f21b1ef1db04e703bbc49865840a745c75fd7deed564ec14b3918269d4887d81", "sigID": "ent_sig_43d5560c9e39d6c41783e770c29c4a8f2dc214665d6ecae6fb0ca7f304e55203", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_174ab9b8ff5f639178088ec94f394168f52a6ff7ef77b9a8214584e1f3667e61", "medProdID": "ent_mep_f21b1ef1db04e703bbc49865840a745c75fd7deed564ec14b3918269d4887d81", "sigID": "ent_sig_4feb594d371aa3e6ef36b3954d218ec217af5cd472f46cb290abf7bbc8a13348", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_4bb9cca94e75e61754c8fb213848ef7eb6602d258862b7cba7cd3f06a9c19869", "medProdID": "ent_mep_f21b1ef1db04e703bbc49865840a745c75fd7deed564ec14b3918269d4887d81", "sigID": "ent_sig_70675324eef0949e005e97d1676f07e1114d2c1a1ba250c940ecf268553e68ad", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_dc5ec3bad7f6f27ee0cb8f18a6c0078fb26e7db5e0ba1b9b9c68785bb80e1922", "medProdID": "ent_mep_f21b1ef1db04e703bbc49865840a745c75fd7deed564ec14b3918269d4887d81", "sigID": "ent_sig_8b6a0a5f44f9325ec7b7eeb3dff1a4deb7834f00d534af1e71e3fe7d6970ede1", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_0391eb3b2136b2d09cc4c7c62e86c1e10dad1196257d190fa0980762a6bf8a64", "medProdID": "ent_mep_3bd97142f3a6c8cf037d60851acc7e95dee9704527ecacf9153e3e975a4ba5b1", "sigID": "ent_sig_269570e632703ee1fd124a11245409695a50d0d3e2f50248dc4b54b21e9bccbd", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_a47dd94a9f534684c02335af9f1574f46c04d977e855031a36aaf384595b6b7b", "medProdID": "ent_mep_3bd97142f3a6c8cf037d60851acc7e95dee9704527ecacf9153e3e975a4ba5b1", "sigID": "ent_sig_fb6f480580063cbe47ba6e6d00b6dbda3e5179466abad256a62b1720cabdfc77", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_555d685091a8e7ace5f960d84e7001600d3ec3fe142f084df0861e0907995b0e", "medProdID": "ent_mep_3bd97142f3a6c8cf037d60851acc7e95dee9704527ecacf9153e3e975a4ba5b1", "sigID": "ent_sig_35c4e3487d8aef823aca763e5e44189b2876941b8fba604123680fcac6d08781", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_39f1dd2a0a90c02de6674a274ed7c7ae3ee5ede76dc773820c0bcf631c92de30", "medProdID": "ent_mep_3bd97142f3a6c8cf037d60851acc7e95dee9704527ecacf9153e3e975a4ba5b1", "sigID": "ent_sig_43d5560c9e39d6c41783e770c29c4a8f2dc214665d6ecae6fb0ca7f304e55203", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_19bd34272d0b7c0079cd43d1b532b9e0a622a612109df56e33d26bf1e74bff34", "medProdID": "ent_mep_3bd97142f3a6c8cf037d60851acc7e95dee9704527ecacf9153e3e975a4ba5b1", "sigID": "ent_sig_4feb594d371aa3e6ef36b3954d218ec217af5cd472f46cb290abf7bbc8a13348", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_c8b1ade7b3c474ede5a70178025dd70f0ac71644d3bb10c5553b9ea174419725", "medProdID": "ent_mep_3bd97142f3a6c8cf037d60851acc7e95dee9704527ecacf9153e3e975a4ba5b1", "sigID": "ent_sig_70675324eef0949e005e97d1676f07e1114d2c1a1ba250c940ecf268553e68ad", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_c9e16fadac1e1b85f6801d9e0f94ce3a51590d32b20828f3c405b657d3b9f3d4", "medProdID": "ent_mep_3bd97142f3a6c8cf037d60851acc7e95dee9704527ecacf9153e3e975a4ba5b1", "sigID": "ent_sig_8b6a0a5f44f9325ec7b7eeb3dff1a4deb7834f00d534af1e71e3fe7d6970ede1", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_686c192b0d19dce65e72d4a363d18cfe734a6915372432ab46c95df3cdf499de": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_9829fe352a9e122ac316045008c53034a9c327654d73c9eef73e85619a3a3b16", "url": "https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/marktueberwachung/arzneimittel-aus-dem-internet/drug-safety-current-threats/smc-warnt-abhaengigkeitsrisiko-schnupfenspray-und-abfuehrmittel.html", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_decc932a3ac8a696d50a0523d3762569c06cda7bbe7963d9baa528a032a6d3b8", "text": "Wer abschwellende Nasenpr\u00e4parate l\u00e4nger als ca. 10 Tage anwendet, kann abh\u00e4ngig werden. Die langfristige Anwendung von Schnupfensprays bzw. -tropfen kann einen chronischen Schnupfen, die sogenannten Rhinitis medicamentosa, ausl\u00f6sen.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_e171d0a1718a252c36c3ddf2b40dafbd86378f9f6b8afbd9eee5bef87d6e1483", "text": "Schnupfensprays bzw. -tropfen", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_e8479337aa833351d3e09d4cbc2daea51530e9c17e917c32d4ee8da2e286dd6e", "text": "Rhinitis medicamentosa", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_8d16937579d829c2abdab13d722d2cccab33849402373bd5d49749eac75ae1d9", "medProdID": "ent_mep_e171d0a1718a252c36c3ddf2b40dafbd86378f9f6b8afbd9eee5bef87d6e1483", "sigID": "ent_sig_e8479337aa833351d3e09d4cbc2daea51530e9c17e917c32d4ee8da2e286dd6e", "causality": null, "seriousness": null, "severity": 0.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}, {"id_": "ent_5a50e777a14fb4f192abc6c7c1655401dba4dfbf6cdc48e6e0e3ca4bcef7d7b8", "text": "Frei verk\u00e4ufliche Abf\u00fchrmittel mit dem Wirkstoff Bisacodyl k\u00f6nnen zu einem \u00abTeufelskreis\u00bb f\u00fchren: Die st\u00e4ndige Einnahme dieser Tabletten st\u00f6rt den Wasser- und Elektrolythaushalt (zum Beispiel infolge Kaliummangel), was zu einer Verminderung der Darmt\u00e4tigkeit f\u00fchren kann, die wiederum zu einem erneuten Gebrauch eben dieser Abf\u00fchrmittel f\u00fchrt. M\u00f6gliche gesundheitliche Risiken sind Mangelern\u00e4hrung, chronische Darmentz\u00fcndungen und andere durch die Elektrolytst\u00f6rungen ausgel\u00f6ste Krankheiten.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_ef95b541086c7465c248792917a3c917af45780dd126404e99162fad823c564e", "text": "Bisacodyl", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_488fdbe790acbca79dd092a889b5623d9d194e39d80d63e4ec0efa101d492610", "text": "Mangelern\u00e4hrung", "location": null, "probability": null}, {"id_": "ent_sig_14dcbf5344023e5716e120a0862e3919f0cdf19a2d8f0c710267849345572951", "text": "chronische Darmentz\u00fcndung", "location": null, "probability": null}, {"id_": "ent_sig_3f295cbf2ee6c704010756de4509b0b1874d8a7432c3cf82d573d8a312b04cb7", "text": "Elektrolytst\u00f6rungen", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_b1bb4138954dd12d7af1dc1613f3e8eaf85b1899d7eadece6da1a6f08ec852c5", "medProdID": "ent_mep_ef95b541086c7465c248792917a3c917af45780dd126404e99162fad823c564e", "sigID": "ent_sig_488fdbe790acbca79dd092a889b5623d9d194e39d80d63e4ec0efa101d492610", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_4d0282e17529009e21fa012b8bcde2119f873a726342f1fc09e82b1a04acfb34", "medProdID": "ent_mep_ef95b541086c7465c248792917a3c917af45780dd126404e99162fad823c564e", "sigID": "ent_sig_14dcbf5344023e5716e120a0862e3919f0cdf19a2d8f0c710267849345572951", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_457b36d4174fe593981537f00c344e0dd4c6ad550a50b4eeff204cfce3b30ed0", "medProdID": "ent_mep_ef95b541086c7465c248792917a3c917af45780dd126404e99162fad823c564e", "sigID": "ent_sig_3f295cbf2ee6c704010756de4509b0b1874d8a7432c3cf82d573d8a312b04cb7", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_decc932a3ac8a696d50a0523d3762569c06cda7bbe7963d9baa528a032a6d3b8": 0, "ent_5a50e777a14fb4f192abc6c7c1655401dba4dfbf6cdc48e6e0e3ca4bcef7d7b8": 1}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_a310164c180a71070a349befc7d41d9f50b24704cff41fe3e38a44e8b1297fcd", "url": "https://www.swissmedic.ch/swissmedic/de/home/news/coronavirus-covid-19/covid-19-vaccines-safety-update-18.html", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_987e7e2ff23ce5a3f2dfa98fcd1251132483e12d01476029160ca4f1742a5958", "text": "Nach Impfung mit den Covid-19 mRNA Impfstoffen wurden sehr selten F\u00e4lle von Myokarditis und Perikarditis (Entz\u00fcndungen des Herzmuskels/Herzbeutels) berichtet. Die F\u00e4lle traten in der Regel innerhalb von 14 Tagen nach der Impfung auf, und zwar h\u00e4ufiger nach der zweiten Dosis und bei j\u00fcngeren M\u00e4nnern.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_b118d203c22a6b8484163d7d9b9bb8553e126b5953140b538aac64a10e23d5ec", "text": "Covid-19 mRNA Impfstoffen", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_5b20946ca40483fd9fc0835d5e46d1abfab59a2c511b8dc9104980d828dd3048", "text": "Myokarditis", "location": null, "probability": null}, {"id_": "ent_sig_7241bb246621326272e6c6e9a6fc267cbaf2f3bc174cd7bcacd8f130c6c070d9", "text": "Perikarditis", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_06a87e4add3b14593c90397ccf25833f9e72773a09269770cb67740daede0abb", "medProdID": "ent_mep_b118d203c22a6b8484163d7d9b9bb8553e126b5953140b538aac64a10e23d5ec", "sigID": "ent_sig_5b20946ca40483fd9fc0835d5e46d1abfab59a2c511b8dc9104980d828dd3048", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_d3466254c6bdb5431d2ffb730c1d94004b377656d5a9189818ebc48d6c57b1b6", "medProdID": "ent_mep_b118d203c22a6b8484163d7d9b9bb8553e126b5953140b538aac64a10e23d5ec", "sigID": "ent_sig_7241bb246621326272e6c6e9a6fc267cbaf2f3bc174cd7bcacd8f130c6c070d9", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}, {"id_": "ent_4777abcf0c9791ac1fd6bc214adb384e70075a5c57b3f7169ec73c2b1e1b4f40", "text": "Es sind 55 Meldungen eingegangen zu Nebenwirkungen nach Impfung mit einem bivalenten Impfstoff (Spikevax bivalent Original/Omicron oder Comirnaty bivalent). Davon wurden 18 (33%) Meldungen als schwerwiegend eingestuft. Die am h\u00e4ufigsten berichteten Nebenwir-kungen waren Kopfschmerzen, Fieber, Gelenkschmerzen und \u00dcbelkeit.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_b77d55d1d4e1ddc88a65dd4d9042a88ec0776fe252727b0a0f8a21a2757570b9", "text": "Spikevax bivalent Original/Omicron", "location": null, "probability": null}, {"id_": "ent_mep_fcbebcfd519c748ab1e0f29f54513977cbc6180241726df6202222b751e11542", "text": "Comirnaty bivalent", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_fb6f480580063cbe47ba6e6d00b6dbda3e5179466abad256a62b1720cabdfc77", "text": "Kopfschmerzen", "location": null, "probability": null}, {"id_": "ent_sig_269570e632703ee1fd124a11245409695a50d0d3e2f50248dc4b54b21e9bccbd", "text": "Fieber", "location": null, "probability": null}, {"id_": "ent_sig_93c470ba25ae820e64e80cd569342c1c03827c5ce34904640233848f254bb588", "text": "Gelenkschmerzen", "location": null, "probability": null}, {"id_": "ent_sig_4feb594d371aa3e6ef36b3954d218ec217af5cd472f46cb290abf7bbc8a13348", "text": "\u00dcbelkeit", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_4b774a4c6993874c019b46c125c0a1c218d54ee3dd6c2c566baacd5d582c5979", "medProdID": "ent_mep_b77d55d1d4e1ddc88a65dd4d9042a88ec0776fe252727b0a0f8a21a2757570b9", "sigID": "ent_sig_fb6f480580063cbe47ba6e6d00b6dbda3e5179466abad256a62b1720cabdfc77", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_8c803869c9f32bd17e9f8350021e0302ed0462cf914753368e13b6cac1e830ac", "medProdID": "ent_mep_b77d55d1d4e1ddc88a65dd4d9042a88ec0776fe252727b0a0f8a21a2757570b9", "sigID": "ent_sig_269570e632703ee1fd124a11245409695a50d0d3e2f50248dc4b54b21e9bccbd", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_863cddc443d80a3da9ce65d7d98870561ba7ff8921165a85fc9f0c59ee12ae43", "medProdID": "ent_mep_b77d55d1d4e1ddc88a65dd4d9042a88ec0776fe252727b0a0f8a21a2757570b9", "sigID": "ent_sig_93c470ba25ae820e64e80cd569342c1c03827c5ce34904640233848f254bb588", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_4b26096648d91e6675271445c2ed04b49e5431450c0dcce75d5caa4c267cc8bd", "medProdID": "ent_mep_b77d55d1d4e1ddc88a65dd4d9042a88ec0776fe252727b0a0f8a21a2757570b9", "sigID": "ent_sig_4feb594d371aa3e6ef36b3954d218ec217af5cd472f46cb290abf7bbc8a13348", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_634c1adfea34415480b831bc257fcdd72d8a569d2bf934129f35880922c73337", "medProdID": "ent_mep_fcbebcfd519c748ab1e0f29f54513977cbc6180241726df6202222b751e11542", "sigID": "ent_sig_fb6f480580063cbe47ba6e6d00b6dbda3e5179466abad256a62b1720cabdfc77", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_2bd309ad488a8bc37402b00c287f6b1bff6191139fd84b984a0745407bff8931", "medProdID": "ent_mep_fcbebcfd519c748ab1e0f29f54513977cbc6180241726df6202222b751e11542", "sigID": "ent_sig_269570e632703ee1fd124a11245409695a50d0d3e2f50248dc4b54b21e9bccbd", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_0fe521a8e950e43930a195110d15a68a37e4ac99647e692e4a7f64ee5de251fb", "medProdID": "ent_mep_fcbebcfd519c748ab1e0f29f54513977cbc6180241726df6202222b751e11542", "sigID": "ent_sig_93c470ba25ae820e64e80cd569342c1c03827c5ce34904640233848f254bb588", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_ce6487996f4d55ff22af89760224b0b142b40b1babd31a20119360f299eadeb8", "medProdID": "ent_mep_fcbebcfd519c748ab1e0f29f54513977cbc6180241726df6202222b751e11542", "sigID": "ent_sig_4feb594d371aa3e6ef36b3954d218ec217af5cd472f46cb290abf7bbc8a13348", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}, {"id_": "ent_ee9101bb04ca6654bc33e0e3c1b5d5b3f80d77831f245690f8efb64fec9bb768", "text": "Seit Beginn der Impfungen gegen Covid-19 wurden Swissmedic etwa 600 Berichte \u00fcber ver-schiedene Formen von Menstruationsst\u00f6rungen gemeldet, darunter am h\u00e4ufigsten F\u00e4lle von verst\u00e4rkten Blutungen (\u00abheavy menstrual bleeding\u00bb).", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_125b68724959521b8e8ddfc29a934b4e5b08c0d522f5d862bf8139fdde4ae67d", "text": "Impfungen gegen Covid-19", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_6bd39e9fadfbea568fdcb118a26a39aaa1cca8cc821edbb5ec7a29744cb756e6", "text": "Menstruationsst\u00f6rungen", "location": null, "probability": null}, {"id_": "ent_sig_e26e6d7e597a0505857d2951e32b9747f771bc95e17e67624e94e32c644d7f63", "text": "verst\u00e4rkten Blutungen (\u00abheavy menstrual bleeding\u00bb)", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_f0fa788d6c51e1f52bdc36bd36cb5fe908be763186138b9803a3f553dcd01fa6", "medProdID": "ent_mep_125b68724959521b8e8ddfc29a934b4e5b08c0d522f5d862bf8139fdde4ae67d", "sigID": "ent_sig_6bd39e9fadfbea568fdcb118a26a39aaa1cca8cc821edbb5ec7a29744cb756e6", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_122343615dd3a74a7affc90a7141051ed10d1cb74545cc6ed734a4854d1ac0df", "medProdID": "ent_mep_125b68724959521b8e8ddfc29a934b4e5b08c0d522f5d862bf8139fdde4ae67d", "sigID": "ent_sig_e26e6d7e597a0505857d2951e32b9747f771bc95e17e67624e94e32c644d7f63", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_987e7e2ff23ce5a3f2dfa98fcd1251132483e12d01476029160ca4f1742a5958": 0, "ent_4777abcf0c9791ac1fd6bc214adb384e70075a5c57b3f7169ec73c2b1e1b4f40": 1, "ent_ee9101bb04ca6654bc33e0e3c1b5d5b3f80d77831f245690f8efb64fec9bb768": 2}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_44d6cb8560c80885b9fdd2b0a4e13086967449e1d25bcb43d3178871760ba019", "url": "https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/marktueberwachung/pharmacovigilance/vigilance-news/amiodaron-and-hyperthyreosis.html", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_aac5658595e6d2ed79cc367cd7d2141ea172179e0764989bbb77ec0c601d4bc1", "text": "Drei Monate nach Absetzen des Amiodarons wurde der Patient wegen kardialer Dekompensation station\u00e4r aufgenommen. [\u2026] Der Kausalzusammenhang wurde als wahrscheinlich eingestuft.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_eeb038039f9f7320e7994c5a85ba1535214c07d4e8554d53c81beebba3061075", "text": "Amiodarons", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_ade40ebe459d32576c719a49db38ace8ea4e84090c412ecb7807cfb3a62313e1", "text": "kardialer Dekompensation", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_bc5e89c91577ed85eee6f8debdba48883ec56e0c838a7dda751d83e4f592dd6a", "medProdID": "ent_mep_eeb038039f9f7320e7994c5a85ba1535214c07d4e8554d53c81beebba3061075", "sigID": "ent_sig_ade40ebe459d32576c719a49db38ace8ea4e84090c412ecb7807cfb3a62313e1", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}, {"id_": "ent_fc7fd22980ceec5f62636d2cc7a202188db54c3f00f51b0ecf5e66d7c03ad8d6", "text": "Vor Gabe von Amiodaron hatte die Patientin einen TSH-Wert im Normbereich. Acht Monate nach Beginn der Therapie zeigten sich ein erniedrigtes TSH (< 0,01 mU/l) und stark erh\u00f6hte T4-Werte bei normwertigem T3-Spiegel auf. Die Schilddr\u00fcsen-Antik\u00f6rper waren unauff\u00e4llig. Klinische Symptome wie Unruhe, Zittern, schneller Puls, Schwitzen oder Leistungsintoleranz wurden nicht berichtet. Die Hyperthyreose wurde von den behandelnden \u00c4rzten als Folge der Amiodarontherapie gesehen.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_69108eccf165743a109903b7b4c69ca113fb7f139359ccf90de06c78704bd6be", "text": "Amiodaron", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_e527102fe3e0a9efca599bce5cfe61a4b1c531ee94bbc5de52d56280cf05e5c6", "text": "Hyperthyreose", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_cfe7c07a7879faa8dbb86789467ca763c254e115573ef685ebcfea5e7702e623", "medProdID": "ent_mep_69108eccf165743a109903b7b4c69ca113fb7f139359ccf90de06c78704bd6be", "sigID": "ent_sig_e527102fe3e0a9efca599bce5cfe61a4b1c531ee94bbc5de52d56280cf05e5c6", "causality": null, "seriousness": null, "severity": 0.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}, {"id_": "ent_6303508c13f7d5b53840e98b1fb09e72aeaf74502afd41ab5910a1acf14a29bb", "text": "Der Patient wurde wegen eines symptomatischen Vorhofflimmerns mehrfach kurzfristig mit Amiodaron behandelt, das aber nach elektiver Elektrokonversion gestoppt werden konnte. Zu diesem Zeitpunkt wurden ein erh\u00f6htes TSH von 6.08 mU/L [Ref.: 0.5-4.5 mU/L] bei normalem T3 und T4 gemessen. Drei Monate nach Absetzen des Amiodarons wurde der Patient wegen kardialer Dekompensation station\u00e4r aufgenommen. Es wurde eine manifeste Hyperthyreose diagnostiziert und als Amiodaron-induzierte Typ 2 (toxische) Hyperthyreose interpretiert. Klinisch zeigten sich nur eine Gereiztheit und intermittierendes Schwitzen.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_69108eccf165743a109903b7b4c69ca113fb7f139359ccf90de06c78704bd6be", "text": "Amiodaron", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_ade40ebe459d32576c719a49db38ace8ea4e84090c412ecb7807cfb3a62313e1", "text": "kardialer Dekompensation", "location": null, "probability": null}, {"id_": "ent_sig_d12053cc54ff5b04150c0f91b9464f868f2d12ce38c22f58327807b4bd33ddd3", "text": "Amiodaron-induzierte Typ 2 (toxische) Hyperthyreose", "location": null, "probability": null}, {"id_": "ent_sig_b2f6c02c699ce7e453c8e70f59913f52644a4476c8e8bb4347ed75024cb77d53", "text": "Gereiztheit", "location": null, "probability": null}, {"id_": "ent_sig_225daca85f186bc844ab038a34d158e063145adc226fc151ca15708c365cf8f4", "text": "intermittierendes Schwitzen", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_013e21e5f6e10d1a67cd88423a4bef5a6b2a4ea5293036da1820106e6ee2b967", "medProdID": "ent_mep_69108eccf165743a109903b7b4c69ca113fb7f139359ccf90de06c78704bd6be", "sigID": "ent_sig_ade40ebe459d32576c719a49db38ace8ea4e84090c412ecb7807cfb3a62313e1", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_fd51983ec45c8d8debb8ed1a9cdd9a00c3149cff8729369b31f4ec01b0a7e4e7", "medProdID": "ent_mep_69108eccf165743a109903b7b4c69ca113fb7f139359ccf90de06c78704bd6be", "sigID": "ent_sig_d12053cc54ff5b04150c0f91b9464f868f2d12ce38c22f58327807b4bd33ddd3", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_81651c9937dc39607fba87a8106a5939660c3618b00bccd68b58b69154bd4a5e", "medProdID": "ent_mep_69108eccf165743a109903b7b4c69ca113fb7f139359ccf90de06c78704bd6be", "sigID": "ent_sig_b2f6c02c699ce7e453c8e70f59913f52644a4476c8e8bb4347ed75024cb77d53", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_04eb2b06e3c0d7b6619699a4ccf811409e1c6bfdb6e35e4bae4abd9ea7efa81f", "medProdID": "ent_mep_69108eccf165743a109903b7b4c69ca113fb7f139359ccf90de06c78704bd6be", "sigID": "ent_sig_225daca85f186bc844ab038a34d158e063145adc226fc151ca15708c365cf8f4", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}, {"id_": "ent_232b0a159aa15377acc6ded4da0d49dddbf3693001b42981acfbbb0450f48a48", "text": "Es wurde eine manifeste Hyperthyreose diagnostiziert und als Amiodaron-induzierte Typ 2 (toxische) Hyperthyreose interpretiert. Im Verlauf pr\u00e4sentierte er sich erneut notfallm\u00e4ssig im reduziertem Allgemeinzustand mit belastungsabh\u00e4ngigen thorakalen Schmerzen, ausstrahlend ins Epigastrium und in den Unterbauch. Die Schilddr\u00fcsenwerte verschlechterten sich trotz Prednisolon-Therapie, sodass schliesslich notfallm\u00e4ssig eine totale Thyreoidektomie durchgef\u00fchrt wurde.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_69108eccf165743a109903b7b4c69ca113fb7f139359ccf90de06c78704bd6be", "text": "Amiodaron", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_f50ece79a9a447e678fe0f6e130a6db96d273077d3614ed33639870eaf3b77b7", "text": "reduziertem Allgemeinzustand", "location": null, "probability": null}, {"id_": "ent_sig_612c67e09c0cabbfdcffaf1c737ba76f939a8a03e875804a8c6f50322fb52e46", "text": "thorakalen Schmerzen", "location": null, "probability": null}, {"id_": "ent_sig_23fa5a99a564edd151177f6278b621315750434ee0d1b5af8bd24156e28bcbc2", "text": "Thyreoidektomie", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_3391129e5d3af116e159fe5243665dd277e0d76e8e6b12c96a825d5e6cf139e7", "medProdID": "ent_mep_69108eccf165743a109903b7b4c69ca113fb7f139359ccf90de06c78704bd6be", "sigID": "ent_sig_f50ece79a9a447e678fe0f6e130a6db96d273077d3614ed33639870eaf3b77b7", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_4bbb815493251361dd6262118a00da978f2961c29af132976c1d3c4e2e29decd", "medProdID": "ent_mep_69108eccf165743a109903b7b4c69ca113fb7f139359ccf90de06c78704bd6be", "sigID": "ent_sig_612c67e09c0cabbfdcffaf1c737ba76f939a8a03e875804a8c6f50322fb52e46", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_8c4995013e44f178bb574395f3db4585530d92e616b454bcb0a1089a4e75affd", "medProdID": "ent_mep_69108eccf165743a109903b7b4c69ca113fb7f139359ccf90de06c78704bd6be", "sigID": "ent_sig_23fa5a99a564edd151177f6278b621315750434ee0d1b5af8bd24156e28bcbc2", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_aac5658595e6d2ed79cc367cd7d2141ea172179e0764989bbb77ec0c601d4bc1": 0, "ent_fc7fd22980ceec5f62636d2cc7a202188db54c3f00f51b0ecf5e66d7c03ad8d6": 1, "ent_6303508c13f7d5b53840e98b1fb09e72aeaf74502afd41ab5910a1acf14a29bb": 2, "ent_232b0a159aa15377acc6ded4da0d49dddbf3693001b42981acfbbb0450f48a48": 3}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_13c6d3a1f6e5553b03b5a70ab8ce2a16a88d78a411839a3c90573623ab4b0404", "url": "https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/marktueberwachung/pharmacovigilance/vigilance-news/fluoroquinolones-and-tendonitis-tendon-rupture.html", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_d6811d402f158228ca95066eaa991c37175f83fb91a7b4f9e4cb37ccc26208be", "text": "Am dritten Einnahmetag bekam der Patient Beschwerden beim Gehen und konnte am Folgetag nicht mehr laufen. Ciprofloxacin wurde gestoppt. Ein R\u00f6ntgenbild zeigte keine Auff\u00e4lligkeiten. Eine Tendinitis wurde diagnostiziert und der Patient physiotherapeutisch betreut. Im Verlauf kam es zu einer Ruptur beider Achillessehnen, welche operativ behandelt werden musste.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_3097c8a3e1e52386abc827d9face0cfdf841a5bc13e65f09a13d53e91431b648", "text": "Ciprofloxacin", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_3f1da34103ebaf40e020efedb11768ecde9e45c58c36227adc7837f20520eab0", "text": "Beschwerden beim Gehen", "location": null, "probability": null}, {"id_": "ent_sig_8040552b0bf518dee4bd74e2b3995a531f5a85ef5064182e66c7fa094a0981a2", "text": "konnte am Folgetag nicht mehr laufen", "location": null, "probability": null}, {"id_": "ent_sig_7aac99d389c88891c3abbfb45b71d011e8b70e64f7dcdfa014d82a72fb1c85f3", "text": "Tendinitis", "location": null, "probability": null}, {"id_": "ent_sig_77518d363152eef7f8ce26019adf2d4b4e8cfdd3163a1c44d4712ad29cb4aa73", "text": "Ruptur beider Achillessehnen", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_4b98f9d1cdbacb3bb2f58a37b3b598a0b2e72835fd765cc923e33f65d8384c93", "medProdID": "ent_mep_3097c8a3e1e52386abc827d9face0cfdf841a5bc13e65f09a13d53e91431b648", "sigID": "ent_sig_3f1da34103ebaf40e020efedb11768ecde9e45c58c36227adc7837f20520eab0", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_f09c6904c0c6b5fb9f9a545199ad8003fa2617367e6650a6b0a0bfbc03e82413", "medProdID": "ent_mep_3097c8a3e1e52386abc827d9face0cfdf841a5bc13e65f09a13d53e91431b648", "sigID": "ent_sig_8040552b0bf518dee4bd74e2b3995a531f5a85ef5064182e66c7fa094a0981a2", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_95552fbcbdba4fcad091fa8b34748198d0eb926bc491c22c8d140265a4d0a5ce", "medProdID": "ent_mep_3097c8a3e1e52386abc827d9face0cfdf841a5bc13e65f09a13d53e91431b648", "sigID": "ent_sig_7aac99d389c88891c3abbfb45b71d011e8b70e64f7dcdfa014d82a72fb1c85f3", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_b9648ddca5f20b5ec9fa487d97ae599432d169e4188aaaf804b896738e9eaaf6", "medProdID": "ent_mep_3097c8a3e1e52386abc827d9face0cfdf841a5bc13e65f09a13d53e91431b648", "sigID": "ent_sig_77518d363152eef7f8ce26019adf2d4b4e8cfdd3163a1c44d4712ad29cb4aa73", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_d6811d402f158228ca95066eaa991c37175f83fb91a7b4f9e4cb37ccc26208be": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_43ee979c448fe422961f19afddf650e110ac10a6cc54388500a1de27612cebb2", "url": "https://www.swissmedic.ch/dam/swissmedic/de/dokumente/zulassung/swisspar/68003-supemtek-01-swisspar-20221214.pdf.download.pdf/SwissPAR_Supemtek.pdf", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_bb02c1c4dc5d699fdfb115eb09fdb24c0a705eec8a3b22b1b74fd017d86d7d6f", "text": "277 serious adverse events (SAEs) were reported overall during the six months of follow-up after vaccination, 145 (3.4%) and 132 (3.0%) subjects in the RIV4 and IIV4 treatment groups, respectively.\nAttention: signal is far off from imp", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "text": "", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_9fca850761dce2c17e782de1afb4938460dfe183a2d9118010b10e204bbc9bf8", "text": "serious adverse events (SAEs)", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_0fa3153c2c2b128a6e26aa9a2962ecba54aade3f4f19b25347a9e4167179a3d1", "medProdID": "ent_mep_e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "sigID": "ent_sig_9fca850761dce2c17e782de1afb4938460dfe183a2d9118010b10e204bbc9bf8", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_bb02c1c4dc5d699fdfb115eb09fdb24c0a705eec8a3b22b1b74fd017d86d7d6f": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_595cc5411a068895b1693bd046f1f5cb850e229556065fccd5849c4b523cf74a", "url": "https://www.swissmedic.ch/dam/swissmedic/en/dokumente/zulassung/swisspar/67251-evrysdi-02-swisspar-20230130.pdf.download.pdf/SwissPAR_Evrysdi_final.pdf", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_6de9af65992490618fa60b8bf47f2ff1d53c1f96cae6c6186b1039bb6bb4dda0", "text": "The safety data were derived from an interim analysis of 18 patients exposed to risdiplam regardless of treatment duration, with a CCOD of 1 July 2021. The most frequent adverse events (AEs) (> 2 patients) by system organ class (SOC) were: gastrointestinal disorders, and infections and infestations (50.0% [9 patients] each); respiratory, thoracic and mediastinal disorders, and skin and subcutaneous tissue disorders (38.9% [7 patients] each); and general disorders and administration site conditions (27.8% [5 patients]). The most frequent adverse events (AEs) (> 2 patients) by preferred term (PT) were: teething (33.3% [6 patients]); nasal congestion and pyrexia (27.8% [5 patients] each); diarrhoea, vomiting and viral infection (22.2% [4 patients] each); constipation, cough and eczema (16.7% [3 patients] each). Upper respiratory tract infections (basket of terms) were reported in 3 patients (16.7%) who experienced a total of 7 AEs. Lower respiratory tract infections (basket of terms) were reported in 1 patient (5.6%) who experienced 1 AE of bronchiolitis.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_8a367c07655d032b083a1328ecb0d656a25fc74ca3e454b2410e5b0950c3e2dc", "text": "risdiplam", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_8e82d13fdc59b32362acc62a4a24a35fc4c24115e8ddbf9c9b1a6a3bd873422d", "text": "gastrointestinal disorders", "location": null, "probability": null}, {"id_": "ent_sig_f7c719ccac9bfcb69d5a06bb091cce53a8f48edc8f55a49e92418e5a0ef1bcf4", "text": "infections", "location": null, "probability": null}, {"id_": "ent_sig_ee48eea1d737de3cf8bb8f3ab66e2e129dcfeba64227651bcf3feb6b015cdc58", "text": "infestations", "location": null, "probability": null}, {"id_": "ent_sig_9331c3fd1a09c79002d140f46f205bb5af4dc1c8ea45c159b1980cd442f8aeb5", "text": "respiratory, thoracic and mediastinal disorders", "location": null, "probability": null}, {"id_": "ent_sig_c30813ba59c426391e52b13d27dbc441f1983ba0a4e084007fd0bcfffb5812b8", "text": "skin and subcutaneous tissue disorders", "location": null, "probability": null}, {"id_": "ent_sig_51ca884a00d46bf80a68f23223174292ba98a850c91d44b23a47aac32e58ae9c", "text": "general disorders", "location": null, "probability": null}, {"id_": "ent_sig_a43e7ca45df9a7bdfb34fb362246e39a27435d2095cf98b9dbcbce6507cf76e2", "text": "administration site conditions", "location": null, "probability": null}, {"id_": "ent_sig_0e6190d795b0a0a4e3847ad60ae8d84319f61a50935c27538fd0e312c023a446", "text": "teething", "location": null, "probability": null}, {"id_": "ent_sig_54fb6736379f2f0340c18605fb45dc4a2a89380ebfbeca0ecaa06c889094601f", "text": "nasal congestion and pyrexia", "location": null, "probability": null}, {"id_": "ent_sig_036a81a775bd01c6ab064ffcc1fd4727d2cc58aed06d942679a9b5fc864d78ee", "text": "diarrhoea", "location": null, "probability": null}, {"id_": "ent_sig_c629da3c8da3dc80e2e1b7dda8e852a32abce5544acd905d8fcf010780d93528", "text": "vomiting", "location": null, "probability": null}, {"id_": "ent_sig_f962b1f630211a355d6c9875c4ea7be3a5922a1d9aa6036fc1a01d3e280b7321", "text": "viral infection", "location": null, "probability": null}, {"id_": "ent_sig_f79c7ed641f29accf092913c66710a0997459a12412e1dfcce93f73476cf84ea", "text": "constipation", "location": null, "probability": null}, {"id_": "ent_sig_866ab33b8463db1b3906ff42fe1112bb52aaca7c4ae0d82275413ba672a40ee7", "text": "cough", "location": null, "probability": null}, {"id_": "ent_sig_a2daa1375faf5f51e2b9a13a5fb54f657f15d80b35e8f0dbc5ad035703b6a826", "text": "eczema", "location": null, "probability": null}, {"id_": "ent_sig_8e6cbb9b069f609c8780dd8cbe2a629eff67c16550cac91c53aa0d9837d0bfc0", "text": "Upper respiratory tract infections", "location": null, "probability": null}, {"id_": "ent_sig_235875e58c67cde49c8f9f7c803e9cbc9609712b6f0577f4b3aae1d0fea6444b", "text": "Lower respiratory tract infections", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_98d5e434678236e57e668eb89f4f1715b9b4967a0c5f7b12a4c8487fd69649bb", "medProdID": "ent_mep_8a367c07655d032b083a1328ecb0d656a25fc74ca3e454b2410e5b0950c3e2dc", "sigID": "ent_sig_8e82d13fdc59b32362acc62a4a24a35fc4c24115e8ddbf9c9b1a6a3bd873422d", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_f5277d03fe9be967433a81b525cd4d0cb2e2bc3d0bbbdd1ac7c9c0cc90fca55a", "medProdID": "ent_mep_8a367c07655d032b083a1328ecb0d656a25fc74ca3e454b2410e5b0950c3e2dc", "sigID": "ent_sig_f7c719ccac9bfcb69d5a06bb091cce53a8f48edc8f55a49e92418e5a0ef1bcf4", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_ce5db39d85192706c143d8aaadbdc950a4320011cac6ef327eebdcd5d4aae7ed", "medProdID": "ent_mep_8a367c07655d032b083a1328ecb0d656a25fc74ca3e454b2410e5b0950c3e2dc", "sigID": "ent_sig_ee48eea1d737de3cf8bb8f3ab66e2e129dcfeba64227651bcf3feb6b015cdc58", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_02d7695e2c9fa7dd844ff13b37bcb1c2450a111cfe7884acebd67538b356e1a7", "medProdID": "ent_mep_8a367c07655d032b083a1328ecb0d656a25fc74ca3e454b2410e5b0950c3e2dc", "sigID": "ent_sig_9331c3fd1a09c79002d140f46f205bb5af4dc1c8ea45c159b1980cd442f8aeb5", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_04fc8c47ea067b9362fe9a3c8399dc13aa5f901749ad188d66d9d33abeaa2b08", "medProdID": "ent_mep_8a367c07655d032b083a1328ecb0d656a25fc74ca3e454b2410e5b0950c3e2dc", "sigID": "ent_sig_c30813ba59c426391e52b13d27dbc441f1983ba0a4e084007fd0bcfffb5812b8", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_0d3b98d539250dafcd69a6066fb20f333860e35ffeda0ac4779135c6e7534fd6", "medProdID": "ent_mep_8a367c07655d032b083a1328ecb0d656a25fc74ca3e454b2410e5b0950c3e2dc", "sigID": "ent_sig_51ca884a00d46bf80a68f23223174292ba98a850c91d44b23a47aac32e58ae9c", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_49265fd40be5f22d9b232e12762f53d4448243b25804bcd2344fafc5845ccaf3", "medProdID": "ent_mep_8a367c07655d032b083a1328ecb0d656a25fc74ca3e454b2410e5b0950c3e2dc", "sigID": "ent_sig_a43e7ca45df9a7bdfb34fb362246e39a27435d2095cf98b9dbcbce6507cf76e2", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_b4a00966d535dc144d864416ed3e1f9398b8e6c01bef2e063de403c98c24816c", "medProdID": "ent_mep_8a367c07655d032b083a1328ecb0d656a25fc74ca3e454b2410e5b0950c3e2dc", "sigID": "ent_sig_0e6190d795b0a0a4e3847ad60ae8d84319f61a50935c27538fd0e312c023a446", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_c24e2dfbd3ea1a70bf6be897253b8409e6ea05746de32d72fc35c8d2929ab7bb", "medProdID": "ent_mep_8a367c07655d032b083a1328ecb0d656a25fc74ca3e454b2410e5b0950c3e2dc", "sigID": "ent_sig_54fb6736379f2f0340c18605fb45dc4a2a89380ebfbeca0ecaa06c889094601f", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_13efeaa9747de78946621b89e2f8f02d63f45db8746793b14aa760d26d4bfed2", "medProdID": "ent_mep_8a367c07655d032b083a1328ecb0d656a25fc74ca3e454b2410e5b0950c3e2dc", "sigID": "ent_sig_036a81a775bd01c6ab064ffcc1fd4727d2cc58aed06d942679a9b5fc864d78ee", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_8862453a79807b156eae001fe554f5baf83cedb6b12059c3e4b1a3171735c01b", "medProdID": "ent_mep_8a367c07655d032b083a1328ecb0d656a25fc74ca3e454b2410e5b0950c3e2dc", "sigID": "ent_sig_c629da3c8da3dc80e2e1b7dda8e852a32abce5544acd905d8fcf010780d93528", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_cb3824224c68854119e259d096d52b4da04126f33775a2d64a682e781d2831bb", "medProdID": "ent_mep_8a367c07655d032b083a1328ecb0d656a25fc74ca3e454b2410e5b0950c3e2dc", "sigID": "ent_sig_f962b1f630211a355d6c9875c4ea7be3a5922a1d9aa6036fc1a01d3e280b7321", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_8b8e3cd84326100255c36778bad7ffcc6fbe2aa239cd95be82893fc515b2835f", "medProdID": "ent_mep_8a367c07655d032b083a1328ecb0d656a25fc74ca3e454b2410e5b0950c3e2dc", "sigID": "ent_sig_f79c7ed641f29accf092913c66710a0997459a12412e1dfcce93f73476cf84ea", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_3f4d25cbabb39c7c719bcea06cc5f3e1f58751c446874846c2cad78819f891d2", "medProdID": "ent_mep_8a367c07655d032b083a1328ecb0d656a25fc74ca3e454b2410e5b0950c3e2dc", "sigID": "ent_sig_866ab33b8463db1b3906ff42fe1112bb52aaca7c4ae0d82275413ba672a40ee7", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_ef4a4809d3292823563763811de5a31e35a4a897b32a519f9bd3de762fead9a2", "medProdID": "ent_mep_8a367c07655d032b083a1328ecb0d656a25fc74ca3e454b2410e5b0950c3e2dc", "sigID": "ent_sig_a2daa1375faf5f51e2b9a13a5fb54f657f15d80b35e8f0dbc5ad035703b6a826", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_fa62af8f29a304cd66298ad0d867f6ebe32c5c90e2bf8ecb39f0f13b0efc2bfb", "medProdID": "ent_mep_8a367c07655d032b083a1328ecb0d656a25fc74ca3e454b2410e5b0950c3e2dc", "sigID": "ent_sig_8e6cbb9b069f609c8780dd8cbe2a629eff67c16550cac91c53aa0d9837d0bfc0", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_7cb1c7bf15349faccf71ca219ccea792fa61c080d1e4e03fd133d2bbdc13f099", "medProdID": "ent_mep_8a367c07655d032b083a1328ecb0d656a25fc74ca3e454b2410e5b0950c3e2dc", "sigID": "ent_sig_235875e58c67cde49c8f9f7c803e9cbc9609712b6f0577f4b3aae1d0fea6444b", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_6de9af65992490618fa60b8bf47f2ff1d53c1f96cae6c6186b1039bb6bb4dda0": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_10fe441896124d25eb3d70d0ab3d252430012e8dec353c5075837b4ddb872939", "url": "https://www.swissmedic.ch/dam/swissmedic/en/dokumente/zulassung/swisspar/68473-nuvaxovid-02-swisspar-20230105.pdf.download.pdf/Assessment%20Report%20SwissPAR%20Nuvaxovid%20G102682544.pdf", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_d95525a193bc08cd0749f5e9fdca91d1a638a0846713f390e5eade1205d1d6d4", "text": "Of the pooled reactogenicity data, which includes participants aged 18 years and older enrolled in the two phase 3 studies who received any dose of Nuvaxovid (n=20,055) or placebo (n=10,561), the most frequent adverse reactions were injection site tenderness (75%), injection site pain (62%), fatigue (53%), myalgia (51%), headache (50%), malaise (41%), arthralgia (24%), and nausea or vomiting (15%). Adverse reactions were usually mild to moderate in severity with a median duration of less than or equal to 2 days for local events and less than or equal to 1 day for systemic events following vaccination.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_d2f133a7687f8a20009876cf4bb4f8937c26d749691bf4e55d3f0278880ee629", "text": "Nuvaxovid", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_ef8ef30a715e56988b138158f6a9d3521e682b69c08ca74e74a57f41cf3d44b4", "text": "injection site tenderness", "location": null, "probability": null}, {"id_": "ent_sig_9fa85a4aea3619eb6a3599ad830b4226c867775f591a26980346d309e8a9ff67", "text": "injection site pain", "location": null, "probability": null}, {"id_": "ent_sig_4064e6a9a434b058fcae69eb01a5374e91705380e2f4b9fd940120c6696fc050", "text": "fatigue", "location": null, "probability": null}, {"id_": "ent_sig_312146f0f9483510346d526434179a37794be1ce65ff906f0b583e880afa514e", "text": "myalgia", "location": null, "probability": null}, {"id_": "ent_sig_cfa9ac1e084975b5d6463e32652c85bad6355a5ab32399618f89f222e68dc335", "text": "headache", "location": null, "probability": null}, {"id_": "ent_sig_3de60b764fa076129d27a80746610236c1b4253f6d4a2d0ea61b2ee5156611d8", "text": "malaise", "location": null, "probability": null}, {"id_": "ent_sig_50a2bef28f2daf1e709e3427d07f3fb19a7ac154874ab3bc0f026d1e72c6539a", "text": "arthralgia", "location": null, "probability": null}, {"id_": "ent_sig_e31040de4051bb5c21170eea8d3690ac4706d9fd6d119771e743936fae3f878b", "text": "nausea", "location": null, "probability": null}, {"id_": "ent_sig_c629da3c8da3dc80e2e1b7dda8e852a32abce5544acd905d8fcf010780d93528", "text": "vomiting", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_465109fd0f74b0cd6c2463281fed420564ad98e6993cea285ee245539ce89a3a", "medProdID": "ent_mep_d2f133a7687f8a20009876cf4bb4f8937c26d749691bf4e55d3f0278880ee629", "sigID": "ent_sig_ef8ef30a715e56988b138158f6a9d3521e682b69c08ca74e74a57f41cf3d44b4", "causality": null, "seriousness": null, "severity": 0.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_eea9ef1dca7a3d995c708c04e39cee12defb64c1c09e1c77354b090d8e4d4d79", "medProdID": "ent_mep_d2f133a7687f8a20009876cf4bb4f8937c26d749691bf4e55d3f0278880ee629", "sigID": "ent_sig_9fa85a4aea3619eb6a3599ad830b4226c867775f591a26980346d309e8a9ff67", "causality": null, "seriousness": null, "severity": 0.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_8eed8df9ddf4436fe6ad79d72893153e5c822c7539928ab7f54605a96d016fb7", "medProdID": "ent_mep_d2f133a7687f8a20009876cf4bb4f8937c26d749691bf4e55d3f0278880ee629", "sigID": "ent_sig_4064e6a9a434b058fcae69eb01a5374e91705380e2f4b9fd940120c6696fc050", "causality": null, "seriousness": null, "severity": 0.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_ddb173cc78d62de90e77c6b0dfef356408ccdc5baaddd63af62c70a6d2fd9abb", "medProdID": "ent_mep_d2f133a7687f8a20009876cf4bb4f8937c26d749691bf4e55d3f0278880ee629", "sigID": "ent_sig_312146f0f9483510346d526434179a37794be1ce65ff906f0b583e880afa514e", "causality": null, "seriousness": null, "severity": 0.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_75a749c344cdee350e7af56a48edb9fc2d102279dca3685f4b7679a7a3de3a71", "medProdID": "ent_mep_d2f133a7687f8a20009876cf4bb4f8937c26d749691bf4e55d3f0278880ee629", "sigID": "ent_sig_cfa9ac1e084975b5d6463e32652c85bad6355a5ab32399618f89f222e68dc335", "causality": null, "seriousness": null, "severity": 0.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_f462be571535516d0fac16ed865b4c5ee6a95837037adf10de9b4eb7fb3b1258", "medProdID": "ent_mep_d2f133a7687f8a20009876cf4bb4f8937c26d749691bf4e55d3f0278880ee629", "sigID": "ent_sig_3de60b764fa076129d27a80746610236c1b4253f6d4a2d0ea61b2ee5156611d8", "causality": null, "seriousness": null, "severity": 0.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_8854566ada4f6ffc4cf26826efebf6c72458484606a28442ec12896e520d1dc7", "medProdID": "ent_mep_d2f133a7687f8a20009876cf4bb4f8937c26d749691bf4e55d3f0278880ee629", "sigID": "ent_sig_50a2bef28f2daf1e709e3427d07f3fb19a7ac154874ab3bc0f026d1e72c6539a", "causality": null, "seriousness": null, "severity": 0.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_cfa2a62701d129f20f43322f49de66dbf1108f67ec147240a1475ff34ef55dbf", "medProdID": "ent_mep_d2f133a7687f8a20009876cf4bb4f8937c26d749691bf4e55d3f0278880ee629", "sigID": "ent_sig_e31040de4051bb5c21170eea8d3690ac4706d9fd6d119771e743936fae3f878b", "causality": null, "seriousness": null, "severity": 0.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_afe9304fc97f2dd6eb136c58b3219f125a67b1a2a36eaf2c2d6800622d0b9ca0", "medProdID": "ent_mep_d2f133a7687f8a20009876cf4bb4f8937c26d749691bf4e55d3f0278880ee629", "sigID": "ent_sig_c629da3c8da3dc80e2e1b7dda8e852a32abce5544acd905d8fcf010780d93528", "causality": null, "seriousness": null, "severity": 0.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_d95525a193bc08cd0749f5e9fdca91d1a638a0846713f390e5eade1205d1d6d4": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_e77806a693f559d76ae9b907a3408dd31236d1d5a70594cd8d1c43f44c5500c3", "url": "https://www.swissmedic.ch/dam/swissmedic/en/dokumente/zulassung/swisspar/68003-supemtek-01-swisspar-20221214.pdf.download.pdf/SwissPAR_Supemtek.pdf", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_c302888d19902d185f4dec36a525c8836bbe51f7e90a00b04ae93b127aa0ee9c", "text": "Fifteen serious adverse events were reported overall in 12 subjects, 10 (1.0%) of the RIV4 recipients and 2 (0.6%) of the IIV4 recipients, during the 6-month period of follow-up. Of note, 2 subjects (aged 38 and 44) had a myocardial infarction in the RIV4 arm within 5 months after vaccination.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_229af840ae676ecab782651362f298d30cdbfbc3b43ab6a291b1792348b83a7c", "text": "RIV4", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_4a97a2620aef34538370fec30a5666e27b171f7310a669a7188c79ca680f7ac0", "text": "myocardial infarction", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_6e58556d3d3fadaee14e06c0a73a03c362cc2af115d32d24d8f4a6c58ec70ee8", "medProdID": "ent_mep_229af840ae676ecab782651362f298d30cdbfbc3b43ab6a291b1792348b83a7c", "sigID": "ent_sig_4a97a2620aef34538370fec30a5666e27b171f7310a669a7188c79ca680f7ac0", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_c302888d19902d185f4dec36a525c8836bbe51f7e90a00b04ae93b127aa0ee9c": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_6992c049963783a015f3377898d7c1430a6a58bcae360b731ca91f6ca2f53cc0", "url": "https://www.swissmedic.ch/dam/swissmedic/en/dokumente/zulassung/swisspar/68611-rapibloc-01-swisspar-20221129.pdf.download.pdf/SwissPAR%20Rapibloc.pdf", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_b7810a2e06d1e01cec20d9da88cc6eb2699d0bd813bd66c4681add656a361369", "text": "The most frequently observed adverse drug reactions (ADR) reported for clinical trials (1,101 patients) and for postmarketing treatment outcome studies/use surveys (1,257 patients) for landiolol were hypotension and bradycardia (\u22651 to <10 %).", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_1a72b8290d217aa001b21564f75b810d08f7a458ac5187f4783a94397609d681", "text": "landiolol", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_ee6fe3240e4ffeecb777e03cbf67ae51a634833e29198f5086e066d5478397f4", "text": "hypotension", "location": null, "probability": null}, {"id_": "ent_sig_ae9f9882da81ada5783066868c078badec08f7a50bd7940d9b6f4ab64a43b1cd", "text": "bradycardia", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_995d97654bf12244d79d09ec3deee236f205995b5ebe64560ad8abcb310fc454", "medProdID": "ent_mep_1a72b8290d217aa001b21564f75b810d08f7a458ac5187f4783a94397609d681", "sigID": "ent_sig_ee6fe3240e4ffeecb777e03cbf67ae51a634833e29198f5086e066d5478397f4", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_1a1a3cd5d81ecc4c3b9050b78c52883b3f7cea8e52c345f34f2706ba7801859d", "medProdID": "ent_mep_1a72b8290d217aa001b21564f75b810d08f7a458ac5187f4783a94397609d681", "sigID": "ent_sig_ae9f9882da81ada5783066868c078badec08f7a50bd7940d9b6f4ab64a43b1cd", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_b7810a2e06d1e01cec20d9da88cc6eb2699d0bd813bd66c4681add656a361369": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_a30eafc45906c98bebbff6957a5471a51f11361f56a84553cc7de6ff01984ed3", "url": "https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/marktueberwachung/health-professional-communication--hpc-/dhpc-imbruvica.html", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_bd98e9b5bbd22780b29857c07cc9d9b0e6025cfa5b6c25ab335738cc1bd479c0", "text": "DHPC \u2013 Imbruvica\u00ae (Ibrutinib)- Neuaufnahme von Leitlinien zur Dosisanpassung aufgrund kardialer Toxizit\u00e4ten sowie Aktualisierung der Leitlinien bei nicht-kardialen Toxizit\u00e4ten.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_334895d827c307aa180f9cc4b886f52f4dde17af3ee5143d914870a1c5d4917b", "text": "Imbruvica\u00ae (Ibrutinib)", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_ffc0023aab8b42665f09fc232783e1ca74aec0461fb299a0f2a8bbea73fa6e38", "text": "kardialer Toxizit\u00e4ten", "location": null, "probability": null}, {"id_": "ent_sig_0d88f97f59bbb08f3e527be3742bd3d240a2cd166595ef76be010f0b6dea651b", "text": "nicht-kardialen Toxizit\u00e4ten", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_cb64146aa00f634b538c8d74d56cc5509d32a93a319622effa5633dadc5b3779", "medProdID": "ent_mep_334895d827c307aa180f9cc4b886f52f4dde17af3ee5143d914870a1c5d4917b", "sigID": "ent_sig_ffc0023aab8b42665f09fc232783e1ca74aec0461fb299a0f2a8bbea73fa6e38", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_8a66694e297edb6dd0b451bc86825b2beb2b42f0fe28092a3c3ed31f78d4184e", "medProdID": "ent_mep_334895d827c307aa180f9cc4b886f52f4dde17af3ee5143d914870a1c5d4917b", "sigID": "ent_sig_0d88f97f59bbb08f3e527be3742bd3d240a2cd166595ef76be010f0b6dea651b", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_bd98e9b5bbd22780b29857c07cc9d9b0e6025cfa5b6c25ab335738cc1bd479c0": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_d7767bb2d6144116e5346991bfb4e6dcb9100523c4d1abb5c82a81ceb283ac14", "url": "https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/marktueberwachung/health-professional-communication--hpc-/dhpc-xalkori-crizotinib.html", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_b4858275b2abf836afa5558641eb5fda438b34e1542e90cc665b449e505be593", "text": "Sehst\u00f6rungen sind ein bekanntes Risiko bei Crizotinib und wurden in klinischen Studien mit p\u00e4diatrischen Patienten mit einer Vielzahl an Tumorarten, einschliesslich anaplastische Lymphomkinase (ALK)-positivem anaplastischem grosszelligen Lymphom (ALCL) und ALK-positivem inflammatorischen Myofibroblasten-Tumor (IMT), bei 44% der mit Crizotinib behandelten Patienten berichtet.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_91cabd161ba1b66195ae2b86ce76a5d4fc7898f8536b5db6aa57b23624533b44", "text": "Crizotinib", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_7c79a1a410d7ac9399db4c898369d150a50412031547b8a6eeefc7309af9616d", "text": "Sehst\u00f6rungen", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_4c65238cfec240b9c290c3ca462d95ba38bb604ae65826c1be023f56b86972b3", "medProdID": "ent_mep_91cabd161ba1b66195ae2b86ce76a5d4fc7898f8536b5db6aa57b23624533b44", "sigID": "ent_sig_7c79a1a410d7ac9399db4c898369d150a50412031547b8a6eeefc7309af9616d", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_b4858275b2abf836afa5558641eb5fda438b34e1542e90cc665b449e505be593": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_112d153121548ac5f845e73e73e07cef1b07d1a677606392b1db3f82c045094e", "url": "https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/marktueberwachung/health-professional-communication--hpc-/dhpc-ocaliva-obeticholsaeure.html", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_2ff380d21afed73db54160c9d0a65305cd28d8b58ad61d7b19c9ed0b2d59cff8", "text": "Der Abschnitt \u00abWarnhinweise und Vorsichtsmassnahmen\u00bb von OCALIVA enth\u00e4lt neu Informationen \u00fcber Leberdekompensation und Leberversagen, das bei mit OCALIVA behandelten PBC-Patienten mit kompensierter oder dekompensierter Zirrhose mitunter zum Tod oder zu einer Lebertransplantation f\u00fchrte.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_53a8728ba05fff83de694c469f353c29aca5392314cea3537c9d31586ae0d553", "text": "OCALIVA", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_f49a0a5eb1dd469f0f34980bb5a2a5c4df70d574b25eb312d27cb70dc64db70e", "text": "kompensierter oder dekompensierter Zirrhose", "location": null, "probability": null}, {"id_": "ent_sig_551768716253ec1774725bf7243e04a7a8bcf0c3e3bd3cca3c821403897a1138", "text": "Tod", "location": null, "probability": null}, {"id_": "ent_sig_4be0c7eeeb2614fab58421d200089506f105e73f17b9a927d9008147dd0cc963", "text": "Lebertransplantation", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_84f960995f1e5f17472f73d549a98a3c2d3b2d30a64533646ef2b51bbae6ba64", "medProdID": "ent_mep_53a8728ba05fff83de694c469f353c29aca5392314cea3537c9d31586ae0d553", "sigID": "ent_sig_f49a0a5eb1dd469f0f34980bb5a2a5c4df70d574b25eb312d27cb70dc64db70e", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_1617d045d42b6c73adf4351c67315f30e524aee04490a6cfc896311ca1a7a293", "medProdID": "ent_mep_53a8728ba05fff83de694c469f353c29aca5392314cea3537c9d31586ae0d553", "sigID": "ent_sig_551768716253ec1774725bf7243e04a7a8bcf0c3e3bd3cca3c821403897a1138", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_394c687a2adc923d4b8a18109336ea04ea28c322cd7beca68131a491f9b57ab3", "medProdID": "ent_mep_53a8728ba05fff83de694c469f353c29aca5392314cea3537c9d31586ae0d553", "sigID": "ent_sig_4be0c7eeeb2614fab58421d200089506f105e73f17b9a927d9008147dd0cc963", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_2ff380d21afed73db54160c9d0a65305cd28d8b58ad61d7b19c9ed0b2d59cff8": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_215d858b6db552e1dd985391e4fc73f95889a5ccc2dc5cfa1d77e2be1a03bf1d", "url": "https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/marktueberwachung/health-professional-communication--hpc-/dhpc-esbriet-pirfenidon.html", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_7fed85f9646f59be18f88bd2e5efcd9114300e9d5c303a89a1ca681209133884", "text": "In letzter Zeit wurden bei einzelnen Patienten klinische Manifestationen von DILI gemeldet, einschliesslich F\u00e4lle mit t\u00f6dlichem Ausgang, m\u00f6glicherweise verursacht durch idiosynkratische Reaktionen auf Pirfenidon. Auf Basis dieser Erkenntnisse wird die Fachinformation aktualisiert, um das Risiko einer klinisch relevanten DILI angemessen zu beschreiben und eine zus\u00e4tzliche \u00dcberwachung der Leberfunktion zu empfehlen, wenn klinische Anzeichen oder Symptome auftreten, die auf eine Lebersch\u00e4digung hindeuten.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_9fe271577f20d7ba67a127c0c755a1044bcccdd16241e6a924aca05a8ea6fe05", "text": "Pirfenidon", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_4d66dd58bb72aa5ba34fded9927e467b535f8647734a73e5bff9e62791446dce", "text": "DILI", "location": null, "probability": null}, {"id_": "ent_sig_c517ba51f3dfa11764ed0669215ec75e2872086c40c2f5629c8146f932f6e293", "text": "t\u00f6dlichem Ausgang", "location": null, "probability": null}, {"id_": "ent_sig_d17b5c5a9e03041bb407d96575a88b108ac849167d27e18c9b98e1238e08dc7d", "text": "Lebersch\u00e4digung", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_7681bd87c3481153684bb4f9e887abdfdaa18376fdaa344da18f389db2f8ef1b", "medProdID": "ent_mep_9fe271577f20d7ba67a127c0c755a1044bcccdd16241e6a924aca05a8ea6fe05", "sigID": "ent_sig_4d66dd58bb72aa5ba34fded9927e467b535f8647734a73e5bff9e62791446dce", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_42853decbd8661d3d47424bd540e5657947b53cd88e9c5163ed5d100a721d9a0", "medProdID": "ent_mep_9fe271577f20d7ba67a127c0c755a1044bcccdd16241e6a924aca05a8ea6fe05", "sigID": "ent_sig_c517ba51f3dfa11764ed0669215ec75e2872086c40c2f5629c8146f932f6e293", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_b68ea794350bcc8a016c06873cbaf37aa4cd538f1a6c86432149ffa3d3244549", "medProdID": "ent_mep_9fe271577f20d7ba67a127c0c755a1044bcccdd16241e6a924aca05a8ea6fe05", "sigID": "ent_sig_d17b5c5a9e03041bb407d96575a88b108ac849167d27e18c9b98e1238e08dc7d", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_7fed85f9646f59be18f88bd2e5efcd9114300e9d5c303a89a1ca681209133884": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_909c4fbc34bb8ba2cc9e3b33d7ee01151e9d8922aad1cac4f1993de5c923ede8", "url": "https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/marktueberwachung/health-professional-communication--hpc-/dhpc-glatirameracetat.html", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_98a59f2dca1c69dc31b9d585f006f317682da6f1e517df92dae91cf3bc8f2d83", "text": "Seltene F\u00e4lle schwerer Lebersch\u00e4den (einschliesslich Leberversagen, Hepatitis mit Gelbsucht und in Einzelf\u00e4llen Lebertransplantation) wurden nach der Markteinf\u00fchrung von Glatirameracetat berichtet.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_82aeb0a1646d1664556cecb4ae6f0c2e4efe9818fd082338ef1eab1a3656b9da", "text": "Glatirameracetat", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_014eb2e2a3169ad97020ca8493a74ac55c2e76d967347171c2a3fefa45670101", "text": "Lebersch\u00e4den", "location": null, "probability": null}, {"id_": "ent_sig_19e0ab56502c951da183b1c21baaf48c84ad75ee440a6065e4a64d7f2b6e40c5", "text": "Leberversagen", "location": null, "probability": null}, {"id_": "ent_sig_813ab97be8b34683175ee75154759ccc6db55a20e110d2a2e8af6c4ccfc313c2", "text": "Hepatitis", "location": null, "probability": null}, {"id_": "ent_sig_7f165e1dbcd749fcb2d02743be3b2f7b1412a2cfa4c7ffce1d2d938f744026d2", "text": "Gelbsucht", "location": null, "probability": null}, {"id_": "ent_sig_4be0c7eeeb2614fab58421d200089506f105e73f17b9a927d9008147dd0cc963", "text": "Lebertransplantation", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_5effddcf751a8ce40f638a11d929168af025bf8579074ebd17a34e736532618d", "medProdID": "ent_mep_82aeb0a1646d1664556cecb4ae6f0c2e4efe9818fd082338ef1eab1a3656b9da", "sigID": "ent_sig_014eb2e2a3169ad97020ca8493a74ac55c2e76d967347171c2a3fefa45670101", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_220184045ce008c9aece89739ffedf76bda396045bcf084cc50fe53f5b688c93", "medProdID": "ent_mep_82aeb0a1646d1664556cecb4ae6f0c2e4efe9818fd082338ef1eab1a3656b9da", "sigID": "ent_sig_19e0ab56502c951da183b1c21baaf48c84ad75ee440a6065e4a64d7f2b6e40c5", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_7e054d696758309c0cbf888bc5cf02fe9191ed2e25f6b28fc91630674945c5b3", "medProdID": "ent_mep_82aeb0a1646d1664556cecb4ae6f0c2e4efe9818fd082338ef1eab1a3656b9da", "sigID": "ent_sig_813ab97be8b34683175ee75154759ccc6db55a20e110d2a2e8af6c4ccfc313c2", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_938472ade30850efb9d2480a24d591cab683c8dde09e54c6f0ec87af15738551", "medProdID": "ent_mep_82aeb0a1646d1664556cecb4ae6f0c2e4efe9818fd082338ef1eab1a3656b9da", "sigID": "ent_sig_7f165e1dbcd749fcb2d02743be3b2f7b1412a2cfa4c7ffce1d2d938f744026d2", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_7a9d6663e11c61b08d5b4eb88cbec1d7838a257ece0f8783602565cc9313fab6", "medProdID": "ent_mep_82aeb0a1646d1664556cecb4ae6f0c2e4efe9818fd082338ef1eab1a3656b9da", "sigID": "ent_sig_4be0c7eeeb2614fab58421d200089506f105e73f17b9a927d9008147dd0cc963", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_98a59f2dca1c69dc31b9d585f006f317682da6f1e517df92dae91cf3bc8f2d83": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_251d1b2e3c6d2ff2335a96c5ed704a0e863f7938809874c13bce601d3771327d", "url": "https://www.gov.uk/government/publications/hydroxychloroquine-or-chloroquine-in-combination-with-macrolide-antibiotics-review-of-epidemiological-data-for-cardiovascular-safety/hydroxychloroquine-or-chloroquine-in-combination-with-macrolide-antibiotics-review-of-epidemiological-data-for-cardiovascular-safety", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_3cce4afaf8aa670586540595416016a484661fbb9065e87fb605bdec168239e3", "text": "The study showed that people who take hydroxychloroquine at the same time as azithromycin were more likely to get side effects affecting the heart compared with people who take hydroxychloroquine at the same time as amoxicillin.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_07bcbd510992b22d62bc597f0ae7ec6f7a65b009fbd65f3e2cc17789743f27eb", "text": "hydroxychloroquine", "location": null, "probability": null}, {"id_": "ent_mep_649cef64d969c53e549e4a5bb0509b56b0253dac46997603cafde420db3afa5e", "text": "azithromycin", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_eddb1e9973fd90d78c7009844c73b744e452531322a7067bea4529006ee286d2", "text": "side effects affecting the heart", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_ccb2ca0fd9cf38d15a0f3127597146a1aa11985cf7ccf7169ca2cef7a1431aae", "medProdID": "ent_mep_07bcbd510992b22d62bc597f0ae7ec6f7a65b009fbd65f3e2cc17789743f27eb", "sigID": "ent_sig_eddb1e9973fd90d78c7009844c73b744e452531322a7067bea4529006ee286d2", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_993c5b974d2506e9fb5362dc4c8cc1de9d1a802fbf166777903158016b6984d5", "medProdID": "ent_mep_649cef64d969c53e549e4a5bb0509b56b0253dac46997603cafde420db3afa5e", "sigID": "ent_sig_eddb1e9973fd90d78c7009844c73b744e452531322a7067bea4529006ee286d2", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_3cce4afaf8aa670586540595416016a484661fbb9065e87fb605bdec168239e3": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_5741ee44758f62e0a70b5ca879e9748befabf8ec9cb328624bb6210a34db2fab", "url": "https://www.gov.uk/drug-safety-update/topical-testosterone-testogel-risk-of-harm-to-children-following-accidental-exposure", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_f419758d980fe32427ea754c33f7fd88e9ffbb3dd46181941539dac9ea11ae01", "text": "Premature puberty and genital enlargement have been reported in children who were in close physical contact with an adult using topical testosterone and who were repeatedly accidentally exposed to this medicine.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_5aab1597ea819bc0d8122d7b793bd9575dc7acb78dafb012d8dbe4840c22f9e7", "text": "topical testosterone", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_8ecea15539f196b4cd0845eb007bda9ce34c35e89d7ab1e6ddc2d6e05fa9bbf5", "text": "Premature puberty", "location": null, "probability": null}, {"id_": "ent_sig_b2953b0eba38214177b4b62549e940a89e34136eabd52c28d74acb9b06690c5e", "text": "genital enlargement", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_63afb366165f2cffb9525b3c1076ed3fd6af7cbc0af24db038db93b854c0d037", "medProdID": "ent_mep_5aab1597ea819bc0d8122d7b793bd9575dc7acb78dafb012d8dbe4840c22f9e7", "sigID": "ent_sig_8ecea15539f196b4cd0845eb007bda9ce34c35e89d7ab1e6ddc2d6e05fa9bbf5", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_b957630e4ac95bf0490a2717b783a4094db22e7305a6e55ae039216a92c148f7", "medProdID": "ent_mep_5aab1597ea819bc0d8122d7b793bd9575dc7acb78dafb012d8dbe4840c22f9e7", "sigID": "ent_sig_b2953b0eba38214177b4b62549e940a89e34136eabd52c28d74acb9b06690c5e", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_f419758d980fe32427ea754c33f7fd88e9ffbb3dd46181941539dac9ea11ae01": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_283608150a833bfd0b7a7d9e102fee330df3dc903d6d4deabb0332912a9f2f32", "url": "https://www.gov.uk/drug-safety-update/metformin-and-reduced-vitamin-b12-levels-new-advice-for-monitoring-patients-at-risk", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_1109a3e4dd780ee12b0f4fb965de8bae9eb1958d0f90c31b157fdb7d7e11b2c7", "text": "Decreased vitamin B12 levels, or vitamin B12 deficiency, is now considered to be a common side effect in patients on metformin treatment, especially in those receiving a higher dose or longer treatment duration and in those with existing risk factors.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_c18f8cceb7aa87dad5554c146cd5069be3ecf99c66ffc808a81255e4ac7bfed4", "text": "metformin", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_a06d52184acf166a3391427c33e3848e4257d2913f38d01f64f2be7807e3665f", "text": "Decreased vitamin B12 levels", "location": null, "probability": null}, {"id_": "ent_sig_04540aa09f0e6a4fb1bdb70c0cc373a86c56fbd92bba2977889fb9d32b45a71d", "text": "vitamin B12 deficiency", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_8ad40637cadb274827ba36433426192d452fd6a292359cd0b7ebc9b57cf30ee6", "medProdID": "ent_mep_c18f8cceb7aa87dad5554c146cd5069be3ecf99c66ffc808a81255e4ac7bfed4", "sigID": "ent_sig_a06d52184acf166a3391427c33e3848e4257d2913f38d01f64f2be7807e3665f", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_ef83528b9863037223de494c9a84f9e4b4ccc1e9542fe8c523498af8c25d4eec", "medProdID": "ent_mep_c18f8cceb7aa87dad5554c146cd5069be3ecf99c66ffc808a81255e4ac7bfed4", "sigID": "ent_sig_04540aa09f0e6a4fb1bdb70c0cc373a86c56fbd92bba2977889fb9d32b45a71d", "causality": null, "seriousness": null, "severity": 0.5, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_1109a3e4dd780ee12b0f4fb965de8bae9eb1958d0f90c31b157fdb7d7e11b2c7": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_af68e7d6517839f6bac2024ee72b7bd7a09a9749b70684721b3749d5d4024518", "url": "https://www.gov.uk/drug-safety-update/pregabalin-lyrica-findings-of-safety-study-on-risks-during-pregnancy", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_7d8be2c68f575985cdb3a3c691114d25deeb3238803bb606165fed12d14acb6c", "text": "A new study has suggested pregabalin may slightly increase the risk of major congenital malformations if used in pregnancy.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_9f18ea8a7c164bfebfd226854c2c588818eaedd530f0ccabe03239b6cbcb881e", "text": "pregabalin", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_90a7c9b0d5a2b384eb70664d16b2a9e8cf4c5336753ca2a4ed5e670e3e14d54a", "text": "congenital malformations", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_f7612c6a00a010658a0b096eb46fa8b64e9dbddfe267497a46ced7c520e1dbf8", "medProdID": "ent_mep_9f18ea8a7c164bfebfd226854c2c588818eaedd530f0ccabe03239b6cbcb881e", "sigID": "ent_sig_90a7c9b0d5a2b384eb70664d16b2a9e8cf4c5336753ca2a4ed5e670e3e14d54a", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_7d8be2c68f575985cdb3a3c691114d25deeb3238803bb606165fed12d14acb6c": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_8a219acdebfff2059212181863814646cb59e1d18d1278247b18ea393b9e4a95", "url": "https://www.gov.uk/drug-safety-update/bendamustine-levact-increased-risk-of-non-melanoma-skin-cancer-and-progressive-multifocal-encephalopathy-pml", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_85b01f8ea8484f193de17f6431304350ef5fafe4d571573b97df48f999c230fe", "text": "Bendamustine (Levact): increased risk of non-melanoma skin cancer and progressive multifocal encephalopathy (PML)", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_e81a8a9be968d97a628650a0f1039b4ad3693e257f151c9c191087e676631e84", "text": "Bendamustine (Levact)", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_326b1bf9f1e34ab986e03c6eb05d2fd721fe99449713136ed0d65dca398b7eb2", "text": "non-melanoma skin cancer", "location": null, "probability": null}, {"id_": "ent_sig_c8a199a2c9b0735c3380db9409d6bf4a20d706ed927b7a2be172d8c81854d760", "text": "progressive multifocal encephalopathy (PML)", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_0e59a977388d0bdceb28489e6caaec6cc9856803936288c024b94807d6b50ce3", "medProdID": "ent_mep_e81a8a9be968d97a628650a0f1039b4ad3693e257f151c9c191087e676631e84", "sigID": "ent_sig_326b1bf9f1e34ab986e03c6eb05d2fd721fe99449713136ed0d65dca398b7eb2", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_25a3f21441e882f1ae3b7b46d6167d3bb0e8f495dccdfacc60ae173c8cdecb66", "medProdID": "ent_mep_e81a8a9be968d97a628650a0f1039b4ad3693e257f151c9c191087e676631e84", "sigID": "ent_sig_c8a199a2c9b0735c3380db9409d6bf4a20d706ed927b7a2be172d8c81854d760", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_85b01f8ea8484f193de17f6431304350ef5fafe4d571573b97df48f999c230fe": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_844c86c60b18c4131e52c273fb7c806a0ccc58adde131addb4bacd6b357b3e7f", "url": "https://recalls-rappels.canada.ca/en/alert-recall/imbruvica-ibrutinib-risk-serious-and-fatal-cardiac-arrhythmias-or-cardiac-failure", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_6e7d576bf1983cd04a1f18c6fd828dd5847038d11508681e4eb51998d8757c85", "text": "IMBRUVICA (ibrutinib) - Risk of Serious and Fatal Cardiac Arrhythmias or Cardiac Failure", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_1ae711b707bc286f60c92890011ee748720a317f3814f030735f9c9bfe958d01", "text": "IMBRUVICA (ibrutinib)", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_1019311c73d8333a6483d0572f81ba9b3d97824eeb68193f5ea877d340c8fffa", "text": "Risk of Serious and Fatal Cardiac Arrhythmias", "location": null, "probability": null}, {"id_": "ent_sig_7356f7db99e5120eece3b8718f00ff6118cecca06b27656bab282a194bfcb5db", "text": "Cardiac Failure", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_c06a0c0e51882f0b4d3a4dc97f785be83e5ab84edeb13fb0deb7a3c6f26bc119", "medProdID": "ent_mep_1ae711b707bc286f60c92890011ee748720a317f3814f030735f9c9bfe958d01", "sigID": "ent_sig_1019311c73d8333a6483d0572f81ba9b3d97824eeb68193f5ea877d340c8fffa", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_084e0f5efd07483bbc66f0b1151912db9d15ab93995cf6aea5be35ec44080184", "medProdID": "ent_mep_1ae711b707bc286f60c92890011ee748720a317f3814f030735f9c9bfe958d01", "sigID": "ent_sig_7356f7db99e5120eece3b8718f00ff6118cecca06b27656bab282a194bfcb5db", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}, {"id_": "ent_fb82d8a037f496f5e923d0e9f380cb60a16b0f3948846a6a8d9d40d812732a85", "text": "Serious and fatal events of cardiac arrhythmia or cardiac failure have occurred in patients treated with IMBRUVICA", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_930d35090eca9a6d0731a49b37b4fbfd3201de6c4eb8d1f48450f4328760e250", "text": "IMBRUVICA", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_fb86038ecada1c41217aa27b2d07009a2847d09a8c5a5f0086cafd4748d76a9a", "text": "cardiac arrhythmia", "location": null, "probability": null}, {"id_": "ent_sig_f0f7512f4e78fbc7c0a45c469fb84e738cc67ac519b72320e18be3097dc45fb2", "text": "cardiac failure", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_8117bbde9ad485c04bb53959d4d4b13421e1dfdfdddbc392a056febd6fda6204", "medProdID": "ent_mep_930d35090eca9a6d0731a49b37b4fbfd3201de6c4eb8d1f48450f4328760e250", "sigID": "ent_sig_fb86038ecada1c41217aa27b2d07009a2847d09a8c5a5f0086cafd4748d76a9a", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_0558764c7d05eff6e54ead77ffcb292c699149a91e60c47145cc6d503052452d", "medProdID": "ent_mep_930d35090eca9a6d0731a49b37b4fbfd3201de6c4eb8d1f48450f4328760e250", "sigID": "ent_sig_f0f7512f4e78fbc7c0a45c469fb84e738cc67ac519b72320e18be3097dc45fb2", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_6e7d576bf1983cd04a1f18c6fd828dd5847038d11508681e4eb51998d8757c85": 0, "ent_fb82d8a037f496f5e923d0e9f380cb60a16b0f3948846a6a8d9d40d812732a85": 1}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_0548f07791371a021b9fdbc218c9fe43bd7f85234f63aea284c7a1f106216a49", "url": "https://recalls-rappels.canada.ca/en/alert-recall/zolgensma-onasemnogene-abeparvovec-and-fatal-cases-acute-liver-failure", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_f88b063b0f2b6d8fd814cfc61b69684987b29776a654d36e73ce5e09ce6bc771", "text": "Two cases of fatal acute liver failure associated with ZOLGENSMA have recently been reported internationally. The deaths occurred 6-7 weeks post-ZOLGENSMA infusion, following the initiation of corticosteroid taper.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_96e3e58f926b1b4377b2b24a09c61612254384bd3a9400567c9d4fe7783b44e2", "text": "ZOLGENSMA", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_1abc7866da13be83000fab4c44c0d70ae645d25e45e3f4d7e9e12b949d9a61de", "text": "acute liver failure", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_b1cd8b9f0d0991789000006f1ae6e986018033210c7b8ce67118de9e2db7587b", "medProdID": "ent_mep_96e3e58f926b1b4377b2b24a09c61612254384bd3a9400567c9d4fe7783b44e2", "sigID": "ent_sig_1abc7866da13be83000fab4c44c0d70ae645d25e45e3f4d7e9e12b949d9a61de", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_f88b063b0f2b6d8fd814cfc61b69684987b29776a654d36e73ce5e09ce6bc771": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_8257adf3b47787fe192a4dc03f5104cc50f98c2f9822d74a31ca1606f9aa1aa0", "url": "https://www.tga.gov.au/news/safety-updates/clozapine-and-gastrointestinal-hypomotility-severe-complications", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_3b34d4cb812a53efa8788c7a706c942ee265b209ac44f48c3b4b58930183c8dc", "text": "The severe gastrointestinal effects of intestinal obstruction, severe constipation and gastrointestinal hypomotility are among the most serious adverse reactions experienced with clozapine. In post-marketing experience, severe complications of gastrointestinal hypomotility (such as intestinal obstruction, faecal impaction, megacolon, paralytic ileus and intestinal ischaemia or infarction) have resulted in hospitalisation, surgery and death.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_a670530567194409c154c89f76df0a614f51f0d45013c2bda38fbef204f78e6f", "text": "clozapine", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_114bc955c8e8854799df0d2ff87ecfc5491661556fb7e729336ac28813139080", "text": "intestinal obstruction", "location": null, "probability": null}, {"id_": "ent_sig_45719585e4d6c906674408e8bd2daa147a87e9c9dbaf88f57f7cad17aa498d00", "text": "severe constipation", "location": null, "probability": null}, {"id_": "ent_sig_bdb738433160aab9882da0cb082f93f787e1da3a5096a66abc5ddc0caf3f714b", "text": "gastrointestinal hypomotility", "location": null, "probability": null}, {"id_": "ent_sig_44094008f866b93b8c79c411dd0437f8477448eff735d984fc397abe3862d8fe", "text": "hospitalisation", "location": null, "probability": null}, {"id_": "ent_sig_fc00eb484b582cfb374e43802b91124bac34ebae56308ac5f5d6b7af6b554c85", "text": "surgery", "location": null, "probability": null}, {"id_": "ent_sig_52c8e02987ccb1b0eef9c7c966aebf03c92a159aafda37fbcf03f4838dbcd48d", "text": "death", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_340c4a73f388185b885783dace770413f4afa052d2eae3603324ba324e988779", "medProdID": "ent_mep_a670530567194409c154c89f76df0a614f51f0d45013c2bda38fbef204f78e6f", "sigID": "ent_sig_114bc955c8e8854799df0d2ff87ecfc5491661556fb7e729336ac28813139080", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_a76bf7b2045fa6176fc65c71c84fd9315f319d1f7fbfd23af712b7846f06bb49", "medProdID": "ent_mep_a670530567194409c154c89f76df0a614f51f0d45013c2bda38fbef204f78e6f", "sigID": "ent_sig_45719585e4d6c906674408e8bd2daa147a87e9c9dbaf88f57f7cad17aa498d00", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_ece068d22de4332331bbe8c0f9da5fa95d12da3f733b0546172dfff615b22178", "medProdID": "ent_mep_a670530567194409c154c89f76df0a614f51f0d45013c2bda38fbef204f78e6f", "sigID": "ent_sig_bdb738433160aab9882da0cb082f93f787e1da3a5096a66abc5ddc0caf3f714b", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_720af9d221b17cacf34c92128fe2f3dcaacd86d4194aa7539489b724967d68a9", "medProdID": "ent_mep_a670530567194409c154c89f76df0a614f51f0d45013c2bda38fbef204f78e6f", "sigID": "ent_sig_44094008f866b93b8c79c411dd0437f8477448eff735d984fc397abe3862d8fe", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_6add5eca16609f703e4e1fecd8947a4cfadfc5be688e9b3a1a9b318610eb74e3", "medProdID": "ent_mep_a670530567194409c154c89f76df0a614f51f0d45013c2bda38fbef204f78e6f", "sigID": "ent_sig_fc00eb484b582cfb374e43802b91124bac34ebae56308ac5f5d6b7af6b554c85", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_2e8a2bb79d402d465152b4d5a1fe03b2b5283da0ac8834e314f745acc15e953e", "medProdID": "ent_mep_a670530567194409c154c89f76df0a614f51f0d45013c2bda38fbef204f78e6f", "sigID": "ent_sig_52c8e02987ccb1b0eef9c7c966aebf03c92a159aafda37fbcf03f4838dbcd48d", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_3b34d4cb812a53efa8788c7a706c942ee265b209ac44f48c3b4b58930183c8dc": 0}, "_Document__errors": [], "_Document__input": null}, {"id_": "doc_ac34331c0c316ee87e47c116e05b35e52df4b83a8734a8cbdcf77f8dddf797de", "url": "https://recalls-rappels.canada.ca/en/alert-recall/unintentional-exposure-young-children-adult-acetaminophen-tablets-may-pose-serious", "sourceUrl": null, "sourceStorage": "fs", "source": null, "pipelineSource": null, "type": null, "language": null, "text": null, "title": null, "authors": [], "abstract": null, "publicationDate": null, "extractionDate": null, "lastUpdate": null, "documentRelevance": null, "models": {}, "_textEntities": [{"id_": "ent_9d877e225327dc2ad14ad4d2492248b0934ce395913e98a352df4bdfd2f29783", "text": "Unintentional ingestion of acetaminophen products can result in overdose and serious health consequences, including liver damage or death. Symptoms of an overdose include nausea, vomiting, loss of appetite and pain in the upper part of the abdomen or stomach.", "location": [], "outcomes": [], "populationGroups": [], "indications": [], "medicinalProducts": [{"id_": "ent_mep_c87b0ea44ecc6b2406a9449d58a1480ff12e21bceae445a37c303f74cfb4ad5f", "text": "acetaminophen", "location": null, "probability": null}], "signals": [{"id_": "ent_sig_58d826e9c7b9fd95e1a9000b2084ec8a8bb268f7de12dd0af551488ed7a47567", "text": "liver damage", "location": null, "probability": null}, {"id_": "ent_sig_52c8e02987ccb1b0eef9c7c966aebf03c92a159aafda37fbcf03f4838dbcd48d", "text": "death", "location": null, "probability": null}, {"id_": "ent_sig_e31040de4051bb5c21170eea8d3690ac4706d9fd6d119771e743936fae3f878b", "text": "nausea", "location": null, "probability": null}, {"id_": "ent_sig_c629da3c8da3dc80e2e1b7dda8e852a32abce5544acd905d8fcf010780d93528", "text": "vomiting", "location": null, "probability": null}, {"id_": "ent_sig_7272a827243acc032e3cc3a3fd1a1eb3d9cef8167120e73750e33d06121598d9", "text": "loss of appetite", "location": null, "probability": null}, {"id_": "ent_sig_0da71f0c86436a03d97b1152f2a15a1484f2e68a4ac0f546f491cbf68bf3430f", "text": "pain in the upper part of the abdomen or stomach", "location": null, "probability": null}], "medProdSigPairs": [{"id_": "ent_msp_3cd546bc4065f4ab960cecf8f63975776dae979a48ae5e923d5454e84c63563c", "medProdID": "ent_mep_c87b0ea44ecc6b2406a9449d58a1480ff12e21bceae445a37c303f74cfb4ad5f", "sigID": "ent_sig_58d826e9c7b9fd95e1a9000b2084ec8a8bb268f7de12dd0af551488ed7a47567", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_57a2167a2a3423eb08a060d38e8628a97e0e0b924948d8902e62c8c65fb34751", "medProdID": "ent_mep_c87b0ea44ecc6b2406a9449d58a1480ff12e21bceae445a37c303f74cfb4ad5f", "sigID": "ent_sig_52c8e02987ccb1b0eef9c7c966aebf03c92a159aafda37fbcf03f4838dbcd48d", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_d5aee5ffc93b23a5fb829de5046e19ca907871400573416ffeca9e0e88fc0834", "medProdID": "ent_mep_c87b0ea44ecc6b2406a9449d58a1480ff12e21bceae445a37c303f74cfb4ad5f", "sigID": "ent_sig_e31040de4051bb5c21170eea8d3690ac4706d9fd6d119771e743936fae3f878b", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_90ea82daefa15d1681575499014d163ec1b4f8e0a2698250799b61b54c155014", "medProdID": "ent_mep_c87b0ea44ecc6b2406a9449d58a1480ff12e21bceae445a37c303f74cfb4ad5f", "sigID": "ent_sig_c629da3c8da3dc80e2e1b7dda8e852a32abce5544acd905d8fcf010780d93528", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_e977b2bcb2eed3d52094d4d179320c938d190ef2132cc2c74f7722270eeadc94", "medProdID": "ent_mep_c87b0ea44ecc6b2406a9449d58a1480ff12e21bceae445a37c303f74cfb4ad5f", "sigID": "ent_sig_7272a827243acc032e3cc3a3fd1a1eb3d9cef8167120e73750e33d06121598d9", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}, {"id_": "ent_msp_ffc21878b800afe9c6b062fd9b4a87da183be46c5b5644e044c430d68c464b59", "medProdID": "ent_mep_c87b0ea44ecc6b2406a9449d58a1480ff12e21bceae445a37c303f74cfb4ad5f", "sigID": "ent_sig_0da71f0c86436a03d97b1152f2a15a1484f2e68a4ac0f546f491cbf68bf3430f", "causality": null, "seriousness": null, "severity": 1.0, "statistics": null, "relevanceLearning": null, "relevanceAggregation": null}], "_TextEntity__raw_text": ""}], "_Document__raw_text": "", "_Document__textEntityIDIndexMap": {"ent_9d877e225327dc2ad14ad4d2492248b0934ce395913e98a352df4bdfd2f29783": 0}, "_Document__errors": [], "_Document__input": null}]